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A b s t r a c t 
Background 
“Endometriosis is a chronic hormone-dependent inflammatory disorder that affects 6-
10% of women of reproductive age. It is defined by the presence of endometrial-like 
tissue (lesions) found outside the uterine cavity, usually within the pelvis. The most 
widely reported symptoms of endometriosis are chronic pelvic pain and infertility. 
Endometriosis-associated pain can have a significant and debilitating impact on 
quality of life. In the United Kingdom, the impact on society of endometriosis is 
estimated at £8.2 billion in healthcare/treatment costs coupled with lost productivity. 
The exact aetiology of endometriosis is unknown. Standard treatments such as 
analgesic regimens, drugs that induce hormone suppression or invasive surgery can 
be associated with unacceptable side effects or complications. Notably many medical 
treatments are contraceptive, and endometriosis-associated symptoms typically recur 
after women stop taking drug treatments or after surgery. New therapies are therefore 
needed that: (i) can reduce painful symptoms associated with the condition (ii) are 
disease modifying (reduce lesion size) (iii)  preserve the patients’ ability to conceive 
whilst on medication (iv) have no, or limited, side effects and (v) are acceptable to 
women with endometriosis.”  
Objectives 
“The two aims of my thesis were (a) to identify research priorities for endometriosis 
and (b) to determine the feasibility of a future multi-centre, large randomised 
controlled trial (RCT) to evaluate the effectiveness of Omega-3 purified fatty acids 
(PUFA) for endometriosis-associated pain. To achieve these objectives, I have (a) 
engaged with experts in the management of endometriosis, women with 
endometriosis and prepared a report of the research uncertainties, using a template 
provided by the James Lind Alliance (JLA) and (b) undertaken a two-arm, double-





(a) Identifying research priorities for endometriosis 
“The JLA brings patients, carers and clinicians together in Priority Setting 
Partnerships (PSPs) to identify and prioritise the ‘top 10’ uncertainties, or 
unanswered questions, about the effects of treatments. An endometriosis PSP was 
launched in 2016 with the formation of a steering group, I prepared a survey where 
research questions were invited from members of the public (this included women 
with endometriosis and their families) and health care professionals (HCPs). Priority 
setting was carried out using data from (a) online survey complemented by clinical 
guidelines and systematic reviews (b) online voting and (c) a facilitated workshop of 
equal numbers of women with endometriosis and HCPs. In the first online survey, 
4767 research questions were submitted by 1237 UK and Ireland respondents (67.7% 
women with endometriosis and 15.8% HCPs). A further 111 research uncertainties 
were identified from literature searches. After removing questions already addressed 
by systematic reviews or ongoing research and merging similar questions, 72 were 
listed in a second survey allowing participants to vote and rank the questions, 1380 
participants from the UK and Ireland voted. From the 30 uncertainties which 
received most votes, 10 research priorities were agreed during a final face to face 
workshop comprising of equal numbers of women with endometriosis and HCPs.”  
(b) A pilot trial to evaluate the feasibility of performing a future RCT of the 
effectiveness of Omega-3 PUFA for endometriosis-associated pain (PurFECT) 
“In human trials on painful inflammatory conditions, other than endometriosis, 
Omega-3 PUFA have been shown to have minimal side effects with no obvious 
effects on fertility and may therefore be an acceptable treatment for endometriosis-
associated symptoms. I performed a pilot two-armed double-blind RCT in NHS 
Lothian, comparing Omega-3 PUFA to a comparator (olive oil), to assess the 
feasibility of a future large-scale RCT for treatment of women with endometriosis-
associated pain. The primary objectives were to determine recruitment and retention 
rates. The secondary objectives were to evaluate the acceptability of the methods of 
recruitment, randomisation, interventions and assessment tools and any signals of 
effectiveness of the interventions. The analyses by treatment group were by 
intention-to-treat. Between June 2016 and June 2017, of the 92 women who were 
vi 
 
referred to the study, 73 (79.3%) were eligible, 42 (57.5%) recruited and 33 (81.8%) 
women randomised.  These 33 women all of whom had endometriosis-associated 
pain were randomised double-blindly and given either Omega-3 PUFA or the 
comparator. The effects of the interventions were assessed by validated pain scores 
and physical/emotional functioning questionnaires, completed at baseline and at the 
end of the study. The acceptability of the questionnaires was recorded as data 
completion and the absence of missing values. The majority of participants described 
their trial experience favourably. The recruitment rate was 57.5% (i.e. > 50%), the 
retention rate was 81.8% (considered a satisfactory rate), and the primary outcome 
was achieved. For most of the assessment tools, it appeared that there is no evidence 
that the treatment is better than control.” 
Conclusions 
“The top 10 priorities identified by the PSP provide a platform for researchers, funding 
bodies and the pharmaceutical industry to ensure that future research activities focus 
on questions that are important to both women with endometriosis and HCPs. The 
PurFECT trial shows that a future RCT is feasible, but also highlights the need for a 
larger appropriately powered trial to assess the effectiveness of Omega-3 PUFA as 








“The endometrium is the inner lining of the womb (uterus). Endometriosis is defined 
by the presence of endometrial cells outside the uterus ('endometriosis lesions'), most 
commonly on the lining of the pelvic cavity (‘peritoneum’). Endometriosis is 
common among women in the UK. It affects 6-10% of women of reproductive age 
worldwide and is associated with debilitating pelvic pain and subfertility. 
Endometriosis costs the UK £8.2 billion each year in NHS budget and lost income. 
We do not know the exact cause(s) and there is no cure for this condition. Currently 
endometriosis is managed by an operation or with drugs. However, symptoms recur 
after surgery in up to 3 in 4 of women and most drug treatments have unwanted side 
effects and many also act as contraceptives. There is an urgent need for new ways to 
treatment for endometriosis which can relieve pain, reduce the amount of disease, not 
affect a woman’s ability to get pregnant, have no or few side effects and are accepted 
by women.”  
The two aims of my study were (a) to identify the most important unanswered 
questions (research priorities) for endometriosis and (b) to find out if Omega-3 fatty 
acids are acceptable to women with endometriosis so as to determine if a larger study 
is feasible. To achieve these two aims, I have sought the views of professionals who 
treat endometriosis, women with endometriosis and carers of women with this 
condition and prepared a report according to the guidance provided by a charity 
called the James Lind Alliance (JLA) and also carried out a small study, a pilot trial, 
involving women with endometriosis.  
To identify unanswered questions (priorities) for endometriosis research, I followed 
methods developed by the JLA that are designed to capture the views of patients, 
their carers and healthcare professionals (HCPs) by encouraging them to form 
Priority Setting Partnerships (PSPs). In our endometriosis PSP the first step was to 
use a widely publicised online survey and invite public members, including women 
with endometriosis, their carers and HCPs to submit suggestions for unanswered 
(research) questions. This survey generated 4767 questions. Using a combination of 
computer methods and expert evaluation, themes were identified and similar 
questions were merged to give 72 ‘summary’ questions. These questions were 
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publicised using a second survey and participants asked to vote for and rank their 
personal ‘top 10’ questions. From this survey the 30 most popular questions were 
identified and these were discussed at a workshop attended by women with 
endometriosis, carers and HCPs and a research priority ‘top 10’ were agreed. The top 
question was “Can a cure be developed for endometriosis?” 
Omega-3 fatty acids are the ‘good fats’ that you find in fish and fish oil. In human 
studies on other painful conditions, Omega-3 fatty acids seem to reduce pain and 
have no contraceptive effects. We therefore thought that Omega-3 fatty acids might 
be an acceptable treatment for women with endometriosis-associated pain. The aim 
of my pilot clinical trial was to see if a large study of Omega-3 fatty acids would be a 
potential treatment for endometriosis would be feasible or not. To do this I set out to 
see how easy it would be to recruit women to take part, how many would stay till the 
end of the study and if the way my study was conducted was acceptable. During my 
pilot trial, 42 women agreed to take part and 27 completed the trial. Of these, 17 
were randomly assigned to take Omega-3 fatty acid capsules and 16 to olive oil 
capsules. No-one in either group, as well as me, knew what capsules they were 
taking as all capsules looked the same. The women took the capsules for 56 days. 
Women were asked to score their pain before they took the capsules as well as during 
the last month of treatment. Women generally reported a positive experience being 
part of the study and it appeared that there was slight improvement in pain scores in 
the women taking olive oil although the numbers of women being studied was too 
low to draw concrete conclusions. 
In conclusion, I hope that the identification of a ‘top 10’ unanswered questions will 
help make sure that future research into endometriosis answers questions which are 
important to women. The pilot trial showed that women were happy to take a dietary 
supplement and show a larger study is feasible even if the preliminary findings were 
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Chapter 1. Introduction 
1.1. Background 
“Endometriosis is a chronic condition that is associated with debilitating pelvic pain 
and infertility (Gylfason et al., 2010). It is defined as the presence of endometrial-
like tissue or ‘lesions’ outside the uterine cavity, usually within the pelvis and is a 
chronic hormone-dependent inflammatory disorder (Bulun et al., 2009, Giudice and 
Kao, 2004, Vercellini et al., 2014). The World Endometriosis Society (WES) 
(http://endometriosis.ca/) estimates 6-10% of women of reproductive age suffer from 
endometriosis. In the UK this number is similar to the number of women affected by 
diabetes or asthma.”  
“There are three different types of endometriosis: peritoneal endometriosis (PE), 
ovarian endometriomas (OE) “cysts” and deep endometriosis (DE). At the time of 
surgery, endometriosis may be further classified into one of four stages (I-minimal, 
II-mild, III-moderate, and IV-severe) depending on the location, extent and depth of 
invasion of the endometriosis lesions (Schultes, 1999).”  
Endometriosis rarely occurs in prepubescent or menopausal women and the disorder 
is usually considered as being oestrogen-dependent. The number of women with 
endometriosis may be underreported as the presence of lesions may go undetected 
unless symptoms such as infertility or pain prompt surgical investigation and lesions 
are often reported only after they are detected during routine procedures such as 
sterilisation (Gylfason et al., 2010). 
“The impact on the quality of life (QOL) of women with endometriosis, their families 
and the costs to healthcare systems mean that endometriosis has a significant socio-
economic impact (Simoens et al., 2012, Simoens et al., 2007).” 
The following sections of this review outline the current understanding of the 
presentation and aetiology of this complex disorder, the symptoms it may induce and 
current therapeutic strategies to provide the context and background to the aims of 
this thesis.  
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 Subtypes of endometriosis 1.1.1.
1.1.1.1. Peritoneal endometriosis   
“Peritoneal endometriosis “PE” (or superficial endometriosis) is found on the 
peritoneum lining the wall of the pelvic cavity. Lesions range from red, 
haemorrhagic and vesicular; blue-black powder-like burn patterns as shown in 
Figure  1-1 or fibrotic white lesions. Red implants are very vascular, bleed into the 
peritoneal cavity during menstruation and are associated with adhesion formation. 
On the other hand, dark or white lesions characterised by decreased vascularity, 
reduced bleeding and higher amounts of fibrosis. These implants can change 
appearance and might regress with medical treatments, but usually reappear after 
termination of treatment and return of the menstrual period (Brosens et al., 2004).” 
Figure  1-1:- Different subtypes of endometriosis A:- Ovarian and peritoneal 
endometriosis. B:- Brown endometriotic deposits on the pelvic 






1.1.1.2. Ovarian endometriomas (endometriotic cysts)  
“Ovarian endometriosis “OE” usually appears as dark brown cystic structures which 
often called chocolate cysts as shown in Figure  1-2. The OE does not invade the 
ovary, but most likely that endometriotic hematoma attaches to the surface of the 
ovary. These cysts lined, partially or completely,  by surface epithelium, 
endometrial-like mucosa and highly vascularised stroma (Brosens et al., 2004). 
Bleeding, twisting or rupture of these cysts can cause an acute abdominal emergency 
necessitating surgical intervention in about five percent of women with 
endometriosis (Schenken, 1996).”  
Figure  1-2:- Laparoscopic picture of ovarian endometrioma (Endo-Resolved, 2017) 
 
 
1.1.1.3. Deep endometriosis  
Deep endometriosis “DE” is defined as endometrial deposits infiltrating the 
implantation site by more than 5 mm. DE presents in the uterosacral ligaments, 
rectovaginal septum, utero-ovarian ligaments and muscular wall of pelvic organs. DE 
invades into adjacent fibromuscular tissue and the loose connective tissue and is 
responsible for certain endometriosis-associated symptoms such as deep dyspareunia 




 Stages of endometriosis 1.1.2.
“The revised classification of the American Society for Reproductive Medicine 
(rASRM) categorises endometriosis, surgically, into four stages; stages I and II are  
generally considered as being mild/moderate, whereas stages III and IV represent 
advanced (severe) stages of the disease (Canis et al., 1997). This classification is a 
scoring system based on localisation of implants (Figure  1-1), its size and extent of 
adhesions which can only be made by the surgeon undertaking a therapeutic or 
diagnostic laparoscopy.  Importantly without additional analysis of the histology of 
the lesion(s) it cannot take into account the extent of lesion depth (invasiveness) or 
other features such as the presence of inflammatory or neuronal cells.”  
The four stages are:-  
Stage I (Minimal):- characterised by superficial lesions and possibly few filmy 
adhesions. 
Stage II (Mild):- as above, plus some deep lesions in cul-de-sac. 
Stage III (Moderate):- in addition, the presence of endometriomas on the ovary and 
more adhesions. 
Stage IV (Severe):- as above plus large endometrioma(s) and extensive adhesions 
(Figure  1-3).  
“This classification system assesses lesions and adhesions in the pelvic organs and the 
staging assesses physical disease only not the severity of pain or other symptoms 
(Canis et al., 1997). Furthermore, it will not provide any estimate of the presence of 
adenomyosis, a condition where endometrial tissue invades the surrounding 
myometrial tissue which is reported to occur in many women with endometriosis 




Figure  1-3:- Dense peri-tubal adhesions in advanced endometriosis (Endo-Resolved, 
2017) 
 
1.2. Epidemiology of endometriosis 
“Worldwide it has been estimated that  approximately 176 million women may have 
endometriosis (Adamson et al., 2010), endometriosis has a prevalence of 0.5–5% in 
fertile and 25–40% in infertile women (Ozkan et al., 2008). In the UK, endometriosis 
is thought to affect 1.5 million women (www.endometriosis-uk.org) and is 
responsible for approximately 10% of all gynaecological consultations (Bijlani and 
Sonaware, 2012).” 
However, the exact prevalence of endometriosis is not known since a laparoscopy is 
necessary to make the diagnosis, and since the recognition of lesions may vary 
between laparoscopic surgeons (Phillippe, 2011).  
The exact prevalence of endometriosis in asymptomatic women is also not yet 
known. However, it is estimated between 3 and 45% of women were diagnosed with 
endometriosis during laparoscopic sterilisation (Rawson, 1991). This data highlights 
that endometriosis might be a more common finding in asymptomatic fertile women 
than previously expected.  
“It has also been suggested that there is a rise in endometriosis amongst women of 
reproductive age (Viganò et al., 2004). Several epidemiological studies have also 
shown that there are groups of women at a higher risk of developing this condition, 
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such as nulliparous women, women with heavy menstrual bleeding and women with 
short menstrual periods. (Viganò et al., 2004).”  
“The risk of developing endometriosis is influenced by both environmental and 
genetic factors and it is estimated that endometriosis is hereditary in about 51% of 
the cases. The contribution of genetic factors has been supported by many studies 
(Simpson and Bischoff, 2002, Treloar et al., 2002, Vigano et al., 2003, Zondervan et 
al., 2001). Four Genome-wide association studies have been published for 
endometriosis, two in populations of European descent (Painter et al., 
2011; Albertsen et al., 2013) and two in Japanese populations (Adachi et al., 
2010; Unoet al., 2010). Genome-wide significant signals were reported in three of 
these studies.” 
1.3. Aetiology of endometriosis 
“The reason why some, but not all, women develop symptomatic endometriosis is still 
poorly understood but remains a subject of intense research activity (Vitonis et al., 
2014). Several theories have been proposed for its aetiology, including retrograde 
menstruation, altered immunity, germinal epithelium metaplasia and hormone 
components (Macer and Taylor, 2012). In their elegant review, Burney and Giudice 
(Burney and Giudice, 2012) provided a useful summary of the different theories for 
the development of endometriosis lesions as shown in Figure  1-4.” 





“One of the most widely quoted theories is that of ‘retrograde menstruation’, which 
was proposed by Sampson (Sampson, 1925) which is based on evidence that, during 
menstruation, some of the shed endometrial tissue can end up in the peritoneal cavity 
by passing via fallopian tubes and will subsequently attach to the peritoneal surface, 
establish a blood supply, proliferate and produce endometrial deposits (Giudice and 
Kao, 2004). This theory might explain the higher incidence of endometriosis in 
young girls with outflow obstruction (Nunley et al., 1980).” 
As retrograde menstruation may occur in the majority of women, additional 
mechanisms are needed to explain why lesions do not form in all of them. It has been 
proposed that cell-mediated immunity is deficient in women with endometriosis and 
that the lesions are not therefore eliminated. One example is evidence that as white 
blood cells (WBC) are unable to recognise that endometrial deposits are not in its 
normal place (Oosterlynck et al., 1991). Moreover, there is also a rise in the number 
of WBC and macrophages inside and around the endometrial deposits, these cells 
secrete different growth factors and cytokines, which in turns increase the vascular 
supply of endometrial implants (Harada et al., 2001). These factors have growth-
promoting effect on endometriotic implants and as a result elevated peritoneal fluid 
level of cytokine which enhances the spread and progression of endometriotic 
deposits in the peritoneal cavity, this may not only be an initiating factor that helps 
adhesion of endometrial cells to the peritoneum but may also contribute to 
development and progression of endometriosis. Once endometriosis is established, 
the immune system is shown to increase the development, progression and severity 
of the disease (Harada et al., 2001). 
“A prospective laboratory study aiming to determine the effects of endometriotic 
haptoglobin on peritoneal macrophage function showed that, in vivo, there were 
significantly more peritoneal macrophages bound to haptoglobin, reduced 
macrophage phagocytic function and decreased adhesions in women with 
endometriosis in comparison with women without endometriosis. In vitro, 
haptoglobin treatment dramatically reduced peritoneal macrophage adherence only in 
women without endometriosis. It concluded that endometriotic deposits produce a 
distinctive type of haptoglobin which is up-regulated by interleukin-6. Interleukin-6  
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increases endometriotic haptoglobin and promotes the development of endometriosis 
(Sharpe-Timms et al., 2002). There is also an increase in macrophage-derived 
products, in women with endometriosis, which associated with a rise in cell 
adhesion, proliferation and neovascularisation (Young et al., 2013).”  
“Twin and family-based studies have also shown that there is consistent evidence to 
support a hereditary component of endometriosis, but no ‘faulty’ gene has been 
found (Nyholt et al., 2012). Women with a first-degree family member affected by 
endometriosis have a seven times greater risk of developing the disease than women 
without a family history (Simpson et al., 1980). Genome-wide association meta-
analysis of more than 4,600 women with endometriosis and nearly 9,400 controls of 
European and Japanese ethnic descent, showed that there is an association of 
rs7521902 at 1p36.12 near WNT4 (which involves in cell differentiation), and of 
rs13394619 in GREB1 (is oestrogen dependant) at 2p25.1 with endometriosis, and a 
newly associated locus at 12q22 near VEZT (involves in cell communication) was 
identified (Nyholt et al., 2012).”  
“In a Greek study of 166 women with histologically confirmed endometriosis versus 
150 healthy controls, investigated whether single nucleotide polymorphisms  
rs7521902, rs10859871 and rs11031006, mapping to WNT4, VEZT and FSHB 
genetic loci, respectively, are linked to risk of developing endometriosis. A 
substantial relationship was found with the AC genotype of rs7521902 (WNT4) in 
patients with stage III and IV disease only. Evidence for association with 
endometriosis was also detected for the AC genotype of the rs10859871 of VEZT. 
WNT4 and VEZT genes constitute the most constantly related genes with 
endometriosis (Matalliotakis et al., 2017).”  
Germinal epithelium metaplasia might also play a role in the pathogenesis of 
endometriosis, this theory can be explained in different ways including the 
undifferentiated cells in the peritoneum which can differentiate into endometrial cells 
or that menstrual flow travels from the uterine cavity via lymphatic channels and 
veins to distant places, which could attribute to lesions present outside the pelvic 
cavity (Vinatier et al., 2001). Furthermore, different lifestyle exposures which may 
increase or decrease the level of oestrogen can affect risk, such as exercise and 
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smoking reduce the risk, whereas consumption of alcohol or caffeine is associated 
with increased risk of this condition (Cramer and Missmer, 2002). 
A literature review on the potential roles of mesothelial peritoneal cells in the 
development and maintenance of PE showed that several studies indicate that 
differential expression of peritoneal mesothelial adhesion factors occurs in women 
with endometriosis. These cells might also increase lesion invasion and formation of 
fibrotic tissue in and around the endometriotic deposit (Young et al., 2013).   
“Stem cells are undifferentiated type of cells, with the ability to self-differentiate and 
renew into numerous types of specialised cells (Kato, 2012). As the basalis layer of 
the endometrium is not shed with the monthly menstrual shedding of the functional 
layer, the stem cells are believed to be present in this layer of the endometrium 
(Padykula et al., 1989) and the monthly re-development of the endometrium after 
menstrual bleeding, surgical curettage or re-epithelialisation after delivery supports 
the existence of a stem cell pool (Tsuji et al., 2008). Stem cells involved in the 
formation of endometriotic lesions could be due to abnormal translocation of normal 
basalis layers via retrograde menstruation (Masuda et al., 2010).” 
Uterine bleeding in the new-born is the most ignored type of uterine bleeding which 
is hardly recorded or noticed for any further investigations. A search of the old 
German and French literature showed that vaginal bleeding occurs on days three to 
five of neonate’s life and is noticeable in only 3%–5%; however, from the post-
mortem findings, occult bleeding happens in up to 60% of new-born (Brosens et al., 
2013). In the neonates, it seems that both cervico-vaginal anatomy and functional 
outflow obstruction lead to tubal regurgitation as the amount of vaginal bleeding is 
not representing the actual endometrial shedding (Varol et al., 2003) which might 
support the hypothesis that retrograde bleeding in the new-born might be the cause of 
endometriosis in young girls.  
“In a cross-sectional survey of 3680 United State of America (USA) women with a 
surgical diagnosis of endometriosis; hypothyroidism, chronic fatigue syndrome, 
fibromyalgia, allergies, autoimmune diseases and asthma were all significantly 
higher in women with endometriosis than in women in the general USA population. 
The theory of altered immune might explain the association between autoimmune 
diseases and endometriosis (Sinaii et al., 2002).  
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1.4. Symptoms of endometriosis 
“The two most widely reported symptoms of endometriosis are chronic pelvic pain 
(CPP) and sub- or infertility (Giudice, 2010): both these symptoms lead to significant 
healthcare costs and reduced QOL (Simoens et al., 2012).” 
Endometriosis lesions are reported to occur in up to 50% of symptomatic women 
attending infertility clinics (Zondervan et al., 2001, Meuleman et al., 2009). 
Endometriosis-associated pain can have a significant and debilitating impact on 
QOL; pain may be cyclical or constant including pelvic pain, pain during intercourse 
(dyspareunia) and menstruation (dysmenorrhea) with the latter being one of the most 
common symptoms in younger women (Harada, 2013). Additional symptoms may 
include cyclical intestinal complaints, pain and/or bleeding during micturition, 
depression and fatigue (Mirkin et al., 2007).  
The severity of the symptoms does not map to the stage of the disease, therefore a 
patient with initial stages (I or II) might present with very severe symptoms and signs 
of the disease, whereas a patient with advanced stages may experience mild 
symptoms or ever discover the disease accidentally during other procedures. 
 Endometriosis-associated pain 1.4.1.
Endometriosis-associated pain is not always cyclical (Table  1-1), might not be 
confined to the pelvis and is common in the lower back (Kennedy et al., 2005). The 
probability of diagnosis and the severity of symptoms increase with age and 
generally, it presents early in childbearing age and improves after menopause 
(Kitawaki et al., 2002). 
“A large, case-control, primary care-based study of 5540 women revealed that patients 
with endometriosis were 13 times more likely to report pain in the pelvis, ten times 
more likely to have dysmenorrhoea, seven times more likely to report dyspareunia, 
twice as likely to report urinary symptoms, and twice as likely to have dyschezia or 
rectal bleeding (Ballard et al., 2008). In young women with suspected endometriosis, 
other diagnosis should be considered (Bulletti et al., 2010) see Table  1-1.”   
21 
 
Table  1-1:- Common clinical presentations of endometriosis and other differential 
diagnoses 
Endometriosis symptom Other differential diagnoses 
Recurrent dysmenorrhoea Adenomyosis, physiological 
Dyspareunia Psychosexual problems, vaginal atrophy 
Painful micturition Cystitis 
Dyschezia Constipation, anal fissures 
Chronic lower abdominal pain Irritable bowel syndrome, neuropathic pain, 
adhesions 
Chronic lower back pain Musculoskeletal strain 
Adnexal masses Benign and malignant ovarian cysts, hydrosalpinges 
 
“In the study by Vercellini (Vercellini et al., 2007) the relationship between the 
reported stages of endometriosis, type of lesion and the severity of pain, as 
determined using the visual analogue scale (VAS) measurement tool was studied in 
1054 women with endometriosis over 16 years. The primary purpose of this study 
was to determine whether there was a correlation between the location of 
endometrial deposits and specific symptoms and also to assess the statistical power 
of revised American Fertility Society classification (rAFSC) in symptomatic women 
with this condition. Table  1-2, a comprehensive list of literature data 1990-2006, 
summarised the results of the study and reported a strong association between 
posterior cul-de-sac lesions and dyspareunia and substantial inverse association 
between age at surgery and dyspareunia, moderate-to-severe dysmenorrhoea and 
non-menstrual pain. A correlation between severity of symptoms and endometriosis 
stage was only reported for dysmenorrhoea and non-menstrual pain. It concludes that 
the association between severity of pelvic symptoms and endometriosis stage was 





Table  1-2:- Association between endometriosis stages or lesions according to the 








stages or lesions and 
pain symptoms 




No (stage: severity and 
frequency of pain 
symptoms) 
(Cornillie et al., 1990) 179 
Infertility, 
pain 
Yes (depth of 
endometriosis: pelvic 
pain) 
(Koninckx et al., 1991) 452 
Infertility, 
pain 
Yes (depth and volume 
of endometriosis: pelvic 
pain) 
(Mahmood et al., 1991) 201 Various 
No (stage: frequency of 
pain symptoms) 




No (stage, site and type 
of lesions: severity of 
pain) 




Yes (deep lesions: pain) 
No (stages: severity and 
frequency of pain 
symptoms) 
(Stout et al., 1991) 102 Various 











stages or lesions and 
pain symptoms 
(Vercellini et al., 1991) 73 Pain 
Yes (typical lesions: 
deep dyspareunia) 
No (stages: frequency 
and severity of pain 
symptoms) 
(Fedele et al., 1992) 
 
124 Infertility 
Yes (stages III–IV: 
dysmenorrhoea, non-
menstrual pain) 





Yes (severity of 
dysmenorrhoea: number 
of implants) 
No (severity of 
dysmenorrhoea: 
location of implants) 
(Matorras et al., 1996) 
 
174 Infertility 
No (stage: frequency of 
pain symptoms) 
(Vercellini et al., 1996) 
 
244 Pain 
Yes (deep vaginal 
lesions: dyspareunia) 
No (stage: severity and 
frequency of pain 
symptoms) 






Yes (AFS * score: 
severity of 
dysmenorrhoea) 
(Stovall et al., 1997) 
 
48 Pain 
Yes (stage: severity of 











stages or lesions and 
pain symptoms 






Yes (adhesions and 
deep lesions: severity of 
pain) 
No (stage: severity and 
frequency of pain 
symptoms) 
 
(Parazzini et al., 2001) 
 
469 Pain 
No (stage, type, site: 
frequency and severity 
of pain) 
(Fauconnier et al., 2002) 
 
225 Pain 
Yes (specific types of 
pain: site of deep 
lesions) 
(Chapron et al., 2003) 
 
209 Pain 










Yes (deep uterosacral 
ligament lesions: 
dyspareunia) 
(Szendei et al., 2005) 
 
181 Pain 
No (stage: severity of 
pain symptoms) 
(Parazzini et al., 2006) 574 Pain 
No (endometriosis-
associated adhesions: 
severity of pain 
symptoms) 
(Milingos et al., 2006) 95 Pain 
Yes (AFS * score: 
severity and frequency 
of dysmenorrhoea and 
deep dyspareunia) 
 * AFS American Fertility Society   
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 Endometriosis and chronic pelvic pain 1.4.2.
Pain, acute or chronic, is a very distressing experience. Pain experience is private, 
subjective and multi-dimensional and is quite difficult to measure (Melzack, 1987). 
The number of women presenting with CPP in primary care is as common as lower 
back pain or migraine (Zondervan et al., 1999) and it impacts significantly on a 
woman’s ability to function (Grace and Zondervan, 2006).  
The mechanisms to explain why the presence of endometriosis lesions results in 
increased sensitivity or perception of painful symptoms remain poorly understood 
but potential mechanisms include inflammation, local bleeding, hormonal 
stimulation of endometriotic lesions, stimulation of neural pathways, or a mixture of 
all the above-mentioned factors (Morotti et al., 2017). It is also notable that central 
nervous system sensitisation to painful stimuli can cause CPP even without 
continuing stimulation and this may explain the persistence of pain in women even 
after hysterectomy or removal of lesions (Apkarian et al., 2005, Kaya et al., 2013, 
Tracey and Bushnell, 2009). 
“Endometriosis is one of the most common diseases which associated with CPP, 58% 
of women with endometriosis had abdomino-pelvic pain (Hickey, 2014). CPP is a 
symptom rather than a diagnosis and definitions of CPP are based on its anatomical 
location, duration, behavioural and psycho-emotional aspects (Mathias et al., 1996). 
It is defined as constant or intermittent pain in the lower abdomen or pelvis for at 
least a six-month period, not happening solely with intercourse or menstruation and 
not related to pregnancy (Grace and Zondervan, 2006).”  
Based on RCT against placebo, endometriosis appears to be responsible for CPP in 
more than half of histologically confirmed cases. This association may be due to 
repeated cyclical micro-bleeding in the endometriosis deposits or a result of DE 
compresses or infiltrates sub-peritoneal pelvic nerves (Fauconnier et al., 2009). The 
DE-associated painful symptoms characterised by involvement of specific 




 Endometriosis and dysmenorrhoea 1.4.3.
“In a cross-sectional questionnaire-based survey among 931 women with 
endometriosis treated in 12 tertiary care centres in ten countries, dysmenorrhoea was 
reported by 59% of them and QOL was reduced in all dimensions, in comparison 
with normal scores (De Graaff et al., 2013).”  
“In a prospective blind study of 65 women with endometriosis diagnosed at 
laparoscopy for pain, adnexal mass or infertility, patients completed a preoperative 
questionnaire to assess the severity of their dysmenorrhea by means of a 10-point 
linear analog scale. Results showed that there was a substantial association between 
the linear score for painful periods with the partial score for adhesions, partial score 
for DE and the total endometriosis score (Muzii et al., 1997).” 
“In their interesting review Laux-Biehlmann and colleagues (Laux-Biehlmann et al., 
2015) provided an overview of the mechanisms that might link inflammation and 
pain perception in women with endometriosis lesions entitled ‘Menstruation pulls the 
trigger for inflammation and pain in women with endometriosis’ and speculated that 
this new understanding might stimulate new therapies for pain (Laux-Biehlmann et 
al., 2015).” 
 Endometriosis and dyspareunia 1.4.4.
Endometriosis is associated with deep dyspareunia which can occur during or shortly 
after intercourse (Meana and Binik, 2011). In comparison to the general female 
population, patients with endometriosis are at nine-times more likely to report this 
problem (Ballard et al., 2008). Endometriosis-associated deep dyspareunia typically 
occurs when endometriotic deposits infiltrate the posterior vaginal fornix, anterior 
rectal wall, cardinal ligaments, uterosacral ligaments or pouch of Douglas. This type 
of pain can be explained as a result of traction of fibroid tissue, pressure on the 
endometriosis deposits and immobility of pelvic organs (Vercellini et al., 2011).  
Endometriosis-associated dyspareunia can interfere with a woman’s sexual 
relationships which is an essential aspect of QOL and health (Garratt et al., 1995). 
Painful intercourse was reported as a problem for approximately 56% of patients 
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with endometriosis and 50% of these women reported that their relationships had 
been affected at some time during their life (De Graaff et al., 2013). 
 Endometriosis and mood 1.4.5.
“Women with endometriosis are at increased risk of developing depression and 
anxiety, which ultimately affects their social life and career productivity. It has been 
established that levels of depression and anxiety can represent the pain severity and 
have a negative impact on the perception of pain (Sepulcri and do Amaral, 2009). 
The prevalence of depression in endometriosis patients with and without CPP was 
found to be high, but it was higher amongst women with CPP, with 86% and 38% 
respectively (Lorencatto et al., 2006).  On the other hand, patients with CPP, with or 
without endometriosis, were found to be depressed, socially withdrawn and have an 
impaired QOL (Kumar et al., 2010).” 
“A prospective study of over 100 women diagnosed with pelvic endometriosis was 
conducted to evaluate depressive symptoms. The Beck Depression Inventory and the 
Hamilton Rating Scale for Depression were used to evaluate depressive symptoms. 
Whereas, the Spielberger State-Trait Anxiety Inventory and the Hamilton Anxiety 
Rating Scale were used to evaluate anxiety symptoms; and to evaluate the QOL, the 
short version of the World Health Organization QOL Instruments were used 
(Sepulcri and do Amaral, 2009). From the patients examined in this study, 87.5% 
experienced anxiety, 86.5% presented with depressive symptoms and pain and 38% 
of women had depressive symptoms without pain and QOL was found to be 
substandard.” 
 Endometriosis and fatigue 1.4.6.
Women with endometriosis may enter a chronic cycle whereby fear of pain and 
injury leads them to be less active; they feel that pain increases with activity and this 
leads women to avoid exercise, resulting in a vicious and chronic pain-fatigue cycle. 
It is very important to stop this vicious cycle of pain and fatigue and to introduce 
exercise and a physical rehabilitation programme tailored to the need of these women 
(Mendes and Figueiredo, 2012).   
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“In 1998, in the USA, a cross-sectional survey was conducted in 3680 women with a 
surgical diagnosis of endometriosis. In comparison with the general female 
population, patients with endometriosis were at a higher risk of developing 
fibromyalgia (5.9 versus 3.4%, P-value of less than 0.0001) and chronic fatigue 
syndrome (4.6 versus 0.03%,  P-value of less than  0.0001)  (Sinaii et al., 2002). Up 
to 20% of these women had at least one co-morbidity, with approximately 31% 
diagnosed with chronic fatigue syndrome and/or fibromyalgia.”  
 Endometriosis and infertility 1.4.7.
It is estimated that 25–50% of women with infertility have endometriosis and 
approximately 30–50% of patients with endometriosis are infertile (Macer and 
Taylor, 2012). The reasons why some women have endometriosis-associated 
infertility may include endocrine disturbances, anatomical distortions due to 
adhesions in more severe disease as shown in Figure  1-3 or alterations in immune 
cell function. In some circumstances, some or all of these factors appear to act 
together through mechanisms so far not completely identified (Tanbo and Fedorcsak, 
2017). 
All stages of endometriosis can affect women’s ability to conceive. Fertility can be 
impaired in mild endometriosis as a result of peritoneal inflammation, whereas 
severe disease can reduce ovarian reserve, block fallopian tubes, affect oocyte and 
embryo quality and affect implantation (Macer and Taylor, 2012). Endometriosis can 
also damage fertility by disturbing the function of the fallopian tubes, reduced 
endometrial receptivity and affect embryo transport (Macer and Taylor, 2012). 
Common observations at laparoscopy showed that distortion of the pelvic anatomy 
can explain infertility in women with advanced stages of endometriosis. The tubo-
ovarian connection can be disrupted by peri-tubal and pelvic adhesions and these 
adhesions can prevent ovum pickup, or inhibit ovum transport (Schenken et al., 
1984). Ovulatory and endocrine disorders can cause infertility in women with 
endometriosis due to impaired folliculogenesis, luteal phase defect, luteinised 
unruptured follicle syndrome and premature luteinising hormone surges (Medicine 
and Technology, 2009). 
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“Fazleabas group have developed a baboon model of endometriosis by inoculating 
autologous menstrual endometrium intraperitoneal which results in the development 
of endometriotic deposits similar to those in the human. Several factors have been 
implicated in endometriosis-associated infertility including dysregulation of proteins 
involved in invasion, methylation, immunomodulation, angiogenesis, cell growth, 
and steroid hormone action. These factors reduce apoptotic potential, improve 
angiogenic capacity, estrogen hyper-responsiveness, progesterone resistance and 
inability to respond appropriately to embryonic signals. These changes contribute to 
the decreased fertility in women with endometriosis. In addition, baboon models of 
endometriosis have given specific insights into the role of endometriotic lesions in 
infertility (Hastings and Fazleabas, 2006).” 
“The endometrium maintains complex controls on apoptosis and proliferation and as 
part of repetitive menstrual cycles to prepare the endometrium for implantation and 
pregnancy. A large number of studies have investigated mechanisms to explain why 
the eutopic endometrium of women with endometriosis may be less receptive to the 
blastocyst or less able to sustain a pregnancy which causes infertility and abnormal 
bleeding. These have been reviewed by Lessey and Kim with key findings including 
‘progesterone resistance’ and estrogen dominance through aberrant cell signalling 
pathways (Lessey and Kim, 2017) which highlights that eutopic endometrium is 




1.5. Natural history of endometriosis 
It is very difficult to understand the natural course of symptomatic endometriosis as 
nearly all adolescent girls report having painful cycles and it is not possible to 
confirm whether this is or is not due to endometriosis without invasive procedures 
(Hickey, 2014). Although it is widely believed that endometriosis is a benign 
progressive disorder, the factors which regulate the progression are still unknown, it 
might be a result of apoptotic resistance and local invasion (Anglesio et al., 2017). 
Observational studies for untreated women with fertility issues pointed out that a 
third of these women have spontaneous regression, whereas approximately 50% 
progressed over a period of 6–12 months. Furthermore, it is not clear if prompt 
intervention decreases the spread of this disease (Harrison and Barry-Kinsella, 2000).    
“A high percentage of women with endometriosis, about 96.9% reported becoming 
pain-free after menopause (Fagervold et al., 2009). However, endometriosis has been 
reported in women after the menopause (Bulun et al., 1999) and in some 
circumstances, adolescents might have the symptoms and manifestations of 
endometriosis in advance of menarche (Marsh and Laufer, 2005). In a case series of 
five pre-menarcheal girls with CPP where all had laparoscopic biopsies, results show 
the presence of lesions consistent with endometriosis in these groups of girls, without 
an obstructive anomaly. This supports the theory that some cases of endometriosis 
might be due to other aetiologies than retrograde menstruation (Marsh and Laufer, 
2005).” 
Endometriotic deposits have estrogen receptors and aromatase, the latter is an 
enzyme that helps the formation of estrogens from androgens, which suggests that 
production of local estrogen may stimulate the growth of endometriotic implants. 
The expression patterns of progesterone receptors and ER in endometriotic implants 
are different from those in the eutopic endometrium. Furthermore, estrogen 
metabolism is altered in the eutopic endometrium of women with disease in 
comparison to women without endometriosis, which might explain persist of 
endometriosis in the presence of low circulating levels of estrogen as seen after 
menopause (Kitawaki et al., 2002). 
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“Some studies have suggested that there is a small but consistent association between 
endometriosis and ovarian carcinoma, which known as endometriosis-associated 
ovarian cancer (Pearce et al., 2012). A meta-analysis revealed that patients with 
endometriosis might have double the lifetime risk of developing ovarian cancer 
which is usually characterised by early-stage, low-grade disease and a specific 
histology (endometrioid or clear cell carcinoma). Furthermore, once ovarian cancer 
has developed, endometriosis has no effect on its progression (Kim et al., 2014). 
These findings clarify why earlier studies have suggested better prognosis of 
endometriosis-associated ovarian cancer  (Eržen et al., 2001). 27 patients with DE 
were analysed (24 by exomewide sequencing and 3 patients by cancer-driver 
targeted sequencing). It was found that DE deposits, with no risk of malignant 
transformation, harbour somatic cancer driver mutations. The tested somatic 
mutations seemed to be restricted to the epithelial part of endometriotic deposits 
(Anglesio et al., 2017).” 
1.6. Diagnosis of endometriosis 
A preliminary diagnosis of suspected endometriosis may be inferred from women’s 
symptoms alone. However as a number of the common endometriosis-associated 
symptoms are identical or very similar to other gastrointestinal, urological or 
gynaecological diseases, including irritable bowel syndrome, pelvic floor spasm and 
painful bladder syndrome, a definitive diagnosis can only currently be given 
following surgical investigation (Kennedy et al., 2005). The time to diagnosis from 
the first presentation of symptoms can range from four to ten years (Arruda et al., 
2003). There are currently no accurate non-invasive diagnostic tests, ultrasound  
scans or magnetic resonance imaging (MRI) or biomarkers for endometriosis and 
direct visualisation by laparoscopy confirmed by histological examination remains 
essential for diagnosis (Kennedy et al., 2005). In up to one-third of women who had 
a diagnostic laparoscopy, no underlying pathology was found or the identified 
pathology might not necessarily the cause of the pain which can lead to adverse 
consequences on the women, as many women might feel disappointed of not having 
a diagnosis of their symptoms (Howard, 2003). 
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“The European Society of Human Reproduction and Embryology (ESHRE) guidelines 
recommend that HCPs should consider endometriosis if women of childbearing age 
present with non-gynaecological cyclical symptoms, such as dysuria, dyschezia, 
shoulder pain, rectal bleeding and haematuria; or present with gynaecological 
symptoms including non-cyclical pelvic pain, dysmenorrhoea, deep dyspareunia, 
infertility and fatigue, with any of the above symptoms (Dunselman et al., 2014b).” 
A comparative study among bimanual examination, transvaginal ultrasonography, 
and MRI, suggested that clinical examinations are deficient in sensitivity and 
specificity in diagnosing endometriosis with less than 50% accuracy, whereas 
vaginal ultrasonography was superior to MRI in sensitivity, specificity and accuracy 
(Abrao et al., 2007).  
In the following sections, the currently available non-invasive diagnostic tests are 
briefly reviewed. 
 Serum CA-125 1.6.1.
CA125 is the most widely used tumour marker in ovarian cancer. The normal range 
is less than 35 U/ml. It is raised in greater than 90% of patients with advanced 
epithelial ovarian cancer and in around 50% of patients with stage one disease. 
Moreover, it is more associated with serous, rather than mucinous tumours.  It is also 
used in monitoring the progress of patients with epithelial ovarian cancer and 
recurrence (Gupta and Lis, 2009). Serum CA-125 levels might be raised (35 IU/ml or 
more) in some patients with endometriosis as a result of inflammation. However, 
endometriosis may be present despite a normal serum CA125 (NICE, 2017).  This 
serum marker might have value in detecting advanced stage disease, particularly DE 
and endometriomas (Lanišnik Rižner, 2014). Nonetheless, the absolute level of the 
analyte seems to lack satisfactory sensitivity to help in PE and as a result, quantifying 
serum levels of this marker neither diagnoses nor excludes the disease and routine 
testing is not recommended (Hickey, 2014). 
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 Pelvic ultrasound  1.6.2.
A systematic review reported that pelvic ultrasound, mainly transvaginal, can 
identify OE cysts (endometrioma), but that the absence of ovarian cysts cannot 
eliminate the diagnosis of endometriosis (Dunselman et al., 2014b). However, a scan 
cannot reliably detect the depth of infiltration by lesions or small endometriotic 
deposits (less than 1 cm in size). Transrectal ultrasonography and transvaginal 
ultrasonography with bowel preparation can detect deep infiltrating lesions affecting 
the bladder, bowel and rectovaginal pouch (Van Holsbeke et al., 2010). 
 Magnetic resonance imaging  1.6.3.
Pelvic MRI has been used to detect large sub-PE nodules; however, certain factors 
can mask the appearance of small deposits, such as endometrioma, distorted pelvic 
anatomy, bowels and retroverted uterus (Sutton et al., 2005). Pelvic MRI should be 
considered to assess the extent of DE affecting bladder, bowel or ureter and with 
contrast enema, it can be valuable in detecting colorectal invasion (Abrao et al., 
2007). However, comparative studies reveal that MRI is less accurate overall than a 
transvaginal scan in diagnosing endometriosis (Koninckx et al., 2012). Most 
importantly is to ensure that the results are interpreted by a specialist HCP with 
proper training in gynaecological imaging (NICE, 2017). 
 Diagnostic laparoscopy (macroscopic versus histological 1.6.4.
diagnosis) 
“A prospective clinical study of 54 women of reproductive age with CPP, with a total 
of 122 biopsies was obtained from these patients undergoing laparoscopy. Results 
show that endometriosis was confirmed by histology in 54% of the excised deposits. 
The diagnosis was confirmed more often amongst classic endometriotic implants 
than for other atypical lesions. The histologic diagnosis of fibrosis was the most 
common among those biopsies, which lacked the presence of endometriosis. These 
results confirm the need for histologic confirmation to obtain a diagnosis of 
endometriosis and not to relay on macroscopic diagnosis (Marchino et al., 2005).”  
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1.7. Management of endometriosis 
The management of endometriosis is challenging, complex and is often 
unsatisfactory. There is no cure for endometriosis at present and the medical and 
surgical approaches are the main available treatment options for managing the 
symptoms associated with this health condition (Dunselman et al., 2014a).  
Several factors can affect the decision of which treatments are suited to women with 
endometriosis, such as patient’s choice, fertility desire, concerns about long-term 
medical therapy and the availability of laparoscopic surgery and/or the expertise. In a 
recent randomised trial of 450 women with endometriosis who experienced one of 
three different treatment options (medical, surgical, or joint strategies) (Mettler et al., 
2014), results show that joint strategies were the most successful intervention for 
these patients, with a higher disease-free period and pregnancy rates.  
With endometriosis-associated pain, empirical treatments with analgesics and 
hormonal medications can be started before a diagnosis is made. Nevertheless, the 
response to hormonal therapy does not always predict the presence or absence of 
endometriosis. If women are unsatisfied with the treatment or still symptomatic, a 
diagnostic laparoscopy can be offered to either diagnose (and potentially treat) or 
exclude the disease (Dunselman et al., 2014b). Ideally, women with endometriosis 
should have a multi-disciplinary approach to their care.  
 Empirical treatment of endometriosis-associated pain 1.7.1.
“Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the treatments options 
for patients with CPP prior to a diagnosis of endometriosis. NSAIDs reduce the pain 
of primary dysmenorrhoea. However, there are adverse effects with the frequent use 
of these medications, such as gastric ulceration and inhibition of ovulation 
(Marjoribanks et al., 2010). Clinicians should consider a short trial, of three months, 
of NSAIDs or paracetamol alone or together as first-line treatments for 
endometriosis-associated pain. If the trial does not provide a satisfactory pain relief 
or patients do not respond well to these therapies, other treatment options should be 
considered and women to be referred for further assessment (NICE, 2017).” 
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 Hormonal treatments for endometriosis-associated pain 1.7.2.
Treatments targeting the production or action of steroid hormones are widely used 
for endometriosis-associated symptoms. These include progestogens, anti-
progestogens, combined oral contraceptive pills (COC) and gonadotrophin-releasing 
hormone agonist (GnRHa) as shown in Table  1-3. Many of these treatments have 
unwanted side effects that are also summarised in the table. Evidence is limited with 
regard to the comparison between treatments and therefore it is often up to the 
clinician and patient to decide on which is selected (Dunselman et al., 2014a). 
Furthermore, reproductive plan, the severity of symptoms, medical history and 
adverse effect profiles are essential factors in deciding treatment options.  
The currently available medical treatments are contraceptive and as the majority 
interfere with normal ovarian function and production of ovarian steroids, they can 
cause undesirable menopausal-like symptoms as well as unscheduled bleeding 
(Bulun et al., 2000). Some studies showed that approximately 50% of women 
experience recurrence of painful symptoms six months after medical treatment is 
stopped. This might be explained either because large endometriosis deposits react 
poorly to medical therapy, or that endometrioma is not responsive to medical 
intervention, though temporary pain relief might be accomplished (Dunselman et al., 
2014a). 
These hormones work by suppressing ovarian activity and/or reducing endometrial 
shedding at time of menses; however, the extent to which they achieve this differs 
from one type to another (Hughes et al., 2007). If the first choice hormonal treatment 
is not effective, not tolerated or hormonal therapy is contra-indicated, the patient 
should be referred to a gynaecology service, endometriosis centre or paediatric and 
adolescent gynaecology service for investigation and to discuss other treatment 
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1.7.2.1. Combined contraceptive therapies 
Combined oral contraceptives “COC” are widely used for endometriosis-associated 
symptoms and they can be effective in reducing endometriosis-related 
dysmenorrhoea, non-menstrual pain and dyspareunia. COC are generally well- 
tolerated and as some symptom relief may be achieved in the majority of women 
with endometriosis (Moghissi, 1999), they are often the therapy first prescribed to 
younger women even before a definitive diagnosis of endometriosis. Other types of 
combined contraceptive treatments include transdermal patches and vaginal rings 
(Vercellini et al., 2010), both are used as other treatments options for endometriosis-
associated dysmenorrhoea, non-menstrual pain and dyspareunia. 
1.7.2.2. Progestins  
Progestins are steroid hormones produced by the ovarian corpus luteum after 
ovulation; they can alter cell function by binding to progesterone receptors. 
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Progesterone receptors are expressed in the endometrium during the follicular and 
secretory phases of the cycle and the primary action(s) of endogenous progesterone 
are to reduce oestrogen-dependent cell proliferation and stimulate decidual 
transformation of the tissue (Wang et al., 1998). ESHRE guidelines recommend the 
use of different types of progestogens, (oral, injection or levonorgestrel intrauterine 
system “IUS”), the latter can remain in the uterus for up to 5 years (Jeng et al., 2014). 
Different types of progestogens have different side effects; oral 
(medroxyprogesterone) is associated with irregular menstrual bleeding, an injection 
(Depo-Provera) can be given every 12 weeks and is linked with weight gain and 
depression, whereas IUS can lead to persistent abdominal pain (Lockhat et al., 2005). 
1.7.2.3. Levonorgestrel intrauterine system  
The levonorgestrel intrauterine system (LNG-IUS) significantly reduces the risk of 
recurrence of moderate and severe endometriosis-associated dysmenorrhea, if 
inserted after surgery for symptomatic endometriosis (Petta et al., 2005).  
In one RCT study, only 10% of women who had a LNG-IUS inserted after operative 
laparoscopy had moderate or severe dysmenorrhoea, in comparison with 45% of 
patients who had laparoscopy only (Vercellini et al., 2003). In another clinical trial of 
82 patients with endometriosis, it showed that LNG-IUS had similar effectiveness to 
GnRHa, with the advantages of the long-term use of this system and fewer side 
effects (Petta et al., 2005). 
1.7.2.4. Gonadotropin releasing hormone agonist  
Gonadotropin-releasing hormone agonists (GnRHa), such as buserelin or goserelin 
are usually given via intramuscular or subcutaneous injection and they work by 
inducing an artificial menopause, alternatively, they can be delivered via a nasal 
spray (Olive, 2008). GnRHa side effects include dry vagina, mood swings, low libido 
and effects on bone density.  
ESHRE guidelines recommend adding hormone replacement therapy (HRT) for 
women on the prolonged use of GnRHa to prevent these side effects and extend its 
use without reducing treatment efficacy (Farmer et al., 2003). Alternatively, COC, 
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progestogens and LNG-IUS are as effective as the GnRHa and can be used long-term 
with less adverse effects. GnRHa is also used to ‘trial’ how women may react to 
surgical menopause, but the predictive value of this approach is still unknown 
(Brown et al., 2010). 
 Aromatase inhibitors 1.7.3.
Aromatase inhibitors (AIs) work via inhibiting the production of oestrogen 
selectively in endometriotic deposits. Women with rectovaginal endometriosis type 
pain, who are refractory to all medical or surgical therapies, can be offered AIs, if 
they are combined with hormonal treatments, such as progestogens, COC, or 
GnRHa. AIs reduce the pain severity and improve QOL of this type of endometriosis 
(Ferrero et al., 2011).  
AIs are associated with serious adverse effects when used alone, such as 
osteoporosis, arthritis and adrenal insufficiency (Attar and Bulun, 2006). They 
should only be used when all other treatment options are exhausted and women need 
to be reassured that the chance of having these side-effects in combination with 
hormonal contraceptive is remarkably low.   
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  Surgical treatment 1.7.4.
Surgical treatment of endometriosis is usually performed using a laparoscopic 
approach and requires proper training and skill, as well as the involvement of a 
multidisciplinary surgical team if the disease affects the ureters, bowel and other 
organs to avoid surgical complications and associated morbidity. It has been reported 
that surgical treatments, whilst they may be effective in the short term, do carry risks 
and may be associated with up to 75% recurrence rate after two years (Tanos, 2013). 
Surgical intervention is recommended in women with suspected endometriosis, 
where first-line treatments (NSAIDs and hormonal treatment) have failed. Other 
indications for laparoscopy include pain resulting in days off school or work, severe 
pain over several months, or pain requiring admission to hospital (Vercellini et al., 
2000). At laparoscopy, the extent of the disease can be classified using rASRM.  
1.7.4.1. Ablation versus excision 
“When endometriosis is recognised at the time of surgery, removal through ablation or 
excision or even both, i.e. ‘see and treat’, is considered effective in controlling 
endometriosis-associated symptoms (Jacobson et al., 2009). Laparoscopy and open 
surgery are similarly effective in managing endometriosis-associated pain; however, 
women and clinicians commonly prefer laparoscopy to laparotomy as it is associated 
with a shorter hospital stay, quicker recovery, less pain and better cosmetic outcome 
(Wright et al., 2005). An updated recent systematic review and meta-analysis shows 
that at 12 months post-surgery, endometriosis-associated symptoms (dysmenorrhea, 
CPP and dyschezia) showed a significantly greater improvement with laparoscopic 
excision compared with ablation (Pundir et al., 2017).” 
1.7.4.2. Laparoscopic ovarian cystectomy  
Cystectomy is recommended for OE, rather than drainage or coagulation because the 
former method decreases endometriosis-associated pain (Hart et al., 2008). 
Furthermore, surgical removal of the cyst is preferred to carbon dioxide laser 
vaporization as the recurrence rate is reduced following cystectomy (Carmona et al., 
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2011) and women can be reassured that there is no evidence that cystectomy can 
reduce ovarian reserve (Hart et al., 2008).  
1.7.4.3. Deep endometriosis 
Surgical intervention for DE seems to be effective and possible as it improves QOL 
and reduces pain. However, the complication rate is significantly high, mainly when 
the bowels or ureters are involved (Kondo et al., 2011). Women should be referred to 
endometriosis centre if they have confirmed or suspected endometriosis which 
involves other structures (bladder, bowel or ureter) and MRI scan should be offered 
before surgery for the depth of the invasion and consider 3 months of GnRHa prior to 
operative laparoscopy (NICE, 2017). 
To reduce the risk of injuries, it is recommended that women with diagnosed or 
suspected DE are referred to an expert centre that offers all existing treatment 
options, including advanced laparoscopy or laparotomy for this advanced type of 
endometriosis (De Cicco et al., 2011). In RCT of 90 patients with DE comparing 
oestrogen-progesterone combination versus norethindrone acetate for post-surgical 
pain, results showed significant decreases in dysmenorrhoea, dyspareunia and pelvic 
pain after one year of interventions without major between-group differences 
(Vercellini et al., 2005).  
1.7.4.4.  Treatments for endometriosis-associated infertility 
“Treatment choices for women with endometriosis-associated infertility should 
consider woman’s age, ovarian reserve and the extent of disease, the presence of 
endometriomas, pelvic anatomy, male factors and duration of infertility. Choices 
consist of expectant management, in-vitro fertilisation (IVF) or surgical treatments. 
The management of endometriosis-related subfertility should involve 
multidisciplinary team and input from fertility experts, this should include 
preoperative tests and the recommended diagnostic fertility tests (NICE, 2017).” 
A systematic review concluded that, in patients with endometriosis-associated 
subfertility who are trying to conceive, medical treatment is better to be avoided as it 
delays conception and does not improve fertility (Hughes et al., 2007). However, the 
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only exception is patients with the advanced disease, in this case, three months of 
treatment with COC or GnRHa before IVF, improves fertility rates (Sallam et al., 
2006). A subsequent systematic review of laparoscopic intervention in patients with 
endometriosis-associated subfertility showed an enhancement in pregnancy rate 9–12 
months after surgery (Dunselman et al., 2014a).  
“The recommendation is to offer excision or ablation of endometriotic deposits, not 
involving the bladder, bowel or ureter, with adhesiolysis as it increases the chance of 
spontaneous pregnancy  (NICE, 2017) and offer laparoscopic ovarian cystectomy 
with excision of the cyst wall for endometriomas of 4 cm in size or bigger, because 
this improves the chance of spontaneous pregnancy and decreases recurrence (Hart et 
al., 2008). A systematic review comparing laparoscopic excision with ablation in 
treating endometrioma described a rise in pregnancy rate by approximately five-fold 
after excision (Hart et al., 2008). However, the effect of surgery on ovarian reserve 
and the risk of abscess formation after oocyte recovery should be discussed with the 
women.” 
Two meta-analyses concluded that in minimal and mild endometriosis, without 
disruptive anatomy, removal or destruction of all or most of the endometriotic lesions 
improves pregnancy rate (Tanbo and Fedorcsak, 2017). Whereas IVF is the treatment 
of choice for advanced disease to reduce time to pregnancy (Macer and Taylor, 
2012). However, women with advanced stages have lower success rates with IVF in 
comparison with tubal factor infertility, which might be as a result of reduced 
implantation rate and lower ovarian response (Tanbo and Fedorcsak, 2017). Overall, 
treatment focuses on improving fertility by restoring normal pelvic anatomy and 




Table  1-4:- Treatment options for endometriosis-associated infertility (Hickey, 2014) 
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1.7.4.5. Hysterectomy and bilateral salpingo-oophorectomy 
“There is limited or no role for hysterectomy and bilateral salpingo-oophorectomy 
(BSO) in the management of endometriosis-associated symptoms as symptoms may 
persist after this major operation. However, for women with endometriosis who have 
failed to respond to available conservative treatments and have completed their 
family, hysterectomy and BSO and removal of any visible endometriosis lesions may 
be considered.”  
Retrospective studies suggest that hysterectomy alone decreases pain as 
dysmenorrhoea no longer happens but approximately 33% of these women require 
further surgery at five years for their symptoms, in comparison with only 10% of 
those who undertake hysterectomy and BSO (Shakiba et al., 2008). There are many 
theories to explain why endometriosis recurs after hysterectomy, including hormonal 
factors, residual microscopic foci, ovarian remnants, lymphovascular invasion, 
uterine morcellation and de-novo disease. 
1.7.4.6. Recurrence after surgery 
The reported recurrence rates of endometriosis lesions after surgery and its 
associated symptoms are high and vary from approximately 21.5% after 2 years to 
around 40–50% at 5 years and increases more over time (Guo, 2009). Usually, these 
women may require other conservative therapies or repeated surgical intervention. In 
one study results showed that up to a third of women reported recurring of their 
dysmenorrhoea within one year of laparoscopy, in patients who did not receive any 
other treatments (Fedele et al., 2004). 
A systematic review demonstrated that COC can decrease post-surgical pain and 
decrease recurrence of endometrioma. Furthermore, it is as effective as and better 
accepted than mifepristone, gestrinone and GnRHa without hypoestrogenic adverse 
effects (Wu et al., 2013). A RCT showed that LNG-IUS is comparable with GnRHa 
in relieving CPP after surgery in patients with endometriosis (Tekin et al., 2011).  
A systematic review showed that LNG-IUS prevents recurrence of symptoms after 
surgical intervention and does not negatively affect metabolic parameters or bone 
density (Abou‐Setta et al., 2013).  
45 
 
1.7.4.7. Complications of surgery 
“Nowadays, almost all endometriosis operations are done laparoscopically and 
laparoscopy is a relatively safe procedure. Most complications are minor such as 
minor bleeding and bruising and they resolve spontaneously. Serious complications 
are uncommon (2:1000) including uncontrolled bleeding; damage to the bladder, 
bowel and large blood vessels and thromboembolism. A well-trained surgeon should 
be able to manage these complications. A woman should be aware that some 
complications might develop later such as difficulty emptying the bladder, wound 
infection and hernia formation and to be advised to seek medical advice if she 
experiences any of these symptoms (RCOG, 2017).”  
 Counselling, psychotherapy and cognitive behavioural 1.7.5.
therapy       
Other than the multi-disciplinary team and pain management programmes, women 
with endometriosis reported benefits from cognitive behavioural therapy (CBT), 
counselling and psychotherapy. CBT is associated with significant enhancements in 
the mood, social functioning and pain of these women (Kumar et al., 2010).  
In a meta-analysis and systematic review of CBT for women with endometriosis-
associated CPP (Mendes and Figueiredo, 2012), results showed that psychotherapy 
and CBT improve the QOL of these women. Moreover, teaching women self-
management skills, counselling, psycho-educational setting and individual goals, 
reduce anxiety levels, pain and depression for women with endometriosis.  
1.8. Burden of endometriosis 
Endometriosis is a chronic disorder and living with the condition, particularly if it 
causes chronic pain, can reduce the ability of a woman to support and interact with 
family members, reduce their economic productivity and also affect their QOL 
(Simoens et al., 2012). The chronic nature of this health condition is also associated 
with a significant burden on healthcare services as women may make frequent visits 




 Impact on quality of life 1.8.1.
The debilitating effects of endometriosis and its associated-symptoms reverberate 
throughout the life-span of a significant number of women and impacts negatively on 
almost all aspects of their lives, such as their work, emotions and relationships. 
(Nnoaham et al., 2011). Endometriosis not only affects women’s work attendance 
but also work productivity. Endometriosis impairs health-related QOL mainly in the 
domains of pain, social and psychological functioning (Nnoaham et al., 2011). QOL 
represents the main essential predictor of total costs and of direct healthcare costs. 
“Endometriosis has affected work in 51% of the women at some stage during their 
life. QOL was reduced in all dimensions of the 36-item short form health survey (SF-
36v2), in comparison with normal scores from a general USA population (P-value 
of less than 0.01). Multivariate regression analysis indicated that the number of co-
morbidities, dyspareunia and chronic pain had an independent negative effect on 
both the physical and mental element of the SF-36v2 (De Graaff et al., 2013).” 
 Cost to society 1.8.2.
Endometriosis is associated with 45% reduction in work productivity, with the 
annual cost of woman with endometriosis estimated at €9579 in healthcare costs, 
treatment and loss of work. Costs were higher with the presence of infertility, the 
existence of CPP, increasing the severity of endometriosis and a greater number of 
years since diagnosis (Simoens et al., 2012).  
The financial burden of endometriosis-associated symptoms was the subject of a 
multi-centre study (WERF EndoCost study) that involved 909 women in 12 tertiary 
care centres in ten countries (Table  1-5). This study showed that each affected patient 
lost on average 10.8 hours of work per week, primarily due to decreased 
effectiveness and the total average annual cost in the UK was about £8.2 billion. 
Total costs were dominated by indirect costs of productivity loss. The indirect costs 
of productivity loss were twice as large as the direct healthcare costs of 
endometriosis-associated symptoms (Table  1-5).   
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The main important items of healthcare costs were surgery (29%), followed by 
monitoring tests (19%), hospitalisation (18%), physician visits (16%) and finally 
(10%) for medications (Simoens et al., 2012).  
Table  1-5:- Annual costs of endometriosis-associated symptoms (in GBP) 
Item Mean Standard 
deviation 
95% CT of the 
mean 
Direct healthcare costs 2739.5 11654.8 1980.9 – 3498.3 
Physician visits 451.7 1172.1 375.4 – 528 
Medication 281.9 1200.5 203.7 – 360 
Monitoring tests 524.8 1837.2 405.2 – 644.4 
Surgery 791.4 9505.0 172.7 – 1410.1 
Other treatments 134.8 652.2 92.312 – 177.2 
Informal care 73.9 548.4 38.2 – 109.6 
Hospitalisation 481.0 3180.4 274.1 – 688.2 
Direct non-healthcare 
costs 
147.7 423.7 120.1 – 175.3 
Transportation 90.1 282.5 71.7 – 108.5 
Support household 
activities 
57.6 308.3 37.5 – 77.6 
Direct costs 2887.3 11736.0 2123.4 – 3651.2 
Indirect costs 5542.5 6391.1 5126.5 – 5958.6 




1.9. Modification of diet as an alternative therapy for 
endometriosis 
Standard medical treatments of endometriosis are generally hormonal in nature, 
prevent conception, symptoms recur after stopping the treatment and they can cause 
several side effects (Dunselman et al., 2014a). Repeated surgeries carry risks of 
adhesions (Liakakos et al., 2001) and other impacts with a high rate of recurrence of 
lesions reported (Guo, 2009, Tanos, 2013).  
“The limited understanding of the complex aetiology of the disorder (as discussed in 
Section 1.3) means that only a few modifiable risk factors for endometriosis have 
been proposed. Reports that dairy foods and some nutrients can modulate immune 
and inflammatory factors are supported by the observation that high plasma 25 
hydroxy vitamin D levels and higher intake of dairy foods are associated with a 
decreased risk of endometriosis (Harris et al., 2013).”  
“Diet is a highly modifiable risk factor for many other chronic diseases, but its 
influence on endometriosis has not been comprehensively explored. However, 
chronic exposure to the high-fat diet (HFD) has been linked to oxidative stress and 
systemic inflammation, both features of patients with endometriosis. The effects of a 
HFD on endometriosis progression was studied using an immunocompetent mouse 
model, results showed that HFD intake significantly increased the numbers of an 
ectopic lesion in recipient mice with no substantial weight gain (Heard et al., 2016).” 
“In two Italian case-control studies, the diet of 504 women with a laparoscopically 
confirmed endometriosis and 504 healthy controls was evaluated. In this small 
group, there was a reported reduction in risk with higher intake of green vegetables 
and fresh fruit, while an increase in risk was associated with high intake of beef, 
other red meat and ham (Parazzini et al., 2004). A case-control study of 284 women 
with surgically confirmed endometriosis versus 660 age-matched female without 
endometriosis showed that increased intake of total fat and dairy products decrease 
the risk of endometriosis, while higher consumption of β-carotene and servings/d 
fruit were linked to increased risk of the disease (Trabert et al., 2011).”  
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A literature review of 23 studies investigating the relationship between 
endometriosis/dysmenorrhoea and diet, 12 trials discussed endometriosis and diet 
(three were animal studies and 74,708 women in total), found that increased 
consumption of long-chain omega-3 fatty acids is associated with lower risk of 
endometriosis, whereas intake of trans-fatty acid has a relatively strong association 
with the disease. Eleven trials, with a total of 1433 women, investigated the 
relationship between dysmenorrhoea and diet, concluded that consumption of 
omega-3 fatty acids decreases painful periods (Hansen and Knudsen, 2013). 
“The effectiveness of the outcomes of endometriosis-related pain and QOL of a 
gluten-free diet was evaluated in 207 patients with severe painful endometriosis-
related symptoms. Painful symptoms were assessed by VAS, at the baseline and after 
12 months of gluten-free diet. Results showed that 75% of patients reported a 
statistically significant change in painful symptoms (P-value of less than 0.005) and 
no patients reported worsening of pain. Furthermore, there was a substantial rise of 
scores for all domains of physical functioning, vitality, social functioning, mental 
health and general health perception was observed in all patients (P-value of less 
than 0.005) (Marziali et al., 2012).”    
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 Omega-3 PUFA 1.9.1.
“Omega-3 PUFA are dietary supplements, which has minimal side effects and no 
effects on fertility (Saldeen and Saldeen, 2004). The omega-3 fatty acids 
eicosapentaenoic acid (Heard et al.) and docosahexaenoic acid (Ganz et al.) are 
precursors of certain eicosanoids that are known to reduce inflammation in the body; 
they are derived from oily fish and found in fish oil supplements (now one of the 
most popular dietary complements on the market).”  
DHA and EPA fatty acids inhibit inflammation in different ways, such as adhesion, 
molecule expression, leukocyte chemotaxis and leukocyte-endothelial adhesive 
interactions. The mechanisms of these anti-inflammatory activities include lipid rafts 
disruption, cell membrane phospholipid composition alteration, a stimulation of the 
anti-inflammatory transcription factor and an inhibition of activation of the pro-
inflammatory transcription factor (Calder, 2015).  
“Omega-3 PUFA is a Food and Drug Administration (FDA)-approved dietary 
supplement, which plays a role in the regulation of prostaglandin (PG) metabolism 
and cytokine physiology, and are thought to work by competing with Omega-6 
PUFA to produce lipid mediators which are anti-inflammatory as opposed to pro-
inflammatory (Calder, 2015). Intake of food with a high content of Omega-3 PUFA 
have been used in other inflammatory conditions, such as atherosclerosis, asthma, 
and rheumatoid arthritis, and have been shown to have an anti-inflammatory effect 
and clinical trials of fish oil in RA demonstrate benefits (Hino et al., 2004).”  
“In animal models, omega-3 PUFA supplementation has been shown to reduce lesion 
size and local PG/cytokine production in a rat model of endometriosis (Netsu et al., 
2008). In an endometriosis model using Fat-1 mice, in which Omega-6 PUFA can be 
converted to Omega-3 PUFA, the number and weight of endometriotic lesions two 
weeks after inoculation were significantly less in Fat-1 mice, compared to controls 
who cannot convert Omega-6 PUFA to Omega-3 PUFA (Tomio et al., 2013).”  
“In-vitro studies, using endometrium from women with and without endometriosis 
have shown that Omega-3 PUFA might have a suppressive effect on endometrial cell 
survival (Missmer et al., 2010). In a large prospective cohort study investigating 
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dietary exposure and endometriosis risk in women, it was concluded that increasing 
Omega-3 PUFA intake might be the first identified modifiable risk factor for 
endometriosis (Missmer et al., 2010). It is reported that a low ratio of Omega-
3:Omega-6 PUFA intake is correlated with painful menstruation and a high rate of 
autoimmune and endocrine disorders in women with endometriosis (Deutch, 1996).” 
In summary, the data reviewed in brief above suggest Omega-3 PUFA may have the 
potential for reduced inflammation and symptoms associated with endometriosis and 
therefore merit further investigation in a properly controlled trial.  
1.10. Conclusions  
“The current therapeutic options for treatment of endometriosis largely focus on 
surgery, hormonal therapy or a combination of both (Wu et al., 2017). New therapies 
are needed that can: (i) reduce any painful symptoms associated with the condition, 
(ii) reduce lesion size, (iii) preserve the patients’ ability to conceive whilst on 
medication, (iv), have no, or limited, side effects and (v) acceptable to women with 
endometriosis. Moreover, bringing women living with endometriosis and their carers 





1.12. Objectives of thesis 
The two main goals of my thesis were:-  
(a) To identify research priorities for endometriosis.  
(b) To determine the feasibility of a future multi-centre, large RCT, to evaluate 
the effectiveness of PUFA for endometriosis-associated pain.  
To achieve these goals, I have:-  
1. Engaged with experts in the management of endometriosis, women with 
endometriosis and prepared a report of the research uncertainties, using the 
template provided by the JLA. 




Chapter 2. Identifying research priorities for endometriosis  
2.1. Background 
Endometriosis research is significantly underfunded relative to other diseases with 
high healthcare burdens. Traditionally the endometriosis research agenda has been 
set by the pharmaceutical industry and researchers themselves. Since 2008, members 
of the international research community have held three workshops following the tri-
annual World Congress of Endometriosis run by the World Endometriosis Research 
Foundation (WERF) to discuss and capture a consensus statement on research 
priorities in endometriosis. The findings of two of these workshops have been 
published and widely disseminated (Rogers et al., 2009, Rogers et al., 2017). The 
results of the most recent workshop (Vancouver 2017) are awaited. The 2014 
meeting resulted in identification of 66 new recommendations for research with an 
increased focus on translational research. Whilst endometriosis charities have been 
represented at these meetings the engagement with women has not been a focus of 
these workshops and this is a concern for funders and researchers seeking to improve 
the lives of women with endometriosis.  
“The JLA, established in 2004, is a non-profit initiative with the aim of making 
healthcare research funders aware of issues that matter most to patients and their 
clinicians (Cowan and Oliver, 2013). The JLA whose infrastructure is now funded by 
National Institute of Health Research (http://www.jla.nihr.ac.uk/about-the-james-
lind-alliance/about-psps.htm) achieve this through Priority Setting Partnerships 
(PSPs) which bring together patients, carers and clinicians to identify and prioritise 
the top 10 uncertainties, or unanswered questions, about the effects of treatments 
(Cowan and Oliver, 2013). It is recognised that many PSPs now interpret this 
definition more broadly and extend their scope beyond identifying and prioritising 
treatment uncertainties and included other categories such as diagnosis, prevention 
and others. ”  
A total of 83 JLA PSPs have been conducted, Table  2-1 shows some examples 




Table  2-1:- Response rate of other JLA priority setting partnerships 
JLA PSP 
Number of survey 
respondents 
Number of questions 
submitted 
Bipolar 3285 14398 
Depression 3000 10000 
Sight loss and vision 2220 4461 
Dementia 1563 4116 
Autism 1213 3331 
Miscarriage 1093 3279 
Diabetes (Type 1) 583 1141 
Multiple Sclerosis (MS) 507 1084 
Vitiligo 461 1427 
Lyme Disease 253 967 
Asthma 370 267 
Stroke in Scotland 106 548 
 
“The first PSP focused on asthma (Elwyn et al., 2010) it attracted 370 respondents 
with priorities in their final top 10 including ‘’What are the adverse effects 
associated with long-term use of short and long acting bronchodilators; inhaled and 
oral steroids; and combination and additive therapies in adults and children?’’. It is 
notable that the NIHR has since funded a £1.2 million study into the benefit of 
breathing exercises (Bruton et al., 2013). In women’s health, PSPs have formed to 
agree on priorities in preterm birth, stillbirth and most recently, endometrial cancer 
(Duley et al., 2014, Heazell et al., 2015, Wan et al., 2016) with 1093, 386 and 577 
people taking part in their initial surveys respectively.”  
“The endometriosis PSP was formed with the objective of identifying the key 
questions about endometriosis that were most important to both patients and 
healthcare professionals (HCPs) involved in their care. Using methods established by 
the JLA (www.jla.nihr.ac.uk), a shortlist of those considered priorities for research in 
the UK and Ireland by both women with endometriosis and HCPs was agreed. Care 
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was taken to form a PSP steering group (SG) that included women with 
endometriosis, their supporters, key HCPs, endometriosis researchers and 
representatives from organisations involved with women with endometriosis draw 
from across the UK and Ireland.” 
“To begin to tackle this, we developed a consensus of the top ten unanswered research 
questions in endometriosis shared by both HCPs, women who have or have had 
endometriosis and carers of women with endometriosis, using an inclusive decision-
making approach. Identification of these questions was the first step in developing 
research questions that would maximise health benefits for women with 
endometriosis.”  
“Research questions were gathered from women with endometriosis, HCPs and 
researchers using surveys complemented by clinical guidelines and systematic 
reviews. Priority setting was carried out using data from (a) online survey, (b) online 
voting and (c) a facilitated workshop of equal numbers of women with endometriosis 
and HCPs.” 
“It is intended that these 10 priorities will provide a platform for researchers, funding 
bodies and the pharmaceutical industry to ensure that future research funding and 
research activities focus on and target unanswered questions that are important to 
women with endometriosis and to HCPs caring for women with endometriosis.” 
2.2. Methodology 
“The oversight was provided by a SG listed in Appendix  A.1 
(http://endometriosis.org/resources/jla/psp-steering-group) independently chaired by 
JLA facilitators (Leanne Metcalf and Katherine Cowan), consisting of women who 
have or have had endometriosis, carers/charities representing them and HCPs. The 
six stages of the PSP are outlined in Figure  2-1 and follow the PSP process described 
by the JLA (Cowan and Oliver, 2013). The protocol was agreed and published on the 
JLA website before the PSP began (Endometriosis-PSP-protocol, 2015). PSPs are 
considered service evaluations and therefore approval from an NHS ethics committee 
was not required.”   
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Stage 4: Refining uncertainties 
Uncertainties categorised, refined and agreed by the steering group (October –
November 2016) 
Stage 2: Consultation 
Initial steering group meeting. Scope and protocol agreed (December 2015) 
Stage 3: Identifying Uncertainties 
First survey and literature search (March-May 2016) 
Stage 1: Initiation 
Key stakeholder group identified and a steering group established 
Stage 6: Final workshop 
Stakeholder consensus workshop (April 2017) 
Stage 5: Interim prioritisation 




“Key stakeholder groups were identified through a process of peer knowledge and 
consultation. First, the chair of the endometriosis PSP (Andrew Horne, University of 
Edinburgh “UoE”) approached all organisations known to represent the following 
groups: women who have or have had endometriosis; partners, family members of 
women who have or have had endometriosis; and doctors, nurses and professionals 
allied to medicine with clinical experience of managing endometriosis.”  
“Organisations approached were Endometriosis UK (EUK), the Pelvic Pain Support 
Network, Endometriosis Association of Ireland, the Royal College of Obstetricians 
and Gynaecologists (RCOG), the RCOG Womens Network, the Royal College of 
Nursing and the Royal College of General Practitioners. These organisations were 
consulted about the PSP, invited to participate and identify groups who had been 
excluded, so we invited them also. Partner organisations identified interested 
individuals to form a SG.”  
“Non-clinical researchers and representatives of the pharmaceutical industry were 
excluded in accordance with the JLA guideline which states “traditionally the health 
research agenda has been largely determined by the researchers and pharmaceutical 
industry themselves. This has usually been with minimal input from patients and 
their carers, or patients, carers and clinicians combined”. The JLA process was 
developed to give people who do not usually get a chance to influence the research 
agenda a voice and to address a mismatch between what researchers are interested in 
and what the beneficiaries of research are interested in. For this reason, researchers 
with no current clinical practice are excluded from voting within the PSP process 
(Cowan, 2018). However, it was felt that researchers involved in the process should 
have the opportunity to vote and to participate in the decision making process. I 
oversaw the steering group declaration of interest and biographies. The declaration 
included declaring competing interests which could be seen to influence participation 
in the endometriosis PSP; any publicly declared strong opinions about endometriosis, 
receipt of any funding which may influence participants’ contribution and 




2.4. The consultative process 
“The SG was a balanced composition of women who have or have had endometriosis, 
charities which represented them and clinicians. Some members representing 
charities or HCPs also had personal experience of endometriosis. All aspects of 
endometriosis including causes, natural history, awareness, symptoms (including 
subfertility), diagnostic approaches, prevention, treatment options (including lifestyle 
factors), treatment outcome and co-morbidities were included within the scope of the 
priority setting process.”   
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2.5. Gathering uncertainties  
“The process started with me writing up the endometriosis PSP protocol, with support 
from my supervisors, which was published on the JLA website on 7
th
 of September 
2016, followed by creating an online pilot survey using Survey Monkey, I designed 
the first survey and drafted the questions, with support from the SG. Participants of 
the survey were asked: “What unanswered questions about endometriosis would you 
like to see answered by research?” The format of the survey allowed each participant 
to complete up to three free text responses and another space for any other 
comments. Socio-demographic data of the participants were monitored throughout 
the data gathering period and where particular groups appeared under-represented, 
targeted recruitment strategies were employed. Our target recruitment strategy was to 
have a maximum of 2000 participants or to wait two months from the beginning of 
the survey. The survey tool was peer-reviewed by the SG and piloted by a group of 
women and HCPs. This peer review and piloting process ensured content validity. 
Given the range of different constructs measured, internal consistency calculations 
were not undertaken.”  
“The feedback received was used to rephrase medical language in the description and 
refine the accompanying text for clarity. The refined survey was hosted at 
(Endometriosis.org, 2016) and distributed by partner organisations using their own 
networks; promoted in newsletters and at conferences; distributed via printed flyers 
in clinics, and posted via online forums and social media. Participants could answer 
the initial survey anonymously. In addition to the public survey, I also performed a 
literature search of the Cochrane Library, ESHRE guidelines for endometriosis, USA 
guidelines for endometriosis, Australian guidelines for endometriosis and the Health 
Technology Assessment (HTA) database for previously published research questions 
falling within the scope of the PSP.” 
2.6. Data analysis and verifying uncertainties  
The results of the first survey were downloaded into an Excel file. The location of 
the respondent was noted and data from respondents self-identifying as not living in 
the UK or Ireland were removed prior to any further analysis. I have completed the 
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majority of the first survey data analysis. I realised that the analysis would be better 
performed using Microsoft Excel (ME) than Nvivo software. So, I have used ME 
with Visual Basic for Applications (VBA) and coding  to arrange the questions and 
comments into columns instead of rows for better analysis (Appendix  A.2). This was 
followed by breaking down the long statements/stories into individual questions; 
some of them ended up with 26 questions, I did this part of data analysis in three 
steps “and Lyndsey Hogg (LH), a patient representative on the SG, helped me in the 
middle step”. The primary purpose of the analysis was to create a list of summary 
questions. First, we removed non-questions (94 distinct comments). The remaining 
questions (~5000 questions) were assigned into 10 categories (including the 9 main 
categories and the out of the scope questions) by me and I qualitatively developed a 
taxonomy based on the focus of each uncertainty in turn. For example, “How can 
doctors and nurses receive education to lead to more effective diagnosis, treatment 
and care of women with endometriosis?” was assigned to “awareness” category. In 
total, there were nine categories as shown in Table  2-2 with examples of questions 
under each category. Questions not related to endometriosis or personal stories rather 
than research questions deemed being out of scope. The pathway of every single 
question from the time submitted by participants to the final stage under which that 
question been allocated and the ID, UI and all the demographics were duplicated by 




Table  2-2:- Taxonomy for endometriosis questions 
Category Total Example  
Symptoms 415 What are early symptoms of endometriosis? 
Natural history 83 
Can endometriosis keep growing even after 
menopause? 
Prevention 207 What can be done to prevent endometriosis? 
Awareness 510 
Why are GP's telling women that it is normal 
to experience very painful periods? 
Treatment options 1004 
What is the most effective treatment for 
endometriosis? 
Co-morbidities 161 
What is the link between miscarriages and 
endometriosis? 
Treatment outcomes 532 
Will the endometriosis come back after a 
laparoscopy? 
Causes 818 What are the causes of endometriosis? 
Diagnosis 453 
Why does it take so long to diagnose 
endometriosis? 
 
“Where a respondent included more than one uncertainty in the same question, the 
response was duplicated and assigned to each category. At least one HCP and one 
patient representative from the SG reviewed each category jointly. At this stage 
duplicates were excluded and questions were combined and rephrased to create 
summary questions which SG refined into a standard format using a template which I 
designed for them to put ID and UI for individual questions under each summary 
question. Then I revised all the summary questions made by the SG and I identified, 
using VBA, all the missing questions and duplicate entries, then the full list of 
summary questions was checked and agreed by the SG.”  
“Every question was searched against existing literature (the Cochrane Library, 
MEDLINE, EMBASE, CINAHL, plus CINAHL or PsycINFO) from 1946 until (2
nd
 
February) 2017. Literature searches were performed by an independent team of 
health information specialists from the Central Manchester University Hospitals 
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Foundation Trust, as per JLA guideline “ PSP needs an information specialist who 
can review the summary questions against the existing evidence”, and all papers 
were rechecked by me after input from SG, using systematic pre-agreed search 
criteria for systematic reviews of interventions for the management of endometriosis, 
an example of search terms, what is the role of therapeutic hysterectomy in 
endometriosis in the absence of malignancy, is shown in Table  2-3, which was one of 
the search strategies we have used to check if any of our survey questions were 
answered. All summary questions were checked against the evidence base to 
determine if they were true questions or if the survey respondent was unaware there 
was already evidence to answer their question. Searches deemed answered by 
research were defined as those with recent level 1 evidence (i.e. systematic review of 
randomised controlled trials within 3 years), (Phillips et al., 2011) where the review 
did not conclude that there was insufficient evidence.”   
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Table  2-3:- An example of search strategy Ovid MEDLINE®“1946 to 2017” what is 
the role of therapeutic hysterectomy in endometriosis in the absence of malignancy 
No Searches Results 
1.  (endometrio*or endometrial*or 
endometrium*).ab.ti. 
76680 
2.  Endometriosis/ 20364 
3.  1or 2 79873 
4.  “hysterectom**.ab.ti. 29357 
5.  Hysterectomy/ 27486 
6.  4 or 5 41106 
7.  (cancer*or neoplasm*).ab.ti. 1457674 
8.  Exp Neoplasms/ 3221266 
9.  7 or 8 3432250 
10.  3 and 6 7467 
11.  10 not 9 2157 
12.  Limit 11 to “therapy (best balance of 
sensitivity and specificity) * 
172 
13.  Limit 10 to “therapy (best balance of 
sensitivity and specificity) * 
415 
14.  13 not 12 243 
15.  Endometriosis.mp.or Endometriosis/ 23480 




2.7. Interim prioritisation 
“The aim of the interim stage was to rank the summary questions into those 
considered important by women who have or have had endometriosis, carers and 
those considered important by HCPs. To do this, the refined set of questions were put 
into a new online survey and displayed in a randomised sequence each time it was 
accessed. The second survey was posted on the endometriosis.org website 
(Endometriosis.org, 2017). Participants were invited by partner organisations to 
complete the survey, and wider dissemination was achieved by advertising the 
survey via newsletters, posting online and via social media. Moreover, more than 
1500 participants provided their emails from the first survey and were keen to be 
contacted to take part in interim prioritisation, LH and I sent emails to those 
participants to take part in the second survey. Participants were asked to read the list 
of questions and identify their ten priorities. Participants could answer this survey 
anonymously. I ranked the questions based on the frequency they had been chosen 
and I analysed the top priorities for patients and HCPs, and women from different 
ethnic origins to ensure the overall rankings were represented all groups 
(Appendix  A.4.1 to  A.4.5).  
There is usually an obvious place in the list of questions to draw the line, for 
example, scores may drop off rapidly after priority 25 or 30, or there may be a 
particular reason for including questions which are on the margins, such as a 
question which may be about important aspect of the condition or may have 
particularly important to one group of respondents (Cowan, 2018). The top 30 
questions were taken to the final workshop.” 
2.8. Final priority setting 
“Participants were invited to the final priority-setting workshop, representing women 
and partners affected by endometriosis, including representatives from charities and 
HCPs. Prior to the meeting, participants completed a declaration of interest form and 
individually prioritised the top 30 questions presented in random order labelled A-
DD. This allowed them to attend the workshop with an idea of their own top ten. The 
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workshop was chaired by an independent JLA facilitator (Katherine Cowan) with no 
personal experience of endometriosis.”  
“Ground rules were agreed at the start of the meeting to ensure confidentiality of 
individual’s responses and respect others’ views and compromise. This process was 
intended to prevent discussions being dominated by a single member and to 
encourage quieter members of the group to speak and to highlight that consensus 
meant people were unlikely to leave the meeting with all their views being 
represented in the final top 10. Participants were divided into three groups of mixed 
representation of women who have or have had endometriosis, patient 
representatives/relatives and HCPs and nominal group technique was adapted.”   
“Each group, chaired by a separate JLA facilitator was asked to prioritise all 30 
questions which were printed on A4 cards. Each card had the interim prioritisation 
for each group “women who have or have had endometriosis; professionals and 
professionals who have or have had endometriosis” written on the back, to assist 
with decision making. The three sets of rankings were combined into one list. 
Participants were then divided into three different groups, again with mixed 
representation. In the second round, the groups were presented with the combined 
prioritisation from round one. Participants were asked to focus on whether the 
correct questions were in the top 10 and had the right prioritisation. In the final 
round, all three groups’ priorities were combined and presented to the entire group as 
shown in Appendix  A.5. The focus was on the top 10. When disagreement arose, a 
consensus was reached by ‘raised-hands’ voting. The top 10 research priorities in 





A flow diagram of the endometriosis PSP process and results are shown in 
(Figure  2-2) 



















4878 uncertainties identified 
Initial survey 





Out of scope = 406 
Non-questions = 94 
4378 Unique uncertainties  
Assigned to 9 categories 
Duplicates removed and 
questions combined 
72 refined uncertainties 
Interim prioritisation survey 
ranking all 72 uncertainties      
(1380 respondents) 
Top 30 priorities for final 
workshop 
42 lowest ranked uncertainties removed 
from further prioritisation 
Top 10 priorities agreed 
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2.10. Consultation and identifying questions stage (‘question-
gathering’) 
“The initial survey was open from 9 March 2016 until 31 May 2016. Overall, 1237 
participants from UK/Ireland submitted 4767 questions via the survey and 111 were 
identified by a literature search as explained in Figure  2-2. Survey respondents 
included 909 women with endometriosis, 19 partners of women with endometriosis, 
22 family members, 39 friends or colleagues, 195 HCPs, 44 others and 9 did not 
choose their role as shown in Figure  2-3. Participants were distributed according to 
geographical regions as shown in Table  2-4. Figures 2.4 to 2.7 show the rest of 
socio-demographic data. Majority of participants were white British/Irish (76%) and 
Table  2-8 shows respondents’ gender and age group.”    
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Figure  2-3:- Initial survey participants 
 




Figure  2-5:- Initial survey time for diagnosis  
 









Table  2-4:- Primary residence of survey respondents  
















England - greater 
London 
121 10% 152 11% 
England - south 
west 
91 7.5% 137 10% 
England - east 
midlands 
50 4.1% 64 4.7% 












86 7.1% 117 8.5% 
Wales 60 4.9% 71 5.2% 
Scotland 220 18.1% 151 11% 
Northern Ireland 32 2.6% 25 1.8% 
Republic of Ireland 58 4.8% 34 2.5% 
Rather not say 42 3.5% 45 3.3 % 




2.11. Verification of uncertainties (‘refining questions’) 
“Submissions that were either non-questions or not related to endometriosis were 
removed and 4378 questions remained. Qualitative sorting generated taxonomy of 9 
categories as shown in Table  2-2. Each category was assigned to at least one patient 
representative and one HCP from SG. Duplicates were excluded and submissions 
refined to summary questions. An example of this exhausting task of how I have 
counted the weights of different sources formed each question for the whole data is 
shown in Table  2-5 and a full data can be found in Appendix  A.6. Referring to the 
existing literature, no questions could be resolved at this stage. An example of 
refined uncertainties is shown in Table  2-6, whereas a full data can be found in 




Table  2-5:- Example of weights and sources of summary questions of interim prioritisation  
Number Summary Questions 
Weight Pt/Pt rep Past 
History 
Undiagnosed HCPs Research Guideline 
Symptoms 
 
1.  Why does endometriosis cause pain?  109 76 (6 HCP) 2 1 27 2 1 
2.  
Why do women with endometriosis have 
difficulty getting pregnant? 
90 73 (4 HCP) 3 1 12 1 0 
3.  
Why is endometriosis and endometriosis 
associated pain and/ or symptoms not related 
to the severity of the disease? 
60 23 (1 HCP) 3 0 33 0 1 
4.  
Why do the symptoms of endometriosis 
affect different women in different ways? 
47 32 3 0 11 0 1 
5.  
Why do women with endometriosis suffer 
from fatigue? 
17 17 (2 HCP) 0 0 0 0 0 
6.  Why does endometriosis cause painful sex? 16 15 0 0 1 0 0 
7.  
Does endometriosis cause damage to nerves 
and/or neuropathy and/or visceral 
hyperalgesia? 
8 6 0 0 2 0 0 
8.  
Do symptoms of endometriosis correlate 
with location of adhesions? 
2 0 0 0 2 0 0 
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Number Summary Questions 
Weight Pt/Pt rep Past 
History 
Undiagnosed HCPs Research Guideline 
Symptoms 
 
9.  Does endometriosis cause food intolerance? 2 2 0 0 0 0 0 
10.  
What are the signs and symptoms of 
endometriosis? 
* ESHRE        
11.  
Is endometriosis linked to dysmenorrhea in 





      
12.  
What is the function of nerve fibres in 





      
  
Definitions of Table  2-5 abbreviations:- 
* ESHRE: - European Society of Human Reproduction and Embryology guideline 
● WES: - World Endometriosis Society  
● WERF: - World Endometriosis Research Foundation  
Pt/Pt rep: - Patient with endometriosis / patient representative     
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Table  2-6:- Example of the refined uncertainties  
No Refined Questions 
1.  Can a cure be developed for endometriosis? 
2.  How can the diagnosis of endometriosis be improved? 
3.  What causes endometriosis? 
4.  
What is the most effective way of stopping endometriosis progressing 
and/or spreading to other organs (e.g. after surgery)? 
5.  
What are the most effective ways of educating HCP throughout the 
healthcare system resulting in reduced time to diagnosis and 
improved treatment and care of women with endometriosis? 
6.  
What can be done to stop endometriosis from recurring (e.g. after 
treatment)? 
7.  
Is there a link between endometriosis and auto-immune diseases, and 
endometriosis and/ or inflammatory disorders (e.g. MS, Lupus, RA, 
osteoarthritis, asthma, eczema and thyroid) and if so why? 
8.  
What is the most effective way of managing the emotional and /or 
psychological and/or fatigue impact of living with endometriosis 
(including medical, non-medical and self-management methods)? 
9.  
Is it possible to develop a non-invasive screening tool to aid diagnosis 
of endometriosis? 
10.  
What is the best way to monitor disease progress (e.g. regular check-
up) once diagnosed with endometriosis? 
11.  
In what circumstances should endometriosis be classified and/or 
recognised as a disability? 
12.  
How can we prevent endometriosis in women and/or young girls with 
a family history of the disease? 
13.  
Are women with endometriosis at an increased risk of cancers, and if 
so which and how they can be prevented? 
14.  
What are the most effective non-surgical ways of managing 




2.12. Interim prioritisation 
The interim prioritisation survey was open between 20
th
 February and 20
th
 March 
2017 and completed by 1380 respondents from the UK/Ireland. I did all the analysis 
of this data. Data was divided into three groups, women with endometriosis, HCPs 
and HCPs with endometriosis. Where people have been asked to choose and rank ten 
questions, the most straightforward approach was to apply a reverse scoring system 
to each submission. For each, of these three groups, when a question scored one, it 
replaced by ten, if it scored two replaced by nine and so on till reach ten which was 
replaced by one, this means that where a low number of clinicians, for example, has 
responded compared with patients, their scores will still be given equal weighting. 
Then scores of each question were added together and ranked in a descending order. 
The top rank for each group given a score of 72 (the total number of summary 
questions), followed by 71 till it reaches a score one for the question with the lowest 
score. The scores of each question in the three groups were then added together and 
put into a descending order and finally, the question with the highest score was given 
number one and the lowest score was given number 72. Table  2-7 shows a sample of 
this process, whereas the full data can be found in Appendix  A.4. 
The ranked respondents were distributed by geographical regions as shown in 




Table  2-7:- Sample of endometriosis second survey final results  










3 Can a cure be developed for endometriosis? 72 67 72 211 1 
16 How can the diagnosis of endometriosis be improved? 69 71 70 210 2 
49 What causes endometriosis? 70 72 67 209 3 
60 What is the most effective way of stopping endometriosis 
progressing and/or spreading to other organs (e.g. after 
surgery)? 
68 69 71 208 4 
40 What are the most effective ways of educating healthcare 
professionals throughout the healthcare system resulting 
in reduced time to diagnosis and improved treatment and 
care of women with endometriosis? 
71 64 66 201 5 
48 What can be done to stop endometriosis from recurring 
(e.g. after treatment)? 
65 68 68 201 5 
 
*Pt/Pt Repres Score: - patient or patient representative score. °endo: - endometriosis
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Figure  2-8:- Interim prioritisation primary residence 
 
 
Overall, 1120 women who have or have had endometriosis, 13 partners, 64 family 
members, 79 friends or colleagues and 129 HCPs completed the survey as shown in      
Figure  2-9.  
“The imbalance between those who have or have had endometriosis and HCPs was 
recognised. There was also an ethnic imbalance, 1152 (95%) white British/Irish and 
79 (14.7%) black, Asian and minority ethnic. Considering this, the overall rankings 
were compared with those of each subgroup, lay and HCPs; white and ethnic 
minority. Table  2-8 shows interim prioritisation gender and age group, whereas 
Figures 2.11 to 2.14 show the rest of interim prioritisation socio-demographic data. 
Majority of respondents (70.1%) were white.”   
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Figure  2-9:- Interim prioritisation participants 
 
“The highest 30 overall ranked questions included the following number of questions 
from each group’s top 30: women with endometriosis 30 (score 72), HCPs 25 (score 
67) and HCPs who have endometriosis 30 (score 72). A sample of this analysis is 
demonstrated in Table  2-7 and the Appendix  A.5 shows the full analysis. Given this 











Table  2-8:- Initial survey and interim prioritisation gender and age group 




Female 91% 97.5% 
Male 9% 2.3% 
Age group 
less than  18 - 0.5% 
18-24 7% 10.6% 
25-34 34% 38.2% 
35-44 36% 34.2% 
45-54 14% 11.9% 
50 and over 8% 4.3% 
Prefer not to 
say 
1% 0.2% 
 Gender queer* - 0.1% 
 Non-binary* - 0.1% 
* Were added, following initial survey respondents’ requests. 




Figure  2-12:- Interim prioritisation HCPs role 
 




2.13. Prioritisation the top 10 final workshop  
“The one-day workshop took place on 25
th
 April 2017. There were 26 participants 
including 15 women who have or have had endometriosis, two male partners of 
women affected by endometriosis and 11 HCPs (Appendix  A.8). The top ten to 
research priorities for endometriosis were agreed and are shown in Table  2-9, (JLA 
Endometriosis Top 10 Priorities, 2017).” 
Table  2-9:- Top 10 UK research priorities for endometriosis 
No Research Priority 
1 “Can a cure be developed for endometriosis?” 
2 “What causes endometriosis?” 
3 “What are the most effective ways of educating HCPs throughout the healthcare 
system resulting in reduced time to diagnosis and improved treatment and care 
of women with endometriosis?” 
4 “Is it possible to develop a non-invasive screening tool to aid the diagnosis of 
endometriosis?” 
5 “What are the most effective ways of maximising and/or maintaining fertility in 
women with confirmed or suspected endometriosis?” 
6 “How can the diagnosis of endometriosis be improved?” 
7 “What is the most effective way of managing the emotional and/or 
psychological and/or fatigue impact of living with endometriosis (including 
medical, non-medical and self-management methods)?” 
8 “What are the outcomes and/or success rates for surgical or medical treatments 
which aim to cure or treat endometriosis, rather than manage it?” 
9 “What is the most effective way of stopping endometriosis progressing and/or 
spreading to other organs (e.g. after surgery)?” 
10 “What are the most effective non-surgical ways of managing endometriosis-





“The findings of the endometriosis PSP were disseminated to the research community 
by publishing them in the Lancet (Horne et al., 2017) and by presenting them at 
World Congress on Endometriosis (WCE) held in 2017 in Vancouver.  
A commentary on the findings was published in the BMJ (Mayor, 2017) which is 
widely read by HCPs. Engagement with potential funders has included meetings held 
between SG members and representatives of funders including the NIHR Evaluation, 
Trials and Studies Coordinating Centre (NETSCC), Wellbeing of Women and the 
Medical Research Council. The JLA, WERF and EUK also disseminated the 
findings via their websites and shared them with partner organisations through their 
own networks. The priorities that do not make it to the top 10 were published in the 
JLA website and could be chosen for further work by researchers with areas of 
expertise.  
HTA will be looking further into the following priorities “management of the 
emotional and /or psychological and/or fatigue impact of living with endometriosis 
(including medical, non-medical and self-management methods)? and Benefits of 
different hormonal treatments and the effective way of stopping endometriosis 
progressing and/or spreading to other organs (e.g. after surgery)? Whereas priority on 
improving diagnosis, will be looked by Efficacy and Mechanism Evaluation 
programme as this work is too early for HTA. And finally, priority of best way of 
educating HCPs will be looked by NIHR public health research programme. 
2.15. Discussion  
“Identifying research priorities for endometriosis highlighted the paucity of evidence 
that underpins many aspects of care for women with this health condition. This PSP 
received input from over 2600 respondents via the online surveys across two stages 
of prioritisation. Of the 4378 research questions generated in this study, none of 
these questions had been answered by level 1 evidence (i.e. systematic review of 
randomised controlled trials within the last 3 years). From a long list (72 summary 
questions) a final top 10 research priorities was identified in a face-to-face workshop. 
The primary objective of this PSP was to bring together women living with 
endometriosis, their carers and HCPs to address uncertainties and to prioritise those 
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that require greater research attention. This was achieved and it is hoped that this will 
result in further targeted funding to address topics including the identification of 
causes of endometriosis, educating HCPs about the condition and the development of 




“One of the major strengths of the JLA endometriosis PSP is the systematic and 
transparent methodology that we used to identify the research priorities in a large and 
genuine partnership of people living with endometriosis and HCPs with experience 
of endometriosis. The top ten questions spanned all aspects of endometriosis 
including causes, natural history, awareness, symptoms (including subfertility), 
diagnostic approaches, prevention, treatment options (including lifestyle factors), 
treatment outcomes and co-morbidities. Our PSP successfully established the top ten 
research questions for endometriosis which was the primary aim of the JLA. 
Collaborative priority setting between women with endometriosis and HCPs is seen 
as a novel positive progress in research prioritisation. The results of our PSP reflect 
the varied roles of participants in the collaborative and the involvement of both 
women with endometriosis and HCPs.”  
It was clear that there were disparities in the research questions proposed by women 
who have or have had endometriosis and HCPs, but this reflected their differing 
experiences of this condition. For women with endometriosis, risk factors, causality 
and lack of public awareness were the predominant questions, and as a result the top 
ten priorities included more ‘patient-centred’ topics related to health-service delivery 
such as “what are the most effective ways of educating HCPs throughout the 
healthcare system resulting in reduced time to diagnosis and improved treatment and 
care of women with endometriosis” as empowering women to raise concerns with 
HCPs about such matters. Questions identified by HCPs alone were mainly 
concerned with improving outcome and/or success rate of surgery (excision versus 
ablation) and the desire for non-invasive tools for diagnosis such as “what are the 
outcomes and/or success rates for surgical or medical treatments which aim to cure 
or treat endometriosis”. 
“This collaboration is there unique given it has been developed with  patients’ input, 
and included questions about the effective ways of maximising and/or maintaining 
fertility in women with confirmed or suspected endometriosis. To our knowledge, 
this is the first time where women who have or have had endometriosis have worked 
together with HCPs to prioritise research questions. The response to both surveys 
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was comparable with other PSPs as shown in Table  2-10. The good response rate we 
had was because our surveys were distributed widely in a variety of different media 
formats, including social media platforms. Moreover, our surveys included a very 
wide range of HCPs from different parts of the UK and, as discussed previously, had 
many themes. The positive response to our PSP is encouraging and consideration 
should be given to conducting PSPs for other women-related conditions such as 
infertility as demonstrated previously in dermatology where PSPs have successfully 
produced a growing body of information regarding research priorities for both 




Table  2-10:- Response rate to JLA priority setting partnerships in comparison to 
endometriosis 
JLA PSP 
Number of survey 
respondents 
Number of questions 
submitted 
Bipolar 3285 14398 
Depression 3000 10000 
Sight loss and vision 2220 4461 
Dementia 1563 4116 
Endometriosis 1237 4767 
Autism 1213 3331 
Miscarriage 1093 3279 
Diabetes (Type 1) 583 1141 
MS 507 1084 
Vitiligo 461 1427 
Asthma 370 267 
Lyme Disease 253 967 
Stroke in Scotland 106 548 
 
“Our research prioritisation process is strengthened by the participation of respondents 
from various roles, ages and ethnic groups. Moreover, our research priority has been 
defined by a large number of women with endometriosis, family members/carers and 
professionals with relevant experience and it includes a wide range of topics. The 
involvement of such a diverse mix of women with endometriosis, their carers and lay 
stakeholders is viewed as philosophically correct and gives the resultant priorities 
legitimacy (Wiseman, 2005). The involvement of HCPs, patients and carers not only 
increased the credibility and transparency of the final output as has been recognised 
in many other prioritisation processes (Bryant et al., 2014, Janovsky and World 
Health Organization, 1996) but also ensured that these priorities were relevant and 
feasible. The involvement of a broad base of different stakeholders throughout the 
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decision-making process was helpful to develop much needed priorities for research 
in this under-recognised, under-researched health condition.” 
“The final prioritisation workshop enabled all contributing groups to voice their 
opinions, thus shaping the order of the top ten research questions to reflect these 
different, but equally important perspectives. Without such strong patient 
involvement, it is unlikely that the questions relating to educating HCPs, 
psychological consequences or non-medical non-surgical treatments for 
endometriosis would have ranked so highly and yet these aspects of living with the 
consequences of treatment really matter to patients. As a SG, our common 
experience of this condition, from both patients and HCPs, is the treatment, and this 
is reflected in the large proportion of our research priorities focusing on this aspect of 
care (more than 1000 questions from first survey). Nonetheless, our highest priority 
is the cure for endometriosis.”  
 Limitations 2.15.2.
“Care was taken to account for demographic differences between respondents, 
especially ethnicity and HCPs compared with those who have or have had 
endometriosis. It should be noted that individuals of Asian, black and other ethnicity 
groups as well as older women make up a proportion of women diagnosed with 
endometriosis and were under-represented in these two surveys. Moreover, no data 
were collected on social status, income and level of education, which may bias the 
results as different priorities might emerge from different social classes. 
Unfortunately, meaningful analysis of themes by age could not be conducted in our 
study due to the small numbers in many age groups.”  
“The primary focus of this PSP was on identification of priorities for research funding 
in the UK and Ireland and responses from individuals who gave their location as 
being outside the UK were not included in the analysis described in this chapter not 
in the priority setting workshop, this make results primarily relevant to UK funders 
and researchers, with relevance to other countries uncertain. Data from international 
respondents have been retained and may be subject of further analysis and 
comparison with future international PSP.”  
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“Another limitation is the fact that the questionnaire was internet based and the 
website was English. Although paper versions were available if required, the English 
website may have restricted access to some respondents. Consequently, this internet-
based approach may have excluded potential respondents from socially 
disadvantaged or ethnic minority groups with limited access to the internet. To 
address this issue a purposive sampling method would be required involving 
specialist organisations or focus groups to discuss the interim priorities in minority 
groups.” 
“The main output of a JLA PSP has traditionally been a top 10 list of questions that 
focus on treatment. To consider a treatment uncertainty to be answered an up-to-date 
systematic review is required. Recent PSPs, including this one, have considered 
questions broader than treatment questions. This includes questions which by 
definition, cannot be answered by a systematic review of treatments and cannot be 
addressed by a single research study (Chalmers et al., 2013) such as, “what are the 
most effective ways of educating HCPs throughout the healthcare system resulting in 
reduced time to diagnosis and improved treatment and care of women with 
endometriosis?”. Therefore, none of our 72 summary questions could be answered 
by existing literature. Although this approach has merits in term of inclusivity it may 
also result in priorities being skewed towards common conditions with rarer 
conditions diluted due to wide public consultation.”  
2.16. Comparison with other published research 
recommendations for endometriosis 
Guidelines published by Cochrane, NICE and the ESHRE have highlighted research 
gaps in endometriosis investigation and management. For example, “are specialist 
lifestyle interventions (diet and exercise) effective, compared with no specialist 
lifestyle interventions, for women with endometriosis?”, “Is there a role for 
secondary prevention of endometriosis?”; and “Diagnostic studies establishing the 
test accuracy and clinical utility of urinary peptides and other urinary tests in 
diagnosing endometriosis?”. Our PSP process has confirmed these questions to also 
be important to women with endometriosis and HCPs.  
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Recommendations of priorities set by researchers (Rogers et al., 2017) overlap with 
the top ten identified from this exercise. For instance, “advances in imaging 
techniques should be monitored for application to diagnosis of endometriosis”, 
overlaps with our forth unanswered research question as well as the important of 
including women with endometriosis in research. For example, “women with 
endometriosis should be included in meetings and focus groups to develop new 
insights and approach to research. Moreover, participants in Vancouver 2017 were 
invited to participate in a survey to prioritise the 72 questions used in our second PSP 
survey and the results are awaited.  
“Comparing our priorities with those of the miscarriage and stillbirth demonstrated 
some overlap, as there was desire to see further research into how best to provide 
emotional support to women experiencing all three conditions and both the 
endometriosis and miscarriage partnerships prioritised lifestyle factors seventh and 
fifth, respectively. To complete this spectrum of prioritisation, other PSP might be 
required such as fertility PSP.” 
2.17. Clinical implications 
“Clinicians need to be cognisant of the uncertainty in the treatment of endometriosis 
when counselling women. Our seventh priority in the top 10 is about the emotional 
and/or psychological wellbeing of women with endometriosis and this area of care is 
often overlooked. Most women do not receive any in-depth information about 
endometriosis or are offered any psychological or emotional support. There has been 
very little good quality research on improving emotional health for couples with 
endometriosis (NICE, 2017). The inclusion of questions like this, regarding the 
delivery of clinical care, confirms the findings from other priority setting processes 
and demonstrates the importance of including those affected by the condition in 
research-prioritisation exercises (Boivin et al., 2014).”  
“For those women diagnosed with endometriosis, the challenges lie in personalising 
care and improving QOL during and following treatment. Therefore, we need to 
prioritise research into developing therapies that are not only effective but also have 
minimal side effects. Additionally, recognising that a diagnosis of endometriosis and 
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its treatment has psychological, as well as physical, effects will pave the way for 
much needed research into interventions to improve the psychological wellbeing of 
women with this condition. This focus would allow us the opportunity to identify the 
rising number of women with endometriosis earlier to allow effective treatment 
sooner. Our findings highlighted that early diagnosis can provide better opportunities 
for treatment in specialised centres by experienced professionals.” 
A focus on educating the public about symptoms of endometriosis and training 
primary HCPs to better identify women with endometriosis are two of the main 
priorities that have been identified by women with endometriosis. Our results 
demonstrated that women who have or have had endometriosis are more likely to 
perceive that their healthcare needs are inadequately met therefore highlighting the 
need for further work to educate and train HCPs about endometriosis and its 
management.  
“The top 10 questions represent consensus areas of research priority to guide future 
research, deliver responsive and strategic allocation of research resources, and 
improve the future health and well-being of people living with, and at risk of, 
endometriosis.” 
2.18. Research implications 
“Many other priorities especially psychological and emotional support are less well-
researched areas. We hope our results will encourage both researchers and funders to 
focus on these priorities. More research is also needed into non-drug interventions 
that aim to empower women to improve their overall health and reduce the risk of 
recurrence, thus enhance their physical and emotional wellbeing such as “what are 
the most effective non-surgical ways of managing endometriosis-related pain and/or 
symptoms (medical/non-medical)?”. Some questions cover broad topics, overlap 
with other questions, or do not translate easily into questions or research studies that 
can be designed to be answered.”  
“We understand that future research must be high quality as simply adding more poor 
quality studies will not provide answers to these important questions. Study design 
must be appropriate to the research question, and follow EQUATOR guidelines 
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(Enhancing the QUAlity and Transparency Of health Research) for publication. The 
breadth of topics covered by the top 10 unanswered questions is testament to the 
clear need for further research, not only into the cure of endometriosis, but also into 
the development of non-invasive screening tools to aid the diagnosis of 
endometriosis. Educating HCPs has also been listed as a top priority. It is hoped that 
this approach will address the adverse psychological and emotional effects of 
endometriosis. Such research requires a multidisciplinary approach, reflecting the 
multidisciplinary origin of the research priorities.” 
“Involving women of black and/or minority ethnic groups remains difficult and going 
forward, we will need to seek appropriate advice to ensure the involvement of this 
population given they form a proportion of women with endometriosis. This will aid 




“A significant challenge remains to ensure the PSP findings are taken up by the 
academic community and influence funding agencies. Researchers who focus their 
future work on these top 10 priorities will have a strong basis on which to build 
ongoing public involvement in research and have the clear potential to impact 
significantly on the lives of people living with endometriosis.”  
“We recognise that this primary focus, if successfully delivered, will improve the 
QOL of women with endometriosis for potentially a small investment than research 
into treatment alone. Highlighting a list of top ten unanswered research questions 
does not obviate the need for research into other areas included in this PSP.”  
“The list of top ten priorities should, therefore, serve only to focus the discussion on 
how limited funding could be distributed to best meet needs and not be used as an 
absolute list. We hope, by sharing the remaining list of uncertainties, researchers 
with areas of expertise outside this top ten will continue to address the many other 
issues that affect women with endometriosis and the HCPs who care for them. 
Perhaps the most important part of this process has been the strengthening of 
relationships between partner organisations, patients and HCPs. As a result, we have 
developed a list of core aims to be worked on collaboratively to deliver 




Chapter 3. A pilot randomised double blind controlled 
trial of the efficacy of purified fatty acids for 
the treatment of women with endometriosis-
associated pain (PurFECT) 
3.1. Background 
“An ideal therapy for endometriosis would (i) reduce the painful symptoms associated 
with the condition, (ii) reduce lesion size, by modifying the disease processes 
(Nunley et al.) preserve the patients’ ability to conceive whilst on medication, and 
(iv) have no, or limited, side effects. As reported in Chapter 2, one of the priorities 
for research identified in the endometriosis PSP was to find ‘the most effective non-
surgical ways of managing endometriosis-related pain and/or symptoms’. At an 
international consensus workshop following the 2014 World Endometriosis Congress 
experts reviewing the alternatives for non-surgical treatments reported that many 
women with endometriosis tried dietary modification in an effort to manage 
symptoms but that this tended to be of limited or unproven benefit (Rogers et al., 
2017). A review of the literature published by (Hansen and Knudsen, 2013) 
concluded that specific types of dietary fats might be associated with endometriosis 
but that further research was required.” 
“Omega-3 PUFA are a FDA-approved dietary supplement. Omega-3 PUFA are 
thought to have an impact on inflammatory disorders by competing with Omega-6 
PUFA to produce lipid mediators which are anti-inflammatory as opposed to pro-
inflammatory (Calder, 2015). An epidemiological study in Japan (1920 people) 
reported that dietary Omega-3 PUFA may protect against carotid atheroschlerosis 
(Hino et al., 2004).”  
Notably in a rat model of endometriosis animals fed with N-3 EPA had higher 
N3:N6 in their lesions as well as reduced PG and cytokine production (Netsu et al., 
2008). Transgenic Fat-1 mice have high endogenous levels of Omega 3-PUFA and 
when these mice were used in a model of endometriosis it was found that both 
endogenous and exogenous (EPA administration) had an impact on interleukin-6   
and development of lesions (Tomio et al., 2013).  
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“A low ratio of Omega-3: Omega-6 PUFA intake was reported to be correlated with 
painful menstruation and a high rate of autoimmune and endocrine disorders in 
women with endometriosis (Deutch, 1996). In a large, prospective cohort study using 
12 years of data from the Nurses’ Health Study II that began in 1989 women in the 
highest fifth of long-chain omega-3 PUFA consumption were less likely to be 
diagnosed with endometriosis (Missmer et al., 2010).”   
“These data suggest that dietary modification of the amount of omega-3 PUFA might 
offer a potential treatment for endometriosis and associated symptoms. A definitive 
evaluation of the efficacy of Omega-3 PUFA in the management of endometriosis-
associated pain will require a large-multicentre RCT with adequate numbers of 
patients in each arm. A full scale RCT is expensive and the study described in this 
chapter is a pilot study to provide insights into the feasibility of conducting such a 
trial. Olive oil capsules, which do not contain Omega-3 PUFA, were used as a 
comparator due to lack of availability of a matched placebo.”  
 Primary objectives 3.1.1.
“This was a pilot feasibility trial. The primary objectives were to assess recruitment 
and retention rates. Recruitment was defined as the proportion of eligible patients 
who agreed to participate out of the total number of patients approached. Retention 
was defined as the proportion of the participating patients who completed both the 
baseline and follow-up visits.  Randomisation occurred four weeks after recruitment, 
when eligibility was confirmed with pain scores and a negative pregnancy test.” 
 Secondary objectives 3.1.2.
 Estimation of variability of responses for the sample size calculation for the 
main trial. 
 Acceptability of proposed methods of recruitment, randomisation, treatments 
and questionnaires.   
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3.2. Methods  
 Study design 3.2.1.
“A single centre, two-arm prospective parallel double-blind 1:1 randomised controlled 
pilot trial was conducted as shown in Figure  3-1. Participants, myself, other 
attending clinicians and the trial statistician remained blind to the trial drug 
allocation and the allocated code for the duration of the treatment phase.” 
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 Study settings 3.2.2.
“Women were recruited from gynaecology outpatient clinics, gynaecology wards and 
day surgery units within NHS Lothian, UK (Royal Infirmary of Edinburgh and St 
John’s Hospital).” 
 Study participants 3.2.3.
“Women with a surgical diagnosis of endometriosis and associated pelvic pain were 
recruited over a 12-month period from June 2016 to June 2017.”  
 Ethical approval 3.2.4.
“I have completed ethical approval, IRAS and local REC and the ethical approval was 
obtained from the Scotland A Research Ethics Committee (LREC 16/SS/0010) on 
02/02/2016 as shown on Appendix  B.1.”  
 Ethics, consent and permissions 3.2.5.
All participants gave written informed consent, Appendix  B.2, and agreed to take 
part in the study. 
 Trial registration  3.2.6.
The trial was registered with International Standard Randomised Controlled Trial 
Number (ISRCT) registry and the registration number: ISRCTN44202346 
 Research and development approval 3.2.7.
I have completed research and development (R&D) approval which was obtained 




3.3.   Inclusion and exclusion criteria 
 Inclusion criteria 3.3.1.
Women were eligible for inclusion if they met all of the following criteria:- 
 Aged between 18 and 50 years. 
 Pelvic pain for more than three months. 
 Pain located within the true pelvis. 
 Endometriosis diagnosed visually (macroscopically) by laparoscopy*. 
 A numerical rating average ‘worst’ pain score (NRS) of greater than or equal 
to four (see below for details). 
* I amended the protocol Appendix  B.4, and patient information leaflets (PIL),  B.5, 
in September 2016 and “3 years cut-off since diagnosis” was removed, to reflect the 
changes for the ethical approval which accelerated recruitment as shown in 
Figure  3-4.  
 Exclusion criteria 3.3.2.
Women were excluded if they had one or more of the following: 
 Unable to take/allergic to fish / PUFA / peanuts / soybeans. 
 Insulin-dependent diabetes. 
 Pregnancy. 
 Taking anticoagulants. 
 Breastfeeding. 




3.4. Study outcomes 
 Co-primary outcomes 3.4.1.
 Recruitment and retention rates.   
 Secondary outcomes 3.4.2.
 Estimation of the variability of responses to inform the primary outcome of 
the future definitive RCT.  
 Acceptability of proposed methods of recruitment, randomisation, treatments 
and questionnaires.  
3.5. Participant enrolment 
“At the beginning of the trial all the gynaecology consultants within NHS Lothian 
were sent an email informing them of the study, detailing the inclusion and exclusion 
criteria and requesting permission to approach their patients. This information was 
available to them in all outpatient areas during recruitment period. The 
gynaecologists’ decision to refer patients was based on their knowledge of the 
inclusion and exclusion criteria.”  
“Moreover, I monitored referrals to the NHS Lothian gynaecology outpatient 
department (OPD) over the recruitment period, to identify potentially eligible 
women. I approached any eligible women who agreed to be seen, provided them 
with PIL, offered them the opportunity to discuss the trial and make an informed 
decision as to whether they wished to participate. When a potential participant 
expressed an interest in taking part in the study, she was screened to confirm 
eligibility as detailed in section  3.7. Participants confirmed they were happy to 
volunteer for the study by signing a consent form. The number and reasons for 
screening failures were recorded on a screening log. Data were transferred to a 
password-protected server hosted by the UoE. Women were informed that they could 
withdraw from the study at any time without having to give a reason and that their 




“All participants completed a written consent form (Appendix  B.2) and agreed to take 
part in the study. Consent was only taken once the patient had ample time to read the 
PIL and ask questions about the trial. A further appointment was arranged, by me, 
for the participant to come for this visit.” 
3.7. Screening for eligibility 
“Eligibility for randomisation was confirmed by me based on the worst of four weekly 
NRS (0-10) pain scores collected by text messaging (‘run-in phase’, Figure  3-1). I 
contacted the participants via text messaging to remind them to send me their pain 
scores on weekly basis for the first 4 weeks and the last 4 weeks and I collated the 
scores. A score of four out of ten in two or more weeks was required to be eligible to 
be randomised. Texts were sent by me to the participants’ mobile phones, asking 
about average and worst pain respectively. The woman was asked to reply to the text 
message with her pain score, rating it from zero for no pain at all, to ten being the 
worst pain imaginable. To capture known cyclicity in pain, these texts were sent 
once a week during the eligibility phase (weeks minus one to minus four).”  
3.8. Intervention 
“Participants were randomised to one capsule of Omacor 1000 mg (Omega-3-acid 
ethyl ester filled capsules) or one capsule of the comparator (olive oil soft gelatin 
capsules which do not contain Omega-3 PUFA) which were taken twice a day, once 
in the morning and once at night with food. The allocated treatments were taken for 
eight weeks. Omega-3 PUFA have been used clinically in previous trials (post-
myocardial infarction and for hypertriglyceridemia) at doses of 1000-4000mg daily 
(in divided doses of 1000mg or 2000mg) (Begg et al., 2012). However, high dosage 
(i.e. 4000mg) has been associated with a moderate increase in bleeding time 
(Omacor, 2018) so we chose to pilot a lower dose and frequency of one capsule 
(1000mg) twice a day. I approached the MHRA (Medicines and Healthcare products 
Regulatory Agency) for advice regarding Omega-3 PUFA and olive oil. As both 
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Omega-3 PUFA and olive oil capsules are ‘food supplements’, our trial was not 
deemed Clinical Trial of an Investigational Medicinal Product (CTIMP).” 
3.9. Randomisation procedure 
“The randomisation scheme was drawn up by an independent statistician, using 
random number tables, with 1:1 allocation ratio and the allocated treatment codes put 
into sealed consecutively numbered opaque envelopes. When a participant was 





3.10. Data collection 
 Pain scores 3.10.1.
During the treatment phase of the study, I collected pain scores once a week by text 
messaging. In the last four weeks of the treatment phase (week’s five to eight) the 
same study procedures as during the ‘run-in phase’ were applied.  
 Questionnaires 3.10.2.
Women were given the questionnaires, which I designed, below to complete at 
baseline and eight weeks. Questionnaires can be found in Appendix  B.6, were 
completed in private and participants had the opportunity to ask questions and 
discuss any concerns. Baseline demographic and relevant clinical characteristics of 
the participants were also recorded at baseline. The questionnaires participants 
completed are listed below and explained in sections 3.10.2.1-3.10.2.8:- 
 12-item short-form health survey (SF-12)  
 Brief pain inventory (BPI)   
 Brief fatigue inventory (BFI)        
 Work and productivity impairment questionnaire-specific health problem 
version 2.0 (WPAI-SHP)  
 General health questionnaire-12 (GHQ-12)    
 Pain catastrophising questionnaire (PCQ)                                                                        
 Sexual activity questionnaire (SAQ)                                   
 Pain DETECT™ questionnaire (PDQ) 
“An additional acceptability questionnaire was also completed at the end of the study. 
The case report form (Appendix  B.7), which I designed, also included questions 
about whether participants believed that they were receiving Omega-3 PUFA or 
olive oil, the acceptability of the allocated medication, treatment regimens (and 
compliance) and the acceptability of completing trial specific procedures including 
the questionnaires. I have used these questionnaires to cover how endometriosis 
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affecting all aspects of women’s lives.  All questionnaires were anonymised and self-
completed in private.”   
3.10.2.1. 12- Item short-form health survey (SF-12)  
The SF-12 is a health and wellbeing survey. It consists of 12 items and it assesses the 
health of the patient from their perspective. It has summary scores, a physical 
component status and an emotional component. The physical component requests the 
participant to choose from three options (“yes, limited a lot”, “yes, limited a little”, 
or “no, not limited at all”) for example, “how much pain limited their daily activities 
such as climbing stairs?”. 
“The emotional component asks if there are any emotional problems that have 
interfered with work or regular daily activities over the preceding four weeks (Ware 
Jr et al., 1996). The SF-12 was originally developed for the Medical Outcome Study 
of patients with chronic conditions in the US in order to provide an easier and shorter 
alternative to SF-36 (Ware Jr et al., 1996) and it has been validated regularly (and 
repeatedly) for the QOL measures.”  
3.10.2.2. Brief pain inventory (BPI)   
“The BPI questionnaire is one of the tools for pain assessment. There are two 
dimensions to evaluate pain, pain interference and pain intensity. The BPI requests 
participants to rate their pain at the time of completing the questionnaire and rate the 
pain at its worst, least and average over the last 24 hours. Each of these parameters is 
measured on a zero-to-ten scale (where zero represents no pain and ten is the worst 
imaginable pain).” 
“The BPI interference asks with regards to participants medications or treatments they 
are receiving for their pain and to rate how much their pain interferes with their 
general activity, mood, walking ability, normal work (both work outside the home 
and housework), relations with other people, sleep and enjoyment of life. Each of 
these parameters is measured on a zero-to-ten scale (where zero does not interfere 
and ten completely interferes).”  
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“The BPI was developed by the World Health Organisation (WHO) pain research 
group to evaluate the severity of pain and interference in cancer patients (Cleeland 
and Ryan, 1994). Moreover, BPI been recommended by the Initiative on Methods, 
Measurement, and Pain Assessment in Clinical Trials (IMMPACT) to assess the 
physical function and pain intensity (Dworkin et al., 2005). It has been used 
primarily to assess cancer-associated pain followed by non-malignant chronic pain 
(Tan et al., 2004).”  
3.10.2.3. Brief fatigue inventory (BFI) 
“The BFI questionnaire was developed for the rapid assessment of the severity of 
fatigue experienced by cancer patients, as well as its impact on their ability to 
function over the preceding 24 hours (Mendoza et al., 1999). It is a short scale and is 
designed to be well tolerated by patients suffering even the most severe degrees of 
fatigue. The BPI can be used in a clinical setting as part of patient screening 
processes and is useful for clinical trials (Yun et al., 2005). It asks participants to rate 
their fatigue, tiredness and weariness, and to describe the usual and the worst level of 
fatigue they experience (from zero with no fatigue to ten for as bad as they can 
imagine). It also asks, during the past 24 hours, how fatigue has interfered with 
general activity, mood, walking ability, normal work, relations with other people and 
enjoyment of life (where zero means that is does not interfere and ten completely 
interferes).”    
3.10.2.4. Work and productivity impairment questionnaire-specific 
health problem version 2.0 (WPAIQ) 
“The WPAIQ has four outcome measurements, which are: absenteeism, presenteeism, 
work productivity loss and activity impairment. It is a self-administered 
questionnaire, which aims to elicit the impact of CPP on impairment and work loss 
and whether the interventions reduce the number of impairment days and days lost to 
work. The WPAIQ is an instrument that measures impairments in both paid and 
unpaid work as well as absenteeism and presenteeism during the past seven days. It 
has been validated in numerous chronic conditions such as irritable bowel syndrome 
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(Reilly et al., 2004), Crohn’s disease (Margaret et al., 2008) and in rheumatoid 
arthritis (Zhang et al., 2010).” 
3.10.2.5. General health questionnaire-12 (GHQ-12) 
“The GHQ-12 consists of 12 items. It assesses the health of the patient from their 
perspective and is intended to screen for general (non-psychotic) psychiatric 
morbidity (Goldberg and Williams, 2006). It has been widely used, translated into 
many languages and extensively validated in general and clinical populations 
worldwide (Hardy et al., 1999). The 12 items describe mood states, six of which are 
positively phrased and rest are negatively phrased. It includes questions about the 
ability to concentrate and address problems, confidence and happiness and the 
participants are encouraged to answer by choosing from better than usual, the same 
as usual, less than usual or much less than usual.”      
3.10.2.6. Pain catastrophising questionnaire (PCQ) 
It is well documented that catastrophic thinking heightens the pain and distress 
experienced by the catastrophiser (Sullivan et al., 1995). Catastrophising is defined 
as an exaggerated negative mental set brought to bear during an actual or anticipated 
painful experience. The PCQ has 13 items and all have excellent internal 
consistency. It has been used to describe a tendency of the participants to expect the 
worse and to exaggerate or ruminate on pain. Using PCQ helps a study to identify a 
subset of the participants who were catastrophisers and so, if catastrophising affects 
the outcome of the interventions in this subset of catastrophisers.  
It is a comprehensive tool to capture the different aspects of catastrophising: 
rumination “I can’t stop thinking about how much it hurts”, magnification “I worry 
that something serious may happen” and helplessness “it is awful and I feel that it 
overwhelms me”. 
3.10.2.7. Sexual activity questionnaire (SAQ) 
“The SAQ was developed to assess the impact of tamoxifen in a chemoprevention 
trial on the sexual function of women at high risk of developing breast cancer 
(Thirlaway et al., 1996). It requested participants to rate their sexual pleasure (desire, 
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enjoyment and satisfaction), discomfort (dryness and pain) and habit (habitual sexual 
behaviour) during the past month. The questionnaire consists of ten items and it has a 
valid, reliable and is an acceptable measure assessing sexual function in patients with 
cancer. Moreover, it has a satisfactory response rate and good feasibility (Ganz et al., 
2002).”                                   
3.10.2.8. Pain DETECT™ questionnaire (PDQ) 
“The PDQ is a brief, patient-based, self-administered screening tool designed to 
determine the presence and the prevalence of a neuropathic pain component in the 
usual clinical setting. It is well documented that neuropathic and nociceptive 
components both contribute to pain. Since these components require different pain 
management approaches and correct pain diagnosis before and during treatment is 
highly desirable (Freynhagen et al., 2006). PDQ is a reliable screening tool with high 
sensitivity, specificity and positive predictive accuracy (Freynhagen et al., 2006).” 
It asks the participants to describe the character and course of their pain “persistent 
pain with slight fluctuations”, “persistent pain with pain attacks”, “pain attacks 
without pain between them” or “pain attacks with pain between them”. It also asks if 
the pain radiates to other regions of the body and if so, the participants are asked to 
describe the characteristic of the pain “any burning sensation”, “tingling or 




 Treatment diaries 3.10.3.
“Participants were provided with a treatment diary which I have designed, 
Appendix  B.8, at the same time as their medication pack was dispensed at baseline 
visit. All medications other than the trial treatment taken during the treatment phase 
of the study were recorded in the treatment diary as shown in Appendix  B.8. This 
included prescription and non-prescription treatment, such as oral analgesics, 
contraceptives, vitamins, topical preparations and herbal preparations.”  
 Participant log 3.10.4.
I kept an anonymised electronic log of women who fulfilled the eligibility criteria 
which includes, women who are invited to participate in the study, women recruited 
and women who left the trial early. Reasons for non-recruitment, e.g. non-eligible 
and refusal to participate were recorded. During the course of the study, all effort 
was done to collect all reasons why someone would withdraw from the study and lost 
to follow-up.  
 Termination of study (end of study) 3.10.5.
“The plan was to break the blinding code in emergency situations for reasons of 
patient safety, where knowledge of the treatment administered is necessary for the 
treatment of a serious adverse event or when required by local regulatory authorities.  
Participants whose randomisation codes were to be broken would cease treatment but 
would continue to be followed-up. If the participant required to be unblinded in an 
emergency, then chief investigator or pharmacy would be contacted. The end of the 
study was defined when the last participant completed the trial (follow-up of last 
participant was completed on 15 June 2016).” 
 Adverse events 3.10.6.
“Participants collected information about adverse events in their treatment diaries. 
They were also instructed to contact me at any time after consenting to join the trial 
if they had an event that required hospitalisation or an event that resulted in a 
persistent or significant disability or incapacity. Omega-3 PUFA is an FDA-
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approved dietary supplement and serious adverse events (SAEs) were not 
anticipated.”  
“Any SAEs that would occur after joining the trial were to be reported in detail in the 
participant’s medical notes, followed-up until resolution of the event and reported to 
the Academic and Clinical Central Office for Research & Development Research 
Governance (ACCORD) and quality assurance office based at the UoE immediately 
or within 24 hours.”  
“ACCORD onward report all SAEs within seven days. Hospitalisation for a pre-
existing condition e.g. exacerbation of pain due to endometriosis will not be 
considered a SAE but will be documented. In addition, each participant was asked 
about the occurrence of adverse effects at the final visit by using open-ended and 
non-leading verbal questions.”  
3.11. Sample size 
“The emphasis in this study was to establish feasibility, not statistical significance of 
any outcome measure and it was therefore designed primarily to explore the 
recruitment and retention rates. To achieve this, the aim was to recruit as many 
women as possible over a 12-month period.  It was estimated that I would recruit 
approximately four to five patients per month and as a result, 40 patients would be 
recruited by the end of the recruitment period. As we anticipated a recruitment rate 
of 50%, 40 participants would be able to give a 95% confidence interval of 35-65%. 
Data from this pilot study were to be used to refine sample size calculations for any 
future RCT.”    
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3.12. Statistical analysis 
“A statistical analysis plan, as shown in Appendix  B.9 , was agreed with the trial 
statistician (Dr Linda Williams, UoE) prior to a database lock. I calculated the 
proportion of eligible women randomised, of randomised participants who were 
followed-up to 8 weeks and provided estimates of these with 95% confidence 
intervals (CI). In addition, I determined the nature and number of unanswered 
questions in each questionnaire. The analysis by treatment group in this report was 
by intention-to-treat, in which all participants who were randomised into the study 
were analysed into the group to which they were randomised regardless of treatment 
received.”  
“A per protocol analysis was run in which participants who did not attend the three 
visits were removed. The change from baseline to follow-up for PUFA was 
compared to the change from baseline to follow-up with the comparator and analysed 
using the t-test. Only patients followed up at 8 weeks were included. For each 
outcome measured, the difference between the treatment groups was calculated using 
analysis of the difference in mean from baseline scores. Where there was missing 
data for an outcome variable, those records were removed from the analysis for that 
variable. Statistical analysis was performed using ME and SPSS software version 23. 
The study continued until the planned date of finishing recruitment.” 
 Statistical methods 3.12.1.
I completed the PurFECT data analysis following the plan agreed and supported with 
Dr. LW, the trial statistician. 
3.12.1.1. Description of population flow 
A flow diagram, recommended by CONSORT, (Schulz et al., 2010) was produced to 
describe the patient flow through each stage of the study as shown in Figure  3-2. 
3.12.1.2. Baseline characteristics 
Although the baseline and follow up data were skewed, the changes from baseline 
data were not. These values were symmetric and reasonably normally distributed. 
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There was a reasonable sample size (13 and 14 patients) and so there was no 
evidence to suggest that a parametric test was inappropriate. The t-test was used 
because it is robust to small deviations from normality and allows us to generate an 
estimate of effect and precision on the original scale, which would be difficult with 
non-parametric tests. One of the secondary endpoints was to estimate the variability 
of the results to inform a future trial, which would have been impossible with a non-
parametric test. 
The study population was tabulated as per Table  3-1. Categorical data was 
summarised by frequencies and percentages. Continuous data was summarised by the 
number of responses, mean and standard deviation. Median and interquartile range 
(IQR) were used when data appeared skewed (Altman and Doré, 1990). 
3.12.1.3. Compliance to allocation 
Compliance was monitored by self-reported treatment diaries which were returned to 
me at visit 3 (week 8) as shown in Table  3-2. Compliance was defined by the 
following categories: equal to or more than 75% good compliance (both capsules); 
50-75% reasonable compliance (one capsule); less than 50% poor compliance (zero 
capsules).  
3.12.1.4. Analysis methods – primary outcome 
“Using the information collected from the participant log, I determined the number of 
patients recruited from the pool of eligible women and more than 50% recruitment 
was deemed acceptable. While a retention rate of 100% would be ideal, a rate of 
80% would be considered satisfactory. I provided an estimate of the percentages and 
its 95% CI. In addition, I determined the nature and number of unanswered questions 
in each questionnaire. The aim was to determine whether the trial design was 
performed well enough in the field to warrant proceeding with a full trial. All 
analysis was carried out by me, with support from LW and my supervisors, at the 
UoE.” 
“A point estimate and 95% CI were reported for recruitment and retention, in order to 
inform the sample size calculation for a larger trial. For the secondary outcome 
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measures, estimates of treatment effects were presented with 95% two-sided CI. P-
values were reported from two-sided tests at the 5% significance level. A two-sided 
P-value of ≤ 0.01 was considered statistically significant.” 
3.12.1.5. Analysis methods – secondary outcomes 
These areas were assessed quantitatively using questions included in the participant 
questionnaires administered at baseline and eight weeks. Data collected from the 
different questionnaires were used to explore comparisons between the two groups 
and were reported as estimates of difference and corresponding CI in order to 
calculate the sample size. Due to the conflicting literature about the benefits of 
methods such as prescription monitoring, pill counting and devices for monitoring 
the self-administration of medicines, data on blinding and compliance to treatment 
(by asking the participants what they thought they have taken) were derived from 
questionnaires at eight weeks. The aim was to determine if the treatment was 
acceptable in terms of self-reported compliance from treatment diaries. Although this 
is a pilot study and the sample size is small, I calculated the effect of any non-
compliance and retention. This information is to be used to inform the design of the 
future RCT. 
The choice of p<0.01 was to balance the effect of multiple testing with the fact that 
the trial was not powered to detect differences between the groups in terms of the 
questionnaires. This allowed a cautious approach to any significant results, while still 
allowing me to detect any strong effect that might help inform the design of a future 
trial. Moreover, LW advised to go for 0.01 (instead of 0.05) for the secondary 
outcomes as a cut off for statistically significant because they are more exploratory, 
the multiple testing issues and because they are not the primary outcome on which 
the sample size was calculated.  
The result of the secondary outcomes is given in Table  3-3 . Analysis was performed 
in a similar fashion to the primary outcome for all domains in the following 
questionnaires: SF-12, BPI, BFI, GHQ, WPAIQ, PCQ, SAQ and PD-Q and 
acceptability questionnaire for the end of the study. The change from baseline to 
follow up was calculated for each patient, and then these changes were compared 
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between PUFA and olive oil by the t-test. When the distribution was not symmetric, 
transformations were applied to the data. 
 The two summary measures of the SF-12 QOL (Version 2) survey (Ware et 
al., 1995). 
- Mental component summary (0 = worst outcome, 100 = best outcome). 
- Physical component summary (0 = worst outcome, 100 = best outcome). 
Physical component includes questions 1, 2, 3 and 5 and emotional component 
includes questions 4, 6 and 7. 
 The two domains of the BPI short form: a comprehensive instrument for pain 
assessment (Keller et al., 2004). 
- Pain severity (0 = best outcome, 10 = worst outcome). 
- Pain interference (0 = best outcome, 10 = worst outcome). 
Pain severity was calculated from questions 1 to 4 whereas interference from 
questions 5 to 7. 
 The global fatigue score from the BFI: a tool to measure the severity of 
fatigue in adults (0 = best outcome, 10 = worst outcome) (Mendoza et al., 
1999). 
 The GHQ: a tool to identify psychological distress (0 = best outcome, 12 = 
worst outcome) (Jackson, 2007).  
 The four domains of the WPAIQ: a tool for assessing impairments in paid 
work and activities (Margaret et al., 2008). 
- Absenteeism (0 = best outcome, 10 = worst outcome). 
- Presenteeism (0 = best outcome, 10 = worst outcome). 
- Work productivity loss (0 = best outcome, 100 = worst outcome). 
- Activity impairment (0 = best outcome, 100 = worst outcome). 
Absenteeism was calculated by question 2 divided by the sums of question 2 and 4; 
presenteeism was question 5 divided by 10 and then multiplied by 100; work 
productivity loss was calculated by absenteeism plus 1 minus the sums of 
114 
 
absenteeism and presenteeism and activity impairment by question 6 divided by 10 
and then multiplied by 100. 
 The three domains and the total score of the PCQ: one of the most widely 
used instruments for measuring catastrophic thinking related to pain (Sullivan 
et al., 1995). 
- Rumination (0 = best outcome, 16 = worst outcome). 
- Magnification (0 = best outcome, 12 = worst outcome). 
- Helplessness (0 = best outcome, 24 = worst outcome). 
- Total (0 = best outcome, 52 = worst outcome). 
Rumination calculated from questions 8, 9 and 11; magnification from questions 6, 7 
and 13 and helplessness from questions 1 to 5 and 12. 
 The three domains of the SAQ: a valid, reliable and acceptable measure for 
describing the sexual function of women in terms of pleasure and discomfort 
(Thirlaway et al., 1996). 
- Pleasure (0 = worst outcome, 18 = best outcome). 
- Discomfort (0 = best outcome, 6 = worst outcome). 
- Habit (0 = worst outcome, 3 = best outcome).  
- Tired (0 = best outcome, 3 = worst outcome). 
Pleasure was calculated from questions 5-1, 5-2, 5-4, 5-7, 5-8 and 5-10; discomfort 
from questions 5-5 and 5-6; habit from questions 5-9 and tired from questions 5-3. 
 PainDetect™: is a new screening questionnaire to identify neuropathic 
components in patients (0 = best outcome, 35 = worst outcome) (Mathieson 
and Lin, 2013). 
 Acceptability: is a questionnaire to make the running of the study better in the 
future by understanding which works for the trial participants (1 = best 




3.12.1.6. Analysis methods – other summaries 
Other summaries included number of visits to HCPs for CPP as shown in Table  3-4, 
use of concomitant medications, use of analgesia as shown in Table  3-5, blinding 
assessment, overall health and pain scores can be found in  
Table  3-6, Table  3-7 and Table  3-8 respectively. Categorical data was summarised 
by frequencies and percentages. Continuous data was summarised by the number of 
responses, mean and standard deviation. Median and IQR were used when data was 
skewed. 
“The number of visits to HCPs for CPP was recorded in questions at baseline and end 
of treatment questionnaires. Use of concomitant medications was recorded to 
identify any reductions in analgesic use.” 
“Average and worst pain scores were recorded on NRS. Weekly pain scores (ranging 
from zero of no pain to ten for worst pain imaginable) were recorded during the first 
four weeks before randomisation (weeks minus one to minus four) as well as the 
final four weeks of treatment (weeks five to eight post randomisation) in the form of: 
i) ‘average pain this week’ and ii) ‘worst pain this week’. The average pain score was 
taken as the average of i) and worst pain score as the worst response from ii) as 
shown in Table  3-8.” 
3.12.1.7. Timing of outcomes  
Pain scores (average and worst NRS) were recorded in the pre-randomisation phase 
when a participant’s eligibility was assessed (four weekly measurements prior to 
randomisation) and in the final four weeks of treatment (weeks five to eight post 
randomisation) (Table  3-8).  
3.12.1.8. Loss to follow-up 
The loss to follow-up was defined as the number of participants who attended either 
one or two out of the three visits.   
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3.12.1.9. Safety data 
The proportion and percentage of patients experiencing any SAEs were presented by 
different groups. The total number of SAEs in each group was given along with a 
descriptive table of the events including the causality assessment and whether 
hospitalisation was required.  
3.12.1.10. Handling missing data 
“The analysis was completed on received data only after every effort was made to 
follow up all participants to minimise any potential bias. Participants were excluded 
from the primary analyses if they had pain scores less than two or if they withdrew or 
were lost to follow-up prior to the final assessment.”  
3.12.1.11. Statistical software 






 Description of population flow 3.13.1.
Of the 92 women referred, 73 were eligible for the study, 42 were recruited and 33 
randomised. From 73 eligible women, 42 (more than 50%) were interested in 
participating in the trial, ‘one participant failed screening due to positive pregnancy 
test just after the referral, two were ineligible due to the lack of the surgical 
diagnosis, 16 were not keen to pursue the trial, 11 were uncontactable and other 











                                                                                             














Eligible (n = 73) 
Total not eligible (n = 19) 
Diagnostic laparoscopy  
> 3 years (n = 12)* 
Allergic to fish (n = 1) 
Pregnant (n = 1) 
Asymptomatic (n = 3) 
No surgical diagnosis (n = 2) 
 
Randomisation (n = 33) 
1000 mg PUFA capsules    
(n = 17) 
1000 mg olive oil 
capsules (n = 16) 
Lost to 
follow-up 
(n = 3) 
Lost to 
follow-up 
(n = 3) 
Screened (n = 92) 
Lost to follow-up 
 (n = 9) 
Run-in phase ‘confirm 
eligibility’ (n = 42) 
Analysed (n = 14) Analysed (n = 13) 
Not interested (n = 16) 
Uncontactable (n = 11) 




 Baseline characteristics 3.13.2.
“Baseline data was complete and baseline characteristics were evenly distributed 
between the two randomised groups. The age range in the two groups varied from 21 
to 49 years old, and BMIs ranged from approximately 17 to 41. Table  3-1 presents 
participants’ characteristics per group. The majority of participants had a menstrual 
cycle, more than three-quarters of them attained a college/university degree and only 
one participant was non-Caucasian (Asian) in group comparator. More than half of 
the participants in both groups (57%) never smoked. Two thirds of them had never 
been pregnant before and all of them had at least one gynaecological operation. 79% 
of the recruited women had PE diagnosed. Less than half of the participants required 
contraception and Mirena IUS was the most popular method.” 
Response to the treatment may be affected by length and sensitisation of pain. This is 
demonstrated by the average duration of pain of 13.7 years in the PUFA group 
compared to 9.8 years in olive oil group. Four participants (two in the PUFA group 
and two in the olive oil group) chosen vegetarian and seafood for their diet habit and 
none of the participants taken dietary supplements (fish oil or olive oil or vitamins) 





Table  3-1:- Baseline characteristics  
 
Randomised Treatment All 
PUFA Olive Oil Participants 
N % N % N % 
Total number of participants randomised 
 





 Std. Deviation 8.57 9.59 







 Std. Deviation 7.89 4.29 
Range 18.3 - 41.1 16.9 - 33.4 
Highest education received 
Primary school 0 0 0 0 0 0 
Secondary school 3 11.1 3 11.1 6 22.2 
College/university 11 40.7 10 37 21 77.8 
Ethnicity 
Caucasian 14 51.9 12 44.4 26 96.3 




Randomised Treatment All 
PUFA Olive Oil Participants 
N % N % N % 
Smoking 
Smoker 3 10.7 1 3.6 4 14.3 
Ex-smoker 4 14.3 4 14.3 8 28.6 
Never smoked 8 28.6 8 28.6 16 57.1 
Diet habit 
Vegetarian  0 0 0 0 0 0 
Seafood 0 0 0 0 0 0 
Vegetarian and seafood 2 14.3 2 15.4 4 14.8 
Others 12 85.7 11 84.6 23 85.2 
Parity 
None 10 37 8 29.6 18 66.7 
1 or more 4 14.8 5 18.5 9 33.3 
Periods 
Yes 11 40.7 4 14.8 15 55.5 
No 3 11.1 9 33.3 12 44.4 
Pain during periods 
Yes 11 40.7 7 25.9 18 66.6 
No 3 11.1 6 22.2 9 33.3 




Randomised Treatment All 
PUFA Olive Oil Participants 
N % N % N % 
No 3 11.1 4 14.8 7 25.9 
Previous gynaecological operations 
1 4 28.5 7 53.8 11 40.7 
2 3 21.4 3 23 6 22.2 
3 or more 7 50 3 23 10 37 
Type of endometriosis 
Peritoneal 10 41.7 9 37.5 19 79.2 
Ovarian 1 4.2 1 4.2 2 8.3 
Deep 2 8.3 1 4.2 3 12.5 
Contraception 
Patch 0 0 0 0 0 0 
Nexplanon 0 0 0 0 0 0 
COC 1 3.7 1 3.7 2 7.4 
Depo-Provera 0 0 1 3.7 1 3.7 
POP 0 0 2 7.4 2 7.4 
Contraceptive ring 0 0 0 0 0 0 
Mirena 4 14.8 4 14.8 8 29.6 
Other 1 3.7 1 3.7 2 7.4 
Any used 5 18.5 7 25.9 12 44.4 
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 Compliance to allocation 3.13.3.
Of 56 day treatment period, 97% of patients’ days show compliance and most of the 
participants were in the ≥ 75% category. Table  3-2 shows percentage of compliance 
per week as well as the overall compliance.  
Table  3-2:- Compliance to treatment allocation by treatment arm 
Time-point Compliance 
PUFA Olive Oil 
N = 91 (13 participants x 7 
days) 
N = 84 (12 participants x 7 days) 
Week 1 
Both capsules (%) 88 95 
Only one capsule (%) 12 5 
None of capsules (%) 0 0 
Week 2 
Both capsules (%) 98 95 
Only one capsule (%) 2 5 
None of capsules (%) 0 0 
Week 3 
Both capsules (%) 98 93 
Only one capsule (%) 2 6 
None of capsules (%) 0 1 
Week 4 
Both capsules (%) 97 98 
Only one capsule (%) 3 2 
None of capsules (%) 0 0 
Week 5 
Both capsules (%) 100 95 
Only one capsule (%) 0 5 
None of capsules (%) 0 0 
Week 6 
Both capsules (%) 98 88 
Only one capsule (%) 2 8 
None of capsules (%) 0 4 
Week 7 
Both capsules (%) 96 92 
Only one capsule (%) 4 7 
None of capsules (%) 0 1 
Week 8 
Both capsules (%) 99 93 
Only one capsule (%) 1 7 
None of capsules (%) 0 0 
The total 
Time-point Compliance 
PUFA Olive Oil 
N = 728 (91 tablet a week x 8 
weeks) 
N = 672 (84 tablet a week x 8 
weeks) 
8 Weeks 
Both capsules (%) 97 94 
Only one capsule (%) 3 6 
None of capsules (%) 0 0 
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 Primary outcomes 3.13.4.
3.13.4.1. Recruitment rates 
The proportion of eligible participants who were recruited, randomised and 
completed the trial was 57.5% (42/73), 78.6% (33/42) and 81.8% (27/33) 
respectively. Seventeen participants were randomised into the PUFA group and 16 
assigned olive oil. It was not possible to capture all of the reasons why eligible 
women did not participate in the trial because some of them were uncontactable. 
Examples of reasons recorded included ‘recurrent miscarriage and trying to 
conceive’, ‘strict vegetarian and will not accept fish oil, want only olive oil’, and 
‘already taken the fish oil without much help’.  
Figure  3-3 summarises the recruitment history and presents the number of 
participants who were expressed interest into the study over the 12-month 
recruitment period. I aimed to recruit three to four women per month and I had a total 
of 42 participants and the primary outcome was achieved. A protocol amendment in 
October 2016 improved the recruitment rate so that the target of recruiting 40 women 



















































































3.13.4.2. Retention rates 
Figure  3-4 presents the number of participants who fulfilled the required criteria, 
completed the three visits and filled in the trial paperwork. The retention rate was 
81.8% (27/33) from the women who were randomised. The number of participants 
with follow-up data (retention rate) was equally distributed between the two 
treatment groups with 14 in PUFA and 13 in olive oil groups. Six participants lost to 
follow-up, three from PUFA and the same number from olive oil treatment groups 
and as a result 81.8% had data available from the final follow-up.  
Figure  3-4:- PurFECT recruitment and randomisation chart 
 





























* Protocol amended 
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 Secondary outcomes  3.13.5.
3.13.5.1. Acceptability of interventions 
The acceptability of the interventions was evaluated by calculating the proportion of 
participants who attended all visits and completed their treatments:  82 % of 
participants (14/17) in the PUFA group and 81 % of participants (13/16) in the olive 
oil group attended all visits.  
3.13.5.2. Acceptability of questionnaires 
“Table  3-3 shows results of secondary outcome measures relating to the 
questionnaires’ data. The majority of participants described their overall trial 
experience favourably and rated it one or two on a five-point scale from positive to 
negative. Positive responses were recorded for the recruitment approach used, 
paperwork burden for participants and the experience of randomisation process of 
participants. Negative feedback was largely related to the size of the pills as some 
women experienced discomfort when swallowing the large capsules. A few found 
the treatment diary time-consuming to complete, although all participants did 
complete it.”  
The majority of participants found the questionnaires’ questions acceptable and not 
difficult to fill in apart from the GHQ and WPAIQ questionnaires because the 
options were slightly confusing to some of them. All women (N=27) who completed 
all three visits, completed all the data collection forms and all of these took their 
medications in full, except two participants who did not return their treatment diaries. 
These two participants confirmed that they had completed their trial treatments. 
3.13.5.3. Results of questionnaires 
As this was a pilot trial, it was not powered to definitively answer the question of 
whether taking PUFA resulted in a better or worse outcome with regard to scores in 
the questionnaires than olive oil, but rather to estimate the recruitment and retention 
in order to inform a full-scale RCT. However, analysis did suggest that there is no 
evidence that the treatment is better than control. 
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Data from the PCQ helplessness responses showed improvement and reduction in 
pain scores mainly with olive oil. Using the WPAIQ questionnaire, women recorded 
nine hours of absenteeism in the PUFA group and seven hours in the olive oil group.  
For the BPI pain questionnaire, participants from the olive oil group had a 13% 
(0.67/5.21) improvement in their pain scores whereas there was a very minimal 
improvement with PUFA. Moving to the BPI pain interference, although there was 
no statistical significant difference between the changes at baseline and follow-up 
between the two treatments (P=0.16), olive oil had an average fall of 21% (1.23/5.84) 
in interference score, while the change in PUFA was marginal (0.7%). There was an 
enhancement in the participants’ mood noted, they felt stronger and had more 
energy, more in olive oil group. Many participants acknowledged that because they 
experienced less pain, they were more positive, happier and were enjoying their life 
more than before. They were able to function and cope better. Some were hoping this 
positive attitude would continue after completing the trial intervention.  
BFI showed a drop in the scores with olive oil (0.77) with more than three times 
reduction in their fatigue scores than women who received PUFA. Moving to GHQ, 
participants with olive oil group showed improvement, whereas PUFA group got 
worse.  
The ability to walk was better after interventions in 37% of participants in both 
groups, which reflected the overall improvement in general activities. One particular 
participant (ID 1019) reported her ability to ride her bike after a long time of being 
unable to do so. Another woman reported that she was able to walk much longer and 
was pain-free. It was a great achievement, she added.   
A mixed sleep pattern was reported by different participants from the two groups. 
Some women (approximately 36 % for PUFA and 54% olive oil) reported that they 
enjoyed better sleep. However, sleep patterns did not change in 18.5%.  
In most cases, it appeared that there was a persistent trend of improvement (i.e. 
therapeutic benefit in BPI-pain severity, interference and sleep) in the olive oil as 
opposed to the PUFA group. 
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Table  3-3:- Results of secondary outcome measures  




N Mean SD 
 










   (higher score = better) 
Physical_component_summary_baseline_ 
score 
14 2.58 0.59 
 
13 2.65 0.76 - - - 
Physical_component_summary_8_weeks_
score 
14 2.62 0.43 
 
13 2.6 0.76 - - - 
Change from baseline (8 weeks-baseline)  14 0.04 0.52 
 
13 -0.05 0.53 0.09 (-0.33  ̶  0.50) 0.670 
Mental_component_summary_baseline_ 
score 
14 2.94 0.63 
 
13 2.79 0.67 - - - 
Mental_component_summary_8_weeks_ 
score 





0.81 - - - 
Change from baseline (8 weeks-baseline)   14 -0.05 0.54 
 









N Mean SD 
 








 (higher score = worse) 
Pain severity baseline score 14 4.92 2 
 
13 5.21 2.50 - - - 
Pain severity week 8 score 14 4.96 1.73 
 
13 4.54 2.44 - - - 
Change from baseline (8 weeks-baseline)   14 0.04 1.78 
 
13 -0.67 2.35 0.71 (-0.93 - 2.35 ) 0.383 
Pain interference baseline score 14 4.57 2.33 
 
13 5.83 2.55 - - - 
Pain interference week 8 score 14 4.54 2.41 
 
13 4.60 3.36 - - - 
Change from baseline (8 weeks-baseline)   14 -0.03 1.95 
 
13 -1.23 2.39 1.20 (-0.52 - 2.92) 0.164 
Change from baseline (8 weeks-baseline)  
(pain interference_diff_transformed) 
14 0.13 0.33 
 









N Mean SD 
 








 (higher score = worse) 
Global fatigue baseline Score 14 5.21 2.03 
 
13 6.00 2.4 
   
Global fatigue week 8 score 14 5.00 2.15 
 
13 5.23 2.88 
   
Change from baseline (8 weeks -baseline)   14 -0.21 1.86 
 










N Mean SD 
 








 (higher score = worse) 
Global baseline score 14 0.39 0.36 
 
13 0.47 0.36 - - - 
Global week 8 score 14 0.43 0.25 
 
13 0.42 0.27 - - - 
Change from baseline (8 weeks -baseline)   14 0.04 0.31 
 









N Mean SD 
 








 (higher score = worse) 
Absenteeism_baseline_score 9 2.15 4.3 
 
7 18.37 37.54 - - - 
Absenteeism_week_8_score 9 14 32.8 
 
7 10.32 17.86 - - - 
Change from baseline (8 weeks -baseline)   9 11.85 33.11 
 
7 -8.05 42.17 19.89 (-20.37 - 60.17) 0.307 
Change from baseline (8 weeks -baseline)  
(absenteeism diff transformed) 
9 0.35 0.68 
 
7 0.66 0.86 -0.31 (-1.14 - 0.51) 0.428 
Presenteesism_baseline_score 9 35.6 23.51 
 
7 48.58 34.36 - - - 
Presenteesism_week_8_score 9 46.7 33.17 
 
7 54.29 36.9 - - - 
Change from baseline (8 weeks -baseline)   9 11.11 32.19 
 
7 5.71 51.59 5.39 (-39.59 - 50.39) 0.801 
Change from baseline (8 weeks -baseline)  
(presenteesism diff transformed) 
9 0.94 0.62 
 
7 1.43 0.38 -0.49 (-1.08 - 0.10) 0.095 
Work_productivity_loss_baseline_score 9 -34.56 23.51 
 
7 -47.58 34.36 - - - 
Work_productivity_loss_week_8_score 9 -45.67 33.17 
 








N Mean SD 
 








 (higher score = worse) 
Change from baseline (8 weeks -baseline)   9 -11.11 32.19 
 
7 -5.71 51.59 -5.39 (-50.39 - 39.59) 0.801 
Change from baseline (8 weeks -baseline)  
(work_productivity_loss diff_transformed) 
9 0.97 0.64 
 
7 1.42 0.39 -0.45 (-1.04 - 0.14) 0.125 
Activity_impairment_baseline_score 9 44.45 26 
 
7 42.86 23.6 - - - 
Activity_impairment_week_8_score 9 48.89 31.8 
 
7 58.57 36.71 - - - 
Change from baseline (8 weeks-baseline)   9 4.44 27.43 
 
7 15.71 37.79 -11.26 (-46.17 - 23.63) 0.5 
Change from baseline (8 weeks-baseline)  
(activity_impairment  diff_transformed) 
9 0.89 0.71 
 









N Mean SD 
 






PCQ (higher score = worse) 
Rumination
7
_baseline_score 14 1.92 1.13 
 
13 2.44 1.06 - - - 
Rumination_week_8_score 14 1.54 0.85 
 
13 1.52 1.06 - - - 
Change from baseline (8 weeks-baseline)   14 -0.38 0.67 
 
13 -0.92 1.1 0.54 (-0.17  ̶   1.26) 0.128 
Magnification
8
_baseline_score 14 1.53 0.78 
 
13 1.89 1.03 - - - 
Magnification_week_8_score 14 1.55 0.87 
 
13 1.48 0.97 - - - 
Change from baseline (8 weeks -baseline)   14 0.02 0.80 
 
13 -0.41 1.08 0.43 (-0.32  ̶  1.18) 0.245 
Helplessness
9
_baseline_score 14 1.74 1.17 
 
13 2.37 1.01 - - - 
Helplessness_week_8_score 14 1.79 0.70 
 
13 1.52 0.94 - - - 
Change from baseline (8 weeks-baseline)   14 0.05 0.85 
 
13 -0.85 1.15 0.89 (0.1  ̶  1.7) 0.030 
Total
10
_baseline_score 14 1.72 0.90 
 
13 2.24 0.93 - - - 
Total_week_8_score 14 1.62 0.69 
 
13 1.51 0.94 - - - 
Change from baseline (8 weeks -baseline)   14 -0.10 0.58 
 








N Mean SD 
 






SAQ (higher score = better) 
Pleasure
11
_baseline_score 7 1.26 0.8 
 
10 0.63 0.7 - - - 
Pleasure_week_8_score 7 1.19 1.03 
 
10 0.73 0.81 - - - 
Change from baseline (8 weeks-baseline)   7 -0.07 0.83 
 
10 0.1 0.95 -0.17 (-1.12  ̶  0.78) 0.705 
Discomfort
12
_baseline_score 7 0.95 0.61 
 
10 1 1.22 - - - 
Discomfort_week_8_score 7 1.1 0.73 
 
10 0.95 1.23 - - - 
Change from baseline (8 weeks -baseline)   7 0.15 0.9 
 
10 -0.05 0.72 0.19 (-0.65  ̶  1.03) 0.631 
Habit
13
_baseline_score 7 0.43 0.79 
 
10 0.3 0.48 - - - 
Habit_week_8_score 7 0.43 0.79 
 
10 0.4 0.7 - - - 
Change from baseline (8 weeks -baseline)   7 0 0 
 
10 0.1 0.74 -0.1 (-0.70  ̶  0.50) 0.728 
Tired
14
_baseline_score 7 1 1.41 
 
10 1.8 1.23 - - - 
Tired_week_8_score 7 2 1 
 
10 2.1 1.45 - - - 
Change from baseline (8 weeks -baseline)   7 1 1 
 










N Mean SD 
 








 (higher score = worse) 
Global baseline score 14 1.58 0.63 
 
12 1.87 0.72 - - - 
Global week 8 score 14 1.34 0.64 
 
12 1.76 0.86 - - - 
Change from baseline (8 weeks -baseline)   14 -0.24 0.47 
 
12 -0.11 0.48 -0.13 (-0.51  ̶  0.25) 0.499 
1 Difference more than 0 indicates better score with PUFA.  
2 SF-12 version 2 scores range from 0-100, where low scores are bad and high scores are good. 
3 BPI scores range from 0-10, where low scores are good and high scores are bad. 
4 BFI scores range from 0-10, where low scores are good and high scores are bad. 
5 GHQ scores range from 0-12, where higher scores represent higher levels of mental distress. 
6 WPAIQ scores range from 0-100, where low scores are good and high scores are bad indicating greater impairment and less productivity. 
7 PCQ rumination scores range from 0-16, where low scores are good and high scores are bad. 
8 PCQ magnification scores range from 0-12, where low scores are good and high scores are bad. 
9 PCQ helplessness scores range from 0-24, where low scores are good and high scores are bad. 
10 PCQ total scores range from 0-52, where low scores are good and high scores are bad. 
11 SAQ pleasure scores range from 0-18, where low scores are bad and high scores are good. 
12 SAQ discomfort scores range from 0-6, where low scores are bad and high scores are good. 
13 SAQ habit scores range from 0-3, where low scores are bad and high scores are good. 
14 SAQ tired scores range from 0-3, where low scores are bad and high scores are good. 




 Analysis methods – other summaries 3.13.6.
Most of the participants visited their HCPs at least once as shown in Table  3-4 with 
GP and alternative therapists having the highest number of visits. Eleven women 
(approximately 41%) reported taking less analgesia while on the trial, but this was 
not a statistically significant difference (Table  3-5). Overall, the health change with 
trial treatment was in favour of improvement as per Table  3-7 and Table  3-8 shows 
worst and average NRS pain scores.  
Table  3-4:- Number of visits to HCPs for pelvic pain over the last month 
 PUFA (N) Olive Oil (N) 
GP baseline  17 10 
GP follow-up  21 15 
Hospital outpatients baseline 10 8 
Hospital outpatients follow-up 16 1 
Practice nurse baseline 0 1 
Practice nurse follow-up 5 1 
Physiotherapist baseline 3 0 
Physiotherapist follow-up 2 0 
Alternative therapist baseline 9 5 










Use of analgesia since starting the study 
Less  5  6 
More  3  2 
Same  6  5 
 
Table  3-6:- Randomised treatment and treatment participant thought they had 
received 




 (N= 13) 










*One participant was not able to guess which treatment she was allocated to.   
 





Overall health change with treatment
 
Very marked improvement  1
 
 2 
Marked improvement  2
 
4 
Minimal improvement  5
 
2 
No change  3
 
3 
Minimal worsening  2
 
2 
Marked worsening  1
 
0 











N Mean SD 
 






Pain scores (lower score = better)   
Worst_NRS_baseline_score_wk_1_4 14 7.11 1.68 
 
13 7.48 1.54 - - - 
Worst_NRS_weeks_5_8_Score 14 6.88 1.82 
 
12 7.06 1.74 - - - 
Worst_numerical_rating_diff 14 0.23 1.04 
 
12 0.69 1.32 -0.46 





14 5.02 1.65 
 
13 5.69 1.86 - - - 
Average_numerical_rating_scale_weeks_5_
8_score 
14 5.09 1.70 
 
12 5.35 2.06 - - - 
Average_numerical_rating_diff 14 -0.07 1.09 
 






 Loss to follow-up 3.13.7.
Six participants were lost to follow-up, three from PUFA group and three from olive 
oil group. In PUFA group, one withdrew due to ill health and another one left to have 
an operation. In olive oil group, one withdrew because she could not swallow the 
capsules, they were too big she commented. 
 Safety data  3.13.8.
There was no report of any adverse event from any of the participant in either group.  
 Data handling, storage and archiving 3.13.9.
“A log with the patients’ name and date of birth was kept alongside their unique study 
number in a separate file. All the data generated from the study was stored in an 
anonymised form in a bespoke database, which was password protected. Only 
anonymised information was stored on this database, and participants were only 
identifiable by their study number. All paperwork was kept in a locked filing cabinet 
in a locked office. All data was stored on UoE server on a password- protected 
computer with limited access to the research team, in accordance with NHS and the 
UoE guidelines and in accordance with the data protection act. All study 
documentation will be kept for a minimum of five years from the protocol defined 
end of the study point. When the minimum retention period has elapsed, study 
documentation will not be destroyed without permission from the sponsor.”  
 Dissemination  3.13.10.
“The study protocol has been published (Abokhrais et al., 2018). The plan is for the 
data from the trial to be presented at conferences and published in a peer-reviewed 
journal. I will make the information obtained from the study available to the public 
through national bodies, e.g. EUK.”  
142 
 
3.14. Discussion and conclusions 
 Recruitment and retention rates and acceptability 3.14.1.
Dietary modifications including the use of Omega-3 containing supplements have 
been suggested as having the potential to reduce inflammation and negative 
symptoms associated with endometriosis, however definitive evidence of their 
effectiveness is currently lacking. The primary objective of this study was to conduct 
a pilot trial to inform the future design of a full scale RCT.  
The primary objective was to assess the recruitment and retention rates to be able to 
estimate the randomisation with a sensible CI around it and as a result, I was able to 
recruit 57.5% (42/73) of the women who were referred to my study. From these, 
78.6% (33/42) were randomised and 81.8% (27/33) completed the trial: 51.5% 
(17/33) to PUFA and 48.5% (16/33) to olive oil (comparator). The acceptability of 
the questionnaires was shown in data completion and the absence of missing values. 
Six participants in the two groups were lost to follow up.  
 Strengths of study 3.14.2.
Omega-3 PUFA, given in the highest effective dose with the rate and severity of 
adverse effects minimised, may be a potentially more useful aid for endometriosis-
associated pain other than empirical analgesia which have many side-effects as 
discussed previously.  
“Strength of this study was the use of broad inclusion and exclusion criteria designed 
to ensure the eligible group reflected the heterogeneity of symptoms experienced by 
women with endometriosis. During the study, information about non-reproductive 
co-morbidities such as irritable bowel syndrome, fibromyalgia and painful bladder 
syndrome from the participants’ questionnaires and treatment diaries was captured.” 
“Robust data collection tools were used to assess the core domains of pain, physical 
and emotional functioning (including sleeping difficulties), improvement/satisfaction 
with treatment and symptoms and adverse events, following advice from a clinical 
psychologist and a general practitioner, both with a research interest in 
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endometriosis.  These tools were in line with the IMMPACT recommendations for 
chronic pain trials (Dworkin et al., 2005). We assessed the reliability and 
acceptability of these data collection tools in order to refine our methods for the 
subsequent RCT.” 
This pilot trial supportive of no AE which would preclude expansion to a main trial – 
i.e. no safety signals suggesting a larger trial would be unsafe at this stage. If the 
future definitive RCT demonstrates that PUFA and/or olive are effective, both of 
them can be used as alternative treatments for pain in women with endometriosis and 
the novelty of this approach will be useful for these group of women. 
I was able to calculate sample size for the future RCT based on the BPI severity 
score, by comparing the change from baseline to follow-up in PUFA and olive 
groups using SD “pooled” which was equal to 2.08 (square root of the mean of the 
variances, 1.782 and 2.352, since the group sizes are roughly equal). In order to 
detect a difference of one unit on this scale (approximately a fall of 20% from 
baseline) between the two groups, I will need at least 69 analysable patients per 
group. Similarly, for the interference score, the SD pooled is 2.18, so the number per 
group would be 76. The baseline number will differ depending on which of the 
measures will be chosen as a primary outcome, but the process is the same. If I want 
to use more than one variable for the large RCT, co-primary outcome, example BPI 
and PCQ, the largest sample size will be chosen which is usually expected to show 
clinical improvement (Figure  3-5).    
144 
 













Number evaluable (BPI severity score) 
69 patients per group 










Number eligible   









Mean diff = BPI mean (5.2 x 0.02 = 1.04) 
Var-diff = BPI var (1.65) 
Power = 80 % 
Significance = 5 % 
















Number approached is more than three times evaluable 
number (the latter is about third of the former) 
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 Limitations of study 3.14.3.
“Although the broad inclusion and exclusion criteria were chosen to represent the 
heterogeneity of the endometriosis population this could also be viewed as a 
limitation as the criteria do not take into account pain intensity, nor does it exclude 
women with non-reproductive comorbidities (e.g., irritable bowel syndrome, bladder 
pain syndrome). Data from other studies on women with endometriosis have reported 
that co-morbid conditions are common and that they are more likely to report mood 
conditions (Smorgick et al., 2013). A recent review highlighted common 
pathophysiological mechanisms (Viganò et al., 2018) some of which are related to 
inflammatory processes that may or may not respond to omega-3 PUFA. It is 
therefore important to note that non-reproductive comorbidities might explain some 
of the symptoms in our study and I am aware that these characteristics may also 
increase variability in patient responsiveness to treatment and reducing the likelihood 
of detecting a significant response.” 
“Another limitation of this pilot study was the lack of availability of a suitable placebo 
which was particularly challenging when setting up the protocol.  It was not possible 
to find a placebo identical to Omega-3 PUFA and therefore the decision was taken to 
use a ‘comparator’ (olive oil) instead of a true placebo. The drawback of using olive 
oil is that it might has a distinctive taste and there was therefore a theoretical risk of 
the subjects guessing which arm of the trial they have been randomised to. In order 
to determine whether significant ‘unblinding’ was present, I asked the subjects at the 
conclusion of the trial to guess what treatment they received and the primary reason 
for the guess in an attempt to determine the validity of using olive oil as a suitable 
comparator and the results showed that participants were unable to guess which 
treatment they have received.” 
A further limitation of the study was the short follow-up involved in this trial. I am 
aware that a longer trial would likely be necessary to better assess the long-term 
effects of Omega-3 PUFA but this pilot study was to assess the feasibility and ability 
to recruit to the trial and long term effects were not investigated. N-3 fatty acids 
might be good for reducing endometriosis came from epidemiology follow-up of 
longer term dietary modification (Missmer et al., 2010) and I am aware that a short 
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duration treatment window may be less effective. However, “Omega-3 PUFA have 
been used clinically e.g. post myocardial infarction and for hypertriglyceridemia at 
doses of 1000-4000mg daily (in divided doses of 1000mg or 2000mg) (Begg et al., 
2012). However, high dosage (i.e. 4000mg) has been associated with a moderate 
increase in bleeding time (Omacor, 2018) so we chose to pilot a lower dose and 
frequency of one capsule (1000mg) twice a day (Abokhrais et al., 2018)”.  
Recognising the potential difficulties in conducting a trial for the management of 
endometriosis-associated pain using a supplement which is widely available over the 
counter. Type of food is another concern, as four participants (two in the PUFA 
group and two in the olive oil group) highlighted that their food include seafood 
which could be a potential bias to the result. However, none of the participants taken 
dietary supplements (fish oil or olive oil or vitamins) with trial treatment.  I believe 
that a definitive evaluation of the efficacy of Omega-3 PUFA in the management of 
endometriosis requires a multi-centre RCT. Moreover, the participants were 




 Future large RCT  3.14.4.
3.14.4.1. Feasibility of a future RCT 
My pilot study supports the hypothesis that it is feasible to conduct a future large-
scale RCT to determine the effectiveness and acceptability of proposed methods of 
recruitment, randomisation, treatments and assessment tools for Omega-3 PUFA for 
women with endometriosis-associated pain. Feasibility is supported by the ability to 
recruit 42 participants and randomise 33 women over a 12-month recruitment period 
(57.5% and 81.8% of those referred ‘and were eligible’ to the study respectively). In 
27 participants, a 12-week of follow-up was achieved (4 weeks before randomisation 
and 8 afterward). Of note, retention rates in PUFA and olive oil groups were 82% 
and 81% respectively.  
The methods of recruitment, randomisation and interventions were overall acceptable 
to the participants. The recruitment history showed that 11 (12%) out of 92 women 
referred to my study were ‘not interested’ in participating. This suggests that the 
prospect of participating, including filling out many questionnaires and the 
possibility being randomised to the control arm, were not a major obstacle to 
recruitment. Furthermore, the attendance rates between the PUFA and the olive oil 
groups were very similar, which is very reassuring and will help in the interpretation 
of any difference in outcomes in a large trial. In both groups participants were unable 
to tell which treatment they were taking which suggests the blinding of the study was 
intact.  
With regards to the acceptability of the paperwork, all the questionnaires were 
completed in the two trial visits. However, some participants’ highlighted difficulties 
in choosing from the options in some questionnaires (mainly GHQ and WPAIQ) and 
the results might justify excluding them from a larger definitive trial or adding 
explanation of the options, for a larger RCT, to help understanding. There were no 
missing data in any of the questionnaires, suggesting that the participants had no 
objections completing them.  
Overall, estimates of effectiveness in clinical significance between the two groups 
showed that there is no evidence that the treatment is better than control. These 
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results, whilst not from an appropriately powered study, go some way in answering 
the research question as to whether PUFA are effective treatments in reducing pain in 
women with endometriosis, and a cross-over trial design can be used, which involves 
consecutively administering two treatments for each participant recruited, in a large 
RCT, mainly to provide a basis for separating treatment effects from period effects 
(Wellek and Blettner, 2012). A crossover trial would allow us to model within 
patient variability, but we had no evidence for the length of a washout period of the 
PUFA treatment, and so further experiments would need to be conducted to establish 
this. 
“There were no adverse events reported to the PUFA or the olive oil group in my trial, 
suggesting that both of them are safe. This observation is consistent with most of the 
previous studies when PUFA was used. Minor side effects such as oily skin and/or 
bloating can sometimes be associated with PUFA, However, some side effects, (like 
bloating) are also common with bowel endometriosis. The level of recruitment in my 
study fulfilled my expectation of 50% or over and is higher than the comparable pilot 
studies undertaken by (Lewis et al., 2016) for similar conditions. Moreover, the 
retention rates (81.8%) were satisfactory in both groups.” 
In terms of effectiveness, most participants, mainly in olive oil group showed some 
clinical significance and a trend towards an improvement in pain and QOL such as 
feeling more energetic and positive. Most participants in both groups experienced a 
fall in their pain scores after randomisation. The reductions in their pain scores were 
mainly in week 8 which reflected the effect of study interventions. The main 
secondary outcome of my trial was to estimate the variability of responses for sample 
size calculation, which would be the primary aim of a large multi-centred RCT. So, 
the next step would be running the large RCT in multiple centres and determining the 
efficacy of the Omega-3 PUFA as treatment options for women with endometriosis-




3.14.4.2. Lessons learned for future RCT 
It is generally acknowledged that the gold standard for effectiveness of a RCT is the 
use of a matched placebo as a control for the study intervention. I understand that the 
lack of a placebo as a control in my trial might be viewed as a weakness. However, I 
would argue that using olive oil as a comparator might be a strength because all 
women in both groups experienced some degree of pain relief, actually it was higher 
with olive oil group, which might not be the case if a placebo was used and that 
could be one of the reasons why there was a good retention rate. Moreover, these 
days, very few trials involve true placebos, since usually a new treatment compared 
to a current treatment. 
3.14.4.3. Managing expectations 
The larger RCT would be better presented by clinicians as a pain study rather than an 
endometriosis study, as the latter may not be of interest to women who specifically 
experience pain. This would also require a concise and clearly scripted PIL and other 
study documents.    
3.14.4.4. Inclusion criteria 
At the beginning of the trial (September 2016), 12 women were excluded because 
their diagnostic laparoscopy was greater than three years ago, which did not meet our 
original inclusion criteria, and as a result I amended the protocol (after ethical 
approval) and hence the recruitment rate was enhanced as shown in Figure  3-4. The 
age limit was another concern highlighted by participants who had enquired about 
family members with endometriosis and therefore for the definitive RCT we are 
planning to run RCT without an upper age limit. However, we understand that a high 
percentage of women with endometriosis reported becoming pain-free after the 
menopause as discussed in sections 1.4.1 and 1.5 in chapter one.   
3.14.4.5. Exclusion criteria 
There were a number of problems with the exclusion criteria in the pilot study and 
this will need to be refined and further specified for the definitive RCT. For example, 
insulin-dependent diabetes was one of the exclusion criteria in the pilot study but as 
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Omega-3 PUFA increases blood sugar, non-insulin dependent diabetes should also 
be excluded. 
3.14.4.6. Quantitative and qualitative research tools 
On reviewing what questionnaires were appropriate for my trial, the SF-12 
questionnaire was chosen over the SF-36 due to its ease of participant completion. 
The SF-12 however did not show any differences between the two groups and may 
not therefore be taken forward into the definitive trial. GHQ and WPAIQ 
questionnaires’ proved difficult for participants to understand and complete and 
therefore in a large RCT the questions may need to be explained or the 
questionnaires shortened.  Furthermore, only BPI questionnaire includes questions 
regarding average versus the worst pain, and in future large RCT we consider 
including more pain related questionnaires. In the large RCT BPI, BFI, PCQ and 
PDQ, should be considered as the main methods of data collection due to their ease 
of completion. However, the uses of specific questionnaires for a future large RCT 
will, of course, depend on its final design.  
3.14.4.7. Public involvement 
Moving forward, as demonstrated by the JLA project, it is crucial to have patient and 
public involvement (PPI) in the design of the definitive RCT. PPI has been shown to 
improve study design by creating interventions which are acceptable to people taking 
part in the study with a more patient-centred data collection and outcomes as well as 
making the research relevant to them. Good public involvement may therefore lead 
to better involvement, recruitment and retention to the trial.   
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3.15. Summary  
In this pilot feasibility study I have successfully randomised participants to either 
Omega-3 PUFA or olive oil and evaluated recruitment, randomisation and retention 
rates and I have achieved the primary objectives by assessing the recruitment and 
retention rates, 58% and 82% respectively. I have estimated variability for all 
measures which will allow us to calculate how many women we need to recruit for 
the large RCT (approximately 150 women), and then we can calculate how many 
women we will need to approach to find sufficient number of women to recruit, 
randomise and complete the trial (Figure  3-5).  
Analysis of data from the two groups regarding the acceptability of the methods of 
recruitment, randomisation and assessment tools was unanimously positive. PCQ and 
BPI questionnaires have shown clinical improvement (38% improvement with the 
PCQ questionnaire) and will therefore be the measurement tool recommended for use 
in the larger RCT. SF-12 showed no clinical improvement and will therefore not be 
recommended for use in the definitive trial. Patients reported considerable challenges 
with completing the WPAIQ and GHQ, both of which showed little difference 
between baseline and follow-up and therefore again would likely not be taken as a 
measurement tool into the definitive trial. This however is crucial information for the 
design of the future RCT when we want to reduce as many barriers as possible to 
patient completion of questionnaires.  
As expected in this pilot study, because of the relatively small sample size, the 95% 
CI were wide and we would expect in the adequately powered larger RCT, the 95% 
CI to be narrower for the primary outcomes investigated. As discussed previously, 
there was only one non-native English speaker who took part in the study, I were 
therefore unable to assess this population minority. The key finding was that the 
‘whole person effects’ i.e. general activity, mood, walking ability, working ability, 
relations with other people, enhanced sleep, energy and enjoyment of life got better, 
mainly with olive oil group.  
Moreover, participants gave a detailed account of the negative impact of living with 
endometriosis-associated pain, the effect of living with such pain infiltrated almost 
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every aspect of their lives to the extent of being biographically disruptive. The 
biographical disruptions of endometriosis pain could be conceived as having 
negative influence on employment, social and intimate history of the two groups. Of 
the 14 participants in PUFA group, four (28.5%) were unemployed and four (30.7%) 
out of 13 in olive oil group were unemployed. The constant lack of sleep and severe 
fatigue impacted negatively on their ability to function, which in turn might have had 
a negative impact on their career. Endometriosis-associated pain was behind multiple 
losses women suffered, such as relationship breakdown, career goals and lack of self-
confidence as demonstrated in the BPI, WPAIQ and SAQ questionnaires.     
“The findings of my study support the acceptability of methods of recruitment, 
randomisation, questionnaires and interventions (both PUFA and olive oil). 
However, most participants were dissatisfied with the current standard of care due to 
the lack of effective treatments and the associated side effects of any prescribed 
medications. Overall, my study has successfully demonstrated the feasibility of 
conducting a large-scale RCT for women with endometriosis-associated pain. The 
recruitment rate achieved in this pilot trial would allow estimation of recruitment rate 
more accurately and determine the number of centres and the recruitment period that 
would be required. I will also be able to utilise the information from the efficacy to 
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Appendix  A. Identifying research priorities for endometriosis  
A.1. Steering group members 
Members Role Organisation/location 
Ibtisam Abokhrais 
Clinical research fellow, 
obstetrics and gynaecology 
trainee, JLA data analyst and 
PSP coordinator   
Edinburgh 
Judy Birch 
Patient representative and 
chief executive officer 
Pelvic Pain Support Network 
Mary Heslin Patient representative 
Endometriosis Association of 
Ireland 





Dharani Hapangama Gynaecologist Liverpool 
Andrew Horne Gynaecologist Edinburgh  
Rajiv Chawla 











Sarah Edwards Clinical psychologist London 
Philippa Saunders Researcher Edinburgh 
Krina Zondervan Researcher Oxford 
Lone Hummelshoj Patient representative 
World endometriosis research 
foundation (WERF) 
Emma Cox Chief executive officer EUK 
Jackie Young Administrative assistant Edinburgh 
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All data in single questions, neither blank nor incomplete questions, 
with all categories in different colours:- 
 
 Causes   
 Treatments options 
 Prevention  
 Diagnosis 
 Co-morbidities 
 Awareness  
 Symptoms 
 Treatment outcomes 
 Natural history  
 Out of scope  
                                          Number of why (only why) questions 8 
                                          Number of other why questions 1215 
 
415 questions about symptoms include:- 
 
 Pain 
 Bowel/urinary symptoms 
 Subfertility 
 Tiredness /fatigue 
 Spread to other organs 
 Correlation between severity & laparoscopic picture 
 Why some symptomatic/others not 
83 questions about natural history include:- 
                               
 What happened to endo during pregnancy 
 During menopause 
 During adolescent 
 Improves with age 
 Prognosis if untreated 
 Living with endo 
 Experiences of living with endometriosis 































 Pain control/management 
 Improve QOL  
 No treatment/delay in treatment  
 Treatment of chronic fatigue  
 Treatment of adhesion  
 Treatment of bowel endo  
 Fertility treatment including IVF  
 Available support  
 Endometriosis specialist’s clinics 
207 questions about prevention include:- 
 
 Prevention of disease 
 Prevention of recurrence 
 Prevention of spread/progression  
 Prevention of pain/symptoms 
 Prevention of chronic fatigue 
 Prevention/reduce of adhesion 
 Prevention of infertility  
510 questions about awareness include:- 
 
 Awareness of women/GPs/HCPs/girls 
 Training of GPs/HCPs/Gynae 
 Knowledge of GPs/HCPs/Gynae 
 Understanding of GPs/HCPs/Gynae 
 Time for referral/delay in referral  
 More specialist/consultants for endo 
 Counselling patients about it/comorbidities 

























161 questions about co-morbidities include:- 
 
 Mental wellbeing 
 Miscarriage 
 Auto-immune diseases 
 Cancer 
 Bowel & bladder problems 





 Cure/no cure 
 Long term treatment/care/support 
 Support after treatment  
818 questions about causes include:- 
 
 Genetics (inherited it/pass it) 
 Environmental 
 General causes 
 Diet 
















453 questions about diagnosis include:- 
 
 Methods of diagnosis (including symptoms) 
 Impact of early diagnosis  
 Effect of delay diagnosis 
 Impact of diagnosis 
 Negative /false diagnosis 
 Diagnosis of recurrence 
 Screening for early disease/ referral 
584 questions about out of scope include:- 
 
 32 questions about disability  
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A.4. JLA interim prioritisation data analysis 
A.4.1. Overall UK participants only 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








Can a cure be developed for 
endometriosis? 
199 75 25 15 27 17 14 16 25 28 3.29 441 7.707 1 
What causes endometriosis? 155 60 27 16 18 20 17 15 23 31 3.63 382 7.372 2 
What are the most effective ways of 
educating healthcare professionals 
throughout the healthcare system 
resulting in reduced time to 
diagnosis and improved treatment 
and care of women with 
endometriosis? 
128 71 54 26 18 22 25 26 30 29 3.97 429 7.035 3 
How can endometriosis be 
prevented? 
34 50 34 12 15 9 13 17 10 12 4.13 206 6.874 4 
How endometriosis in adolescents is 
best managed in a clinical setting? 
7 6 7 8 3 3 6 4 4 0 4.48 48 6.521 5 
What are the most effective non-
surgical ways of managing 
endometriosis-related pain and/or 
symptoms (medical/non-medical)? 
26 31 30 33 35 30 21 19 14 9 4.76 248 6.242 6 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








How can we prevent endometriosis 
in women and/or young girls with a 
family history of the disease? 
36 36 31 22 15 14 32 22 18 14 4.79 240 6.208 7 
What can be done to stop 
endometriosis from recurring (e.g. 
after treatment)? 
28 46 43 39 50 38 34 18 25 13 4.85 334 6.150 8 
How can the diagnosis of 
endometriosis be improved? 
66 48 32 33 32 29 30 34 40 21 4.87 365 6.134 9 
What is the most effective way of 
stopping endometriosis progressing 
and/or spreading to other organs (e.g. 
after surgery)? 
29 44 42 42 42 39 32 36 11 17 4.90 334 6.102 10 
Why do women with endometriosis 
have difficulty getting pregnant? 
21 20 26 19 17 12 22 23 12 7 4.96 179 6.039 11 
Is it possible to develop a non-
invasive screening tool to aid 
diagnosis of endometriosis? 
31 43 36 46 30 25 32 33 27 16 5.02 319 5.984 12 
How can women most effectively 
and safely manage their 
endometriosis symptoms if they 
would like to become pregnant? 
26 24 27 18 17 24 18 18 20 13 5.05 205 5.946 13 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








Are women with endometriosis at an 
increased risk of cancers, and if so 
which and how they can be 
prevented? 
37 33 32 43 42 43 31 33 24 16 5.08 334 5.922 14 
What is the most effective way of 
managing the emotional and /or 
psychological and/or fatigue impact 
of living with endometriosis 
(including medical, non-medical and 
self-management methods)? 
25 51 48 35 31 32 30 36 26 22 5.09 336 5.911 15 
What are the reasons for lack of 
access to treatment for endometriosis 
(e.g. surgical, medical, non-medical, 
lack of specialists)? 
18 25 34 35 26 25 21 17 21 14 5.09 236 5.907 16 
What are the outcomes and/or 
success rates for surgical or medical 
treatments which aim to cure treat 
endometriosis, rather than manage 
it? 
10 15 20 16 25 18 8 14 11 8 5.13 145 5.869 17 
Does having endometriosis also alter 
fertility by having an impact on egg 
quality? 
14 18 14 19 13 14 13 15 9 12 5.17 141 5.830 18 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








Do early referrals to secondary 
and/or tertiary services and/or pain 
management services improve 
outcomes for women with 
endometriosis? 
16 6 13 10 10 13 10 7 12 7 5.18 104 5.817 19 
What is the best way to monitor 
disease progress (e.g. regular check-
up) once diagnosed with 
endometriosis? 
25 37 34 35 32 31 22 32 23 24 5.23 295 5.766 20 
Why does endometriosis cause pain? 30 17 10 8 9 10 18 12 11 26 5.38 151 5.623 21 
What are the outcomes and/or 
success rate of surgery (excision vs. 
ablation) for endometriosis, and does 
a particular type of surgery provide 
more benefits for certain patient 
groups? 
13 16 19 18 21 23 22 20 11 11 5.40 174 5.598 22 
Is there a link between endometriosis 
and auto-immune diseases, and 
endometriosis and/ or inflammatory 
disorders (e.g. MS, Lupus, RA, 
osteoarthritis, asthma, eczema and 
thyroid) and if so why? 
26 39 36 39 43 53 37 31 33 26 5.41 363 5.587 23 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








Is endometriosis associated with 
miscarriages and/or ectopic 
pregnancy, and if so, what are the 
underlying causes? 
15 13 14 21 16 24 14 22 16 8 5.45 163 5.546 24 
Why is pain relief medication for 
endometriosis-related pain and/or 
related symptoms often not effective 
(e.g. over the counter or 
prescription)? 
20 26 23 25 28 18 20 20 28 23 5.50 231 5.498 25 
What are the most effective ways of 
maximising and/or maintaining 
fertility in women with confirmed or 
suspected endometriosis? 
16 22 32 31 38 29 41 25 26 16 5.53 276 5.475 26 
Do any treatments for endometriosis 
have higher risk of causing 
infertility? 
5 11 14 20 15 18 11 10 12 10 5.53 126 5.468 27 
What information is the most 
effective in informing women and 
girls with endometriosis about the 
disease so they are enabled to make 
informed decisions about 
treatment(s) without causing anxiety 
in girls and women? 
8 19 12 10 11 15 13 11 9 16 5.54 124 5.460 28 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








What is the natural history of 
endometriosis (e.g. how, and how 
quickly, does it progress and 
spread)? 
17 17 17 12 16 5 7 14 13 27 5.57 145 5.428 29 
What are the most effective care and 
support pathways that can be offered 
to enable women with endometriosis 
and their support network to have a 
clear understanding of treatments 
and management provided by health 
care providers? 
8 19 22 24 18 16 14 21 18 17 5.60 177 5.395 30 
Is surgery necessary to treat severe 
endometriosis and if so, what is the 
outcome for women with deep 
infiltrating endometriosis and/or 
recto-vaginal endometriosis who do 
or do not undergo surgery? 
6 8 18 26 7 17 7 16 11 13 5.60 129 5.395 31 
What is the most efficient method of 
establishing the outcomes of 
treatments offered and how would 
women access this information to 
enable informed decision making? 
5 13 4 5 13 7 9 13 8 6 5.65 83 5.349 32 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








Are there any ways to predict which 
women are at risk of endometriosis 
to intervene early before the disease 
advanced? 
8 11 14 20 17 16 21 12 20 10 5.74 149 5.255 33 
What is the earliest age at which 
endometriosis can be detected or and 
is it a different disorder in young 
people than in adults? 
2 6 8 9 12 11 6 13 6 5 5.77 78 5.231 34 
Why does endometriosis and/or 
symptoms recur after treatment, and 
how likely and/or quickly is it that 
endometriosis recurs after different 
treatments (medical treatment; 
surgical removal disease; 
hysterectomy)? 
7 15 27 27 37 36 28 23 27 15 5.79 242 5.215 35 
If there is a link between 
endometriosis and other health 
conditions, can one diagnostic tool 
be developed? 
16 9 14 14 13 12 7 16 17 20 5.79 138 5.210 36 
How does endometriosis affect 
mental wellbeing (e.g. low mood, 
depression, lack of energy, stress, 
anxiety)? 
20 27 38 38 43 40 51 38 43 30 5.82 368 5.177 37 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








Does a hysterectomy cure 
(symptoms of) endometriosis, and 
how do factors around hysterectomy 
affect outcomes? (e.g. age at 
hysterectomy; surgical approach 
and/or techniques; removal of 
ovaries)? 
16 7 26 16 18 20 20 19 31 14 5.84 187 5.155 38 
In what circumstances should 
endometriosis be classified and/or 
recognised as a disability? 
37 39 32 34 31 36 34 38 36 65 5.85 382 5.152 39 
What are the benefits of different 
hormonal treatments (e.g. Mirena 
IUS, contraceptive pill, GnRH 
agonists and progestogens) in 
managing the symptoms of 
endometriosis? 
9 15 12 12 15 14 14 14 17 17 5.86 139 5.137 40 
How are endometriosis-related 
digestive and bowel-related 
symptoms best managed (including 
surgical, medical and non-medical 
treatments)? 
10 14 15 21 27 34 21 27 28 9 5.88 206 5.121 41 
How does endometriosis impact on a 
woman’s quality of life (e.g. 
9 14 25 30 20 18 28 20 21 25 5.88 210 5.119 42 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








education, work, relationships)? 
Does bowel resection have better 
results than “shave” operation for 
deep infiltrating endometriosis? 
3 5 8 9 8 0 6 7 9 8 5.90 63 5.095 43 
How do we get endometriosis and its 
impact on employment and 
employability recognised by 
employers and those dealing with the 
unemployed? 
25 27 40 44 32 43 32 34 44 53 5.92 374 5.078 44 
Is there a link between endometriosis 
and/or other chronic medical 
conditions? 
9 23 20 29 33 39 31 33 30 21 5.94 268 5.063 45 
Why does endometriosis cause 
painful sex? 
7 15 13 19 22 14 10 17 15 25 5.97 157 5.032 46 
What can be done to reduce the risk 
and/or development of adhesions 
following treatment for 
endometriosis (e.g. surgery)? 
13 13 22 32 21 38 37 35 24 21 5.98 256 5.020 47 
What is the effect of downregulation 
treatments (e.g. GnRH agonists) 
before or after surgery (e.g. disease 
detection; ease of resection; blood 
loss; improvement in symptoms and 
0 2 5 6 3 5 4 6 1 5 6.03 37 4.973 48 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








quality of life)? 
Why do women with endometriosis 
suffer from fatigue? 
8 26 35 42 43 37 52 32 39 39 6.04 353 4.963 49 
Is endometriosis a single disease or 
are there different disease subtypes 
which represent different, but 
related, pathological entities? 
7 16 12 11 14 18 20 18 17 19 6.08 152 4.921 50 
What are the benefits of HRT after 
surgical and/or natural menopause in 
women with endometriosis? 
4 9 8 3 6 10 13 11 13 7 6.12 84 4.881 51 
Why does endometriosis affect the 
bowel? 
5 12 19 11 15 16 17 28 18 15 6.13 156 4.872 52 
Is endometriosis hereditary and/or 
genetic? 
20 31 20 17 18 30 22 26 29 54 6.15 267 4.846 53 
What impact does pregnancy have 
on endometriosis (e.g. symptoms, 
recurrence)? 
4 9 12 13 15 10 15 17 18 16 6.26 129 4.736 54 
Is there a genetic test for 
endometriosis? 
10 20 15 5 16 15 14 20 22 32 6.28 169 4.722 55 
Is there a link between endometriosis 
and infections (e.g. candidiasis, 
bacterial vaginosis) and if so, could 
4 4 6 16 15 16 19 7 17 15 6.36 119 4.639 56 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








treatment identify infection? 
Why do the symptoms of 
endometriosis affect different 
women in different ways? 
4 4 11 8 13 10 22 10 8 18 6.37 108 4.630 57 
Can endometriosis be diagnosed 
during and after menopause? 
1 2 4 1 1 2 3 2 1 7 6.42 24 4.583 58 
Can we predict the cohort of women 
whose symptoms will not improve 
after excision of endometriosis? 
1 6 5 5 9 9 5 13 10 8 6.42 71 4.577 59 
What is the efficacy of dietary 
regimes and/or nutritional 
supplements (e.g. dairy, non-dairy, 
gluten-free, vitamin B6, fish oils, and 
black cohosh) in managing the 
symptoms of endometriosis? 
7 18 22 23 22 34 33 33 37 37 6.44 266 4.560 60 
What are the outcomes and/or 
success rates of a hysterectomy and 
is it more effective for certain patient 
groups? 
6 8 7 12 21 12 18 16 21 22 6.51 143 4.490 61 
Does the menopause have an impact 
on the severity or experience of 
endometriosis? 
4 3 9 6 3 7 12 9 12 12 6.52 77 4.481 62 
Why do medical practitioners 
suggest that women with 
6 4 7 13 7 11 14 10 12 22 6.55 106 4.453 63 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








endometriosis have a baby as a cure? 
What is the efficacy of non-medical 
therapies in managing symptoms of 
endometriosis (e.g. CBT, 
acupuncture, physiotherapy, 
reflexology and ACT)? 
2 9 12 13 13 12 25 20 23 17 6.55 146 4.445 64 
How can side-effects of medical 
treatments of endometriosis be 
avoided? 
1 3 2 7 3 7 14 3 8 7 6.58 55 4.418 65 
What are the symptoms of bowel 
endometriosis? 
3 7 5 14 17 15 9 14 17 25 6.67 126 4.325 66 
How does endometriosis and its 
treatment (medical or surgical) affect 
women with endometriosis in the 
long term? 
8 6 24 19 16 13 26 36 33 39 6.74 220 4.259 67 
Does life style affect endometriosis 
(e.g. food, exercise, stress, alcohol)? 
8 9 11 25 27 31 22 39 38 42 6.78 252 4.222 68 
When does endometriosis start? 4 3 9 7 9 9 8 8 16 22 6.82 95 4.179 69 
Is there a link between endometriosis 7 4 9 16 12 12 19 22 19 37 6.93 157 4.070 70 
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Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important (you 
can drag into order or select numerically from the drop-down boxes) 








and food intolerance? 
What is the efficacy of non-dietary 
lifestyle changes and self-
management strategies, (e.g. 
exercise, in managing the symptoms 
of endometriosis)? 
1 1 2 8 8 8 16 12 20 25 7.59 101 3.406 71 
What is the link between 
menstruation and endometriosis (e.g. 
heavy bleeding)? 






A.4.2. Women with endometriosis and their representatives scores 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









Are there any ways to predict 
which women are at risk of 
endometriosis to intervene 
early before the disease 
advanced? 
8 9 11 18 15 15 19 12 17 8 5.74 132 694 30 
2 
Are women with endometriosis 
at an increased risk of cancers, 
and if so which and how they 
can be prevented? 
33 32 30 41 39 38 30 32 20 15 5.06 310 1840 62 
3 




72 24 14 26 16 12 13 23 26 3.20 421 3283 72 
4 
Can endometriosis be 
diagnosed during and after 
menopause? 
1 1 4 1 1 2 2 2 1 6 6.43 21 96 1 
5 
Can we predict the cohort of 
women whose symptoms will 
not improve after excision of 
endometriosis? 
0 6 3 4 8 6 5 8 6 8 6.41 54 248 6 
6 
Do any treatments for 
endometriosis have higher risk 
of causing infertility? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









Do early referrals to secondary 
and/or tertiary services and/or 
pain management services 
improve outcomes for women 
with endometriosis? 
12 4 7 9 8 10 9 6 11 6 5.45 82 455 16 
8 
Does a hysterectomy cure 
(symptoms of) endometriosis, 
and how do factors around 
hysterectomy affect outcomes? 
(e.g. age at hysterectomy; 
surgical approach and/or 
techniques; removal of 
ovaries)? 
16 7 25 15 16 20 20 17 27 13 5.76 176 922 41 
9 
Does bowel resection have 
better results than “shave” 
operation for deep infiltrating 
endometriosis? 
2 4 8 7 6 0 5 6 7 8 6.00 53 265 7 
10 
Does having endometriosis 
also alter fertility by having an 
impact on egg quality? 
13 16 14 18 13 12 10 13 8 12 5.13 129 757 35.5 
11 
Does life style affect 
endometriosis (e.g. food, 
exercise, stress, alcohol)? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









Does the menopause have an 
impact on the severity or 
experience of endometriosis? 
4 2 8 6 3 5 12 9 12 10 6.55 71 316 9 
13 
How are endometriosis-related 
digestive and bowel-related 
symptoms best managed 
(including surgical, medical 
and non-medical treatments)? 
8 13 15 19 25 32 17 23 27 8 5.87 187 959 42 
14 
How can endometriosis be 
prevented? 
32 49 30 11 13 8 11 16 9 10 4.04 189 1316 53 
15 
How can side-effects of 
medical treatments of 
endometriosis be avoided? 
1 2 2 7 3 7 14 3 7 7 6.62 53 232 4 
16 
How can the diagnosis of 
endometriosis be improved? 
60 42 30 28 30 27 26 30 34 19 4.83 326 2010 69 
17 
How can we prevent 
endometriosis in women and/or 
young girls with a family 
history of the disease? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









How can women most 
effectively and safely manage 
their endometriosis symptoms 
if they would like to become 
pregnant? 
25 22 25 16 16 20 15 17 19 13 5.05 188 1118 46 
19 
How do we get endometriosis 
and its impact on employment 
and employability recognised 
by employers and those dealing 
with the unemployed? 
23 27 40 43 30 42 32 32 44 52 5.94 365 1848 63 
20 
How does endometriosis affect 
mental wellbeing (e.g. low 
mood, depression, lack of 
energy, stress, anxiety)? 
19 26 37 38 42 37 48 37 40 29 5.80 353 1835 61 
21 
How does endometriosis and 
its treatment (medical or 
surgical) affect women with 
endometriosis in the long term? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









How does endometriosis 
impact on a woman’s quality 
of life (e.g. education, work, 
relationships)? 
9 14 24 30 20 18 25 19 21 22 5.81 202 1049 45 
23 
How endometriosis in 
adolescents is best managed in 
a clinical setting? 
3 4 5 5 2 3 4 3 4 0 4.91 33 201 3 
24 
If there is a link between 
endometriosis and other health 
conditions, can one diagnostic 
tool be developed? 
14 9 12 12 12 12 6 14 14 20 5.82 125 647 29 
25 
In what circumstances should 
endometriosis be classified 
and/or recognised as a 
disability? 
36 38 31 33 31 35 32 36 34 64 5.84 370 1910 66 
26 
Is endometriosis a single 
disease or are there different 
disease subtypes which 
represent different, but related, 
pathological entities? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









Is endometriosis associated 
with miscarriages and/or 
ectopic pregnancy, and if so, 
what are the underlying 
causes? 
13 13 14 19 13 23 12 20 14 8 5.44 149 829 37 
28 
Is endometriosis hereditary 
and/or genetic? 
18 27 17 15 16 23 21 24 28 51 6.26 240 1138 47 
29 
Is it possible to develop a non-
invasive screening tool to aid 
diagnosis of endometriosis? 
28 35 32 41 26 21 27 31 24 15 5.06 280 1663 59 
30 
Is surgery necessary to treat 
severe endometriosis and if so, 
what is the outcome for women 
with deep infiltrating 
endometriosis and/or recto-
vaginal endometriosis who do 
or do not undergo surgery? 
3 8 15 19 7 17 7 14 9 11 5.72 110 581 21.5 
31 
Is there a genetic test for 
endometriosis? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









Is there a link between 
endometriosis and auto-
immune diseases, and 
endometriosis and/ or 
inflammatory disorders (e.g. 
MS, Lupus, RA, osteoarthritis, 
asthma, eczema and thyroid) 
and if so why? 
26 38 33 37 40 52 34 29 29 22 5.33 340 1928 67 
33 
Is there a link between 
endometriosis and food 
intolerance? 
7 4 9 15 12 12 19 21 19 34 6.88 152 626 28 
34 
Is there a link between 
endometriosis and infections 
(e.g. candidiasis, bacterial 
vaginosis) and if so, could 
treatment identify infection? 
4 4 6 15 14 14 18 6 16 15 6.36 112 520 18 
35 
Is there a link between 
endometriosis and/or other 
chronic medical conditions? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









What are the benefits of 
different hormonal treatments 
(e.g. Mirena IUS, contraceptive 
pill, GnRH agonists and 
progestogens) in managing the 
symptoms of endometriosis? 
8 12 10 11 14 12 13 13 14 13 5.83 120 621 27 
37 
What are the benefits of HRT 
after surgical and/or natural 
menopause in women with 
endometriosis? 
3 7 7 3 4 7 13 10 13 5 6.25 72 342 11 
38 
What are the most effective 
care and support pathways that 
can be offered to enable 
women with endometriosis and 
their support network to have a 
clear understanding of 
treatments and management 
provided by health care 
providers? 
8 16 19 22 18 14 14 19 17 14 5.60 161 869 39 
39 
What are the most effective 








Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









What are the most effective 
ways of educating healthcare 
professionals throughout the 
healthcare system resulting in 
reduced time to diagnosis and 
improved treatment and care of 
women with endometriosis? 
12
6 
67 52 21 16 22 21 24 26 28 3.88 403 2868 71 
41 
What are the most effective 
ways of maximising and/or 
maintaining fertility in women 
with confirmed or suspected 
endometriosis? 
15 19 29 27 34 26 39 22 22 16 5.55 249 1358 55 
42 
What are the outcomes and/or 
success rate of surgery 
(excision vs. ablation) for 
endometriosis, and does a 
particular type of surgery 
provide more benefits for 
certain patient groups? 
11 14 18 13 20 19 18 16 11 11 5.44 151 839 38 
43 
What are the outcomes and/or 
success rates for surgical or 
medical treatments which aim 
to cure treat endometriosis, 
rather than manage it? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









What are the outcomes and/or 
success rates of a hysterectomy 
and is it more effective for 
certain patient groups? 
6 8 5 10 17 9 18 14 20 20 6.57 127 563 20 
45 
What are the reasons for lack 
of access to treatment for 
endometriosis (e.g. surgical, 
medical, non-medical, lack of 
specialists)? 
17 24 32 34 24 25 21 16 20 12 5.08 225 1333 54 
46 
What are the symptoms of 
bowel endometriosis? 
3 7 3 14 17 13 9 13 16 24 6.69 119 513 17 
47 
What can be done to reduce the 
risk and/or development of 
adhesions following treatment 
for endometriosis (e.g. 
surgery)? 
13 12 20 31 21 35 35 34 24 19 5.98 244 1225 51 
48 
What can be done to stop 
endometriosis from recurring 
(e.g. after treatment)? 
28 44 38 36 46 34 29 17 23 11 4.78 306 1902 65 
49 What causes endometriosis? 
13
6 
58 26 15 18 17 17 13 22 29 3.68 351 2568 70 
50 
What impact does pregnancy 
have on endometriosis (e.g. 
symptoms, recurrence)? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









What information is the most 
effective in informing women 
and girls with endometriosis 
about the disease so they are 
enabled to make informed 
decisions about treatment(s) 
without causing anxiety in girls 
and women? 
4 18 12 10 8 15 10 11 9 15 5.67 112 597 24 
52 
What is the best way to 
monitor disease progress (e.g. 
regular check-up) once 
diagnosed with endometriosis? 
20 35 33 33 32 30 22 29 21 21 5.24 276 1590 58 
53 
What is the earliest age at 
which endometriosis can be 
detected or and is it a different 
disorder in young people than 
in adults? 
1 4 8 8 11 9 6 11 5 4 5.81 67 348 12 
54 
What is the effect of 
downregulation treatments 
(e.g. GnRH agonists) before or 
after surgery (e.g. disease 
detection; ease of resection; 
blood loss; improvement in 
symptoms and quality of life)? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









What is the efficacy of dietary 
regimes and/or nutritional 
supplements (e.g. dairy, non-
dairy, gluten-free, vitamin B6, 
fish oils, and black cohosh) in 
managing the symptoms of 
endometriosis? 
7 17 21 22 21 32 31 32 33 32 6.37 248 1149 48 
56 
What is the efficacy of non-
dietary lifestyle changes and 
self-management strategies, 
(e.g. exercise, in managing the 
symptoms of endometriosis)? 
1 1 1 8 6 5 13 11 17 22 7.65 85 285 8 
57 
What is the efficacy of non-
medical therapies in managing 
symptoms of endometriosis 
(e.g. CBT, acupuncture, 
physiotherapy, reflexology and 
ACT)? 
1 8 10 11 11 10 22 19 17 16 6.60 125 550 19 
58 
What is the link between 
menstruation and 
endometriosis (e.g. heavy 
bleeding)? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









What is the most effective way 
of managing the emotional and 
/or psychological and/or 
fatigue impact of living with 
endometriosis (including 
medical, non-medical and self-
management methods)? 
25 48 46 32 29 30 27 33 22 20 5.01 312 1869 64 
60 
What is the most effective way 
of stopping endometriosis 
progressing and/or spreading to 
other organs (e.g. after 
surgery)? 
27 44 40 41 38 36 31 33 9 16 4.85 315 1938 68 
61 
What is the most efficient 
method of establishing the 
outcomes of treatments offered 
and how would women access 
this information to enable 
informed decision making? 
4 12 4 3 11 6 9 12 8 5 5.73 74 390 13 
62 
What is the natural history of 
endometriosis (e.g. how, and 
how quickly, does it progress 
and spread)? 
11 13 13 11 14 4 6 12 12 23 5.80 119 619 25.5 
63 
When does endometriosis 
start? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









Why do medical practitioners 
suggest that women with 
endometriosis have a baby as a 
cure? 
6 4 6 12 6 11 14 10 12 21 6.59 102 450 15 
65 
Why do the symptoms of 
endometriosis affect different 
women in different ways? 
2 3 9 7 9 9 19 7 7 17 6.56 89 395 14 
66 
Why do women with 
endometriosis have difficulty 
getting pregnant? 
18 17 26 17 15 10 21 22 9 6 4.95 161 974 43 
67 
Why do women with 
endometriosis suffer from 
fatigue? 
8 26 35 41 43 37 49 31 38 37 6.00 345 1726 60 
68 
Why does endometriosis affect 
the bowel? 
4 11 19 10 14 16 16 27 17 15 6.17 149 719 31 
69 
Why does endometriosis 
and/or symptoms recur after 
treatment, and how likely 
and/or quickly is it that 
endometriosis recurs after 
different treatments (medical 
treatment; surgical removal 
disease; hysterectomy)? 




Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being 
the least important 
  









Why does endometriosis cause 
pain? 
26 13 10 7 8 9 16 12 8 23 5.41 132 738 33 
71 
Why does endometriosis cause 
painful sex? 
7 15 12 18 20 14 9 17 15 23 5.95 150 757 35.5 
72 
Why is pain relief medication 
for endometriosis-related pain 
and/or related symptoms often 
not effective (e.g. over the 
counter or prescription)? 
19 22 22 24 24 16 20 17 28 22 5.56 214 1165 49 
 
answered question 1302     
 




A.4.3. Healthcare professionals scores 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









Are there any ways to 
predict which women are at 
risk of endometriosis to 
intervene early before the 
disease advanced? 
0 3 4 3 2 4 3 1 3 1 5.42 24 134 51 
2 
Are women with 
endometriosis at an 
increased risk of cancers, 
and if so which and how 
they can be prevented? 
3 0 2 1 4 8 2 3 3 2 5.93 28 142 53.5 
3 
Can a cure be developed 
for endometriosis? 
9 9 1 0 1 0 2 2 3 4 4.26 31 209 67 
4 
Can endometriosis be 
diagnosed during and after 
menopause? 
0 1 0 0 0 0 2 0 0 1 6.50 4 18 3 
5 
Can we predict the cohort 
of women whose 
symptoms will not improve 
after excision of 
endometriosis? 
1 0 2 1 3 4 0 5 3 0 6.16 19 92 32.5 
206 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









Do any treatments for 
endometriosis have higher 
risk of causing infertility? 
0 2 1 3 0 1 1 3 0 1 5.50 12 66 20 
7 
Do early referrals to 
secondary and/or tertiary 
services and/or pain 
management services 
improve outcomes for 
women with 
endometriosis? 
4 3 4 1 2 3 2 1 2 1 4.52 23 149 55 
8 
Does a hysterectomy cure 
(symptoms of) 
endometriosis, and how do 
factors around 
hysterectomy affect 
outcomes? (e.g. age at 
hysterectomy; surgical 
approach and/or 
techniques; removal of 
ovaries)? 
0 0 5 1 2 0 3 1 4 1 6.12 17 83 29 
9 
Does bowel resection have 
better results than “shave” 
operation for deep 
infiltrating endometriosis? 
2 1 0 3 2 0 1 2 3 1 5.73 15 79 27 
207 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









Does having endometriosis 
also alter fertility by having 
an impact on egg quality? 
0 1 1 2 0 2 3 1 1 0 5.73 11 58 16 
11 
Does life style affect 
endometriosis (e.g. food, 
exercise, stress, alcohol)? 
3 1 2 3 1 1 1 2 2 4 5.75 20 105 38 
12 
Does the menopause have 
an impact on the severity 
or experience of 
endometriosis? 
0 0 1 0 0 1 0 0 1 4 8.29 7 19 4 
13 
How are endometriosis-
related digestive and 
bowel-related symptoms 
best managed (including 
surgical, medical and non-
medical treatments)? 
0 2 0 0 2 2 4 3 3 0 6.56 16 71 22 
14 
How can endometriosis be 
prevented? 
3 2 4 1 1 2 3 1 0 3 4.95 20 121 46.5 
15 
How can side-effects of 
medical treatments of 
endometriosis be avoided? 
0 0 0 0 0 0 1 0 1 0 8.00 2 6 1 
208 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









How can the diagnosis of 
endometriosis be 
improved? 
11 5 1 6 3 3 3 7 4 0 4.51 43 279 71 
17 
How can we prevent 
endometriosis in women 
and/or young girls with a 
family history of the 
disease? 
4 3 4 1 1 2 5 3 3 0 4.96 26 157 56 
18 
How can women most 
effectively and safely 
manage their endometriosis 
symptoms if they would 
like to become pregnant? 
2 1 2 1 2 4 1 0 2 0 4.87 15 92 32.5 
19 
How do we get 
endometriosis and its 
impact on employment and 
employability recognised 
by employers and those 
dealing with the 
unemployed? 
0 2 3 0 0 3 1 1 0 4 6.14 14 68 21 
209 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









How does endometriosis 
affect mental wellbeing 
(e.g. low mood, depression, 
lack of energy, stress, 
anxiety)? 
1 1 1 3 1 4 5 1 3 2 6.23 22 105 38 
21 
How does endometriosis 
and its treatment (medical 
or surgical) affect women 
with endometriosis in the 
long term? 
1 1 2 1 1 1 2 1 4 4 6.78 18 76 25.5 
22 
How does endometriosis 
impact on a woman’s 
quality of life (e.g. 
education, work, 
relationships)? 
1 0 0 2 1 0 3 2 1 3 6.92 13 53 12.5 
23 
How endometriosis in 
adolescents is best 
managed in a clinical 
setting? 
4 4 2 3 1 1 2 1 0 0 3.50 18 135 52 
210 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









If there is a link between 
endometriosis and other 
health conditions, can one 
diagnostic tool be 
developed? 
3 1 1 1 2 0 2 2 4 3 6.21 19 91 31 
25 
In what circumstances 
should endometriosis be 
classified and/or 
recognised as a disability? 
2 3 2 2 2 2 3 2 3 4 5.92 25 127 49 
26 
Is endometriosis a single 
disease or are there 
different disease subtypes 
which represent different, 
but related, pathological 
entities? 
1 7 3 2 4 1 5 0 3 5 5.48 31 171 61 
27 
Is endometriosis associated 
with miscarriages and/or 
ectopic pregnancy, and if 
so, what are the underlying 
causes? 
1 0 1 3 3 2 3 3 2 1 6.11 19 93 34 
28 
Is endometriosis hereditary 
and/or genetic? 
2 3 3 2 5 5 1 4 1 4 5.60 30 162 59 
211 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









Is it possible to develop a 
non-invasive screening tool 
to aid diagnosis of 
endometriosis? 
5 8 4 5 3 5 5 2 2 2 4.56 41 264 70 
30 
Is surgery necessary to treat 
severe endometriosis and if 
so, what is the outcome for 
women with deep 
infiltrating endometriosis 
and/or recto-vaginal 
endometriosis who do or do 
not undergo surgery? 
4 0 3 7 0 2 1 3 2 2 5.08 24 142 53.5 
31 
Is there a genetic test for 
endometriosis? 
1 1 2 0 0 1 2 1 2 4 6.79 14 59 17.5 
32 
Is there a link between 
endometriosis and auto-
immune diseases, and 
endometriosis and/ or 
inflammatory disorders 
(e.g. MS, Lupus, RA, 
osteoarthritis, asthma, 
eczema and thyroid) and if 
so why? 
4 1 2 5 3 3 4 3 5 4 5.94 34 172 62 
212 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









Is there a link between 
endometriosis and food 
intolerance? 
0 0 0 1 0 0 0 2 0 2 8.00 5 15 2 
34 
Is there a link between 
endometriosis and 
infections (e.g. candidiasis, 
bacterial vaginosis) and if 
so, could treatment identify 
infection? 
0 0 1 1 2 3 1 1 0 2 6.36 11 51 11 
35 
Is there a link between 
endometriosis and/or other 
chronic medical 
conditions? 
0 2 1 2 5 4 4 4 1 0 5.78 23 120 45 
36 
What are the benefits of 
different hormonal 
treatments (e.g. Mirena 
IUS, contraceptive pill, 
GnRH agonists and 
progestogens) in managing 
the symptoms of 
endometriosis? 
2 4 4 2 2 0 1 1 3 3 5.09 22 130 50 
213 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









What are the benefits of 
HRT after surgical and/or 
natural menopause in 
women with 
endometriosis? 
1 2 2 0 2 3 0 1 2 2 5.67 15 80 28 
38 
What are the most effective 
care and support pathways 
that can be offered to 
enable women with 
endometriosis and their 
support network to have a 
clear understanding of 
treatments and 
management provided by 
health care providers? 
0 1 4 3 1 2 2 2 4 1 5.95 20 101 36 
39 
What are the most effective 
non-surgical ways of 
managing endometriosis-
related pain and/or 
symptoms (medical/non-
medical)? 
2 3 3 4 3 4 5 2 1 3 5.40 30 168 60 
214 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









What are the most effective 
ways of educating 
healthcare professionals 
throughout the healthcare 
system resulting in reduced 
time to diagnosis and 
improved treatment and 
care of women with 
endometriosis? 
3 6 4 4 3 1 4 2 1 2 4.57 30 193 64 
41 
What are the most effective 
ways of maximising and/or 
maintaining fertility in 
women with confirmed or 
suspected endometriosis? 
1 1 3 4 6 4 3 4 4 0 5.70 30 159 58 
42 
What are the outcomes 
and/or success rate of 
surgery (excision vs. 
ablation) for endometriosis, 
and does a particular type 
of surgery provide more 
benefits for certain patient 
groups? 
1 2 1 3 1 4 3 6 0 2 6.00 23 115 43 
215 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









What are the outcomes 
and/or success rates for 
surgical or medical 
treatments which aim to 
cure treat endometriosis, 
rather than manage it? 
3 4 3 4 2 1 0 6 1 3 5.15 27 158 57 
44 
What are the outcomes 
and/or success rates of a 
hysterectomy and is it more 
effective for certain patient 
groups? 
0 0 0 3 3 3 1 3 1 3 6.76 17 72 23 
45 
What are the reasons for 
lack of access to treatment 
for endometriosis (e.g. 
surgical, medical, non-
medical, lack of 
specialists)? 
1 0 3 2 1 1 1 2 1 2 5.79 14 73 24 
46 
What are the symptoms of 
bowel endometriosis? 
0 0 1 1 0 2 0 1 3 1 7.11 9 35 6 
216 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









What can be done to 
reduce the risk and/or 
development of adhesions 
following treatment for 
endometriosis (e.g. 
surgery)? 
0 2 4 4 1 4 3 2 1 1 5.32 22 125 48 
48 
What can be done to stop 
endometriosis from 
recurring (e.g. after 
treatment)? 




22 6 1 0 0 1 0 2 1 3 2.72 36 298 72 
50 
What impact does 
pregnancy have on 
endometriosis (e.g. 
symptoms, recurrence)? 
0 0 0 1 4 0 1 3 3 4 7.63 16 54 14 
217 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









What information is the 
most effective in informing 
women and girls with 
endometriosis about the 
disease so they are enabled 
to make informed decisions 
about treatment(s) without 
causing anxiety in girls and 
women? 
4 2 0 0 3 0 1 1 0 1 4.00 12 84 30 
52 
What is the best way to 
monitor disease progress 
(e.g. regular check-up) 
once diagnosed with 
endometriosis? 
6 2 4 5 1 2 1 4 2 1 4.50 28 182 63 
53 
What is the earliest age at 
which endometriosis can 
be detected or and is it a 
different disorder in young 
people than in adults? 
1 1 2 2 3 0 0 2 1 1 5.15 13 76 25.5 
218 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









What is the effect of 
downregulation treatments 
(e.g. GnRH agonists) 
before or after surgery (e.g. 
disease detection; ease of 
resection; blood loss; 
improvement in symptoms 
and quality of life)? 
0 0 1 2 0 1 1 2 0 1 6.25 8 38 9 
55 
What is the efficacy of 
dietary regimes and/or 
nutritional supplements 
(e.g. dairy, non-dairy, 
gluten-free, vitamin B6, 
fish oils, and black cohosh) 
in managing the symptoms 
of endometriosis? 
0 1 1 4 0 5 2 2 4 6 7.08 25 98 35 
56 




(e.g. exercise, in managing 
the symptoms of 
endometriosis)? 
0 0 2 0 1 3 2 1 4 3 7.31 16 59 17.5 
219 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









What is the efficacy of 
non-medical therapies in 
managing symptoms of 




1 3 2 2 2 3 3 1 4 1 5.64 22 118 44 
58 
What is the link between 
menstruation and 
endometriosis (e.g. heavy 
bleeding)? 
0 0 1 0 4 0 0 1 0 1 5.86 7 36 7 
59 
What is the most effective 
way of managing the 
emotional and /or 
psychological and/or 





1 6 2 5 4 3 5 4 5 1 5.53 36 197 65 
60 
What is the most effective 
way of stopping 
endometriosis progressing 
and/or spreading to other 
organs (e.g. after surgery)? 
2 6 2 5 10 3 2 7 1 2 5.18 40 233 69 
220 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









What is the most efficient 
method of establishing the 
outcomes of treatments 
offered and how would 
women access this 
information to enable 
informed decision making? 
1 1 0 2 2 1 0 0 0 3 5.70 10 53 12.5 
62 
What is the natural history 
of endometriosis (e.g. how, 
and how quickly, does it 
progress and spread)? 
6 7 6 1 2 1 0 1 2 4 4.13 30 206 66 
63 
When does endometriosis 
start? 
0 1 1 0 1 3 0 0 4 1 6.73 11 47 10 
64 
Why do medical 
practitioners suggest that 
women with endometriosis 
have a baby as a cure? 
0 0 1 0 1 1 2 0 0 0 5.60 5 27 5 
65 
Why do the symptoms of 
endometriosis affect 
different women in 
different ways? 
2 1 3 1 3 1 3 3 1 2 5.60 20 108 41.5 
66 
Why do women with 
endometriosis have 
difficulty getting pregnant? 
2 3 2 2 2 2 2 2 4 0 5.24 21 121 46.5 
221 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









Why do women with 
endometriosis suffer from 
fatigue? 
0 0 1 2 3 0 2 2 3 3 7.06 16 63 19 
68 
Why does endometriosis 
affect the bowel? 
1 2 0 1 1 1 0 2 2 1 5.82 11 57 15 
69 
Why does endometriosis 
and/or symptoms recur 
after treatment, and how 
likely and/or quickly is it 
that endometriosis recurs 
after different treatments 
(medical treatment; 
surgical removal disease; 
hysterectomy)? 
1 0 3 0 5 4 4 1 1 1 5.70 20 106 40 
70 
Why does endometriosis 
cause pain? 
6 2 0 1 1 0 2 0 2 5 5.32 19 108 41.5 
71 
Why does endometriosis 
cause painful sex? 
0 0 1 1 1 1 1 0 2 3 7.30 10 37 8 
222 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10(bottom) being the least important 









Why is pain relief 
medication for 
endometriosis-related pain 
and/or related symptoms 
often not effective (e.g. 
over the counter or 
prescription)? 
0 5 2 2 3 1 0 2 0 1 4.44 16 105 38 
 
answered question 144 
  
 




A.4.4. Healthcare professionals with endometriosis scores 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









Are there any ways to 
predict which women are at 
risk of endometriosis to 
intervene early before the 
disease advanced? 
0 0 0 1 1 2 0 1 0 0 5.80 5 26 31 
2 
Are women with 
endometriosis at an 
increased risk of cancers, 
and if so which and how 
they can be prevented? 
1 0 0 0 3 3 2 3 0 0 6.00 12 60 56 
3 
Can a cure be developed 
for endometriosis? 
6 6 1 0 1 0 2 0 1 2 3.63 19 140 72 
4 
Can endometriosis be 
diagnosed during and after 
menopause? 
0 0 0 0 0 0 1 0 0 0 7.00 1 4 4 
5 
Can we predict the cohort 
of women whose 
symptoms will not improve 
after excision of 
endometriosis? 
0 0 0 0 2 0 0 0 0 0 5.00 2 12 14.5 
224 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









Do any treatments for 
endometriosis have higher 
risk of causing infertility? 
0 0 0 0 0 0 0 1 0 1 9.00 2 4 4 
7 
Do early referrals to 
secondary and/or tertiary 
services and/or pain 
management services 
improve outcomes for 
women with 
endometriosis? 
0 1 0 0 0 0 1 0 1 0 6.00 3 15 19 
8 
Does a hysterectomy cure 
(symptoms of) 
endometriosis, and how do 
factors around 
hysterectomy affect 
outcomes? (e.g. age at 
hysterectomy; surgical 
approach and/or 
techniques; removal of 
ovaries)? 
0 0 3 0 0 0 2 0 0 0 4.60 5 32 35 
9 
Does bowel resection have 
better results than “shave” 
operation for deep 
infiltrating endometriosis? 
0 0 0 1 0 0 0 0 1 1 7.67 3 10 10.5 
225 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









Does having endometriosis 
also alter fertility by having 
an impact on egg quality? 
0 0 1 0 0 1 0 0 0 0 4.50 2 13 17 
11 
Does life style affect 
endometriosis (e.g. food, 
exercise, stress, alcohol)? 
2 0 0 1 0 1 0 0 2 1 5.71 7 37 41.5 
12 
Does the menopause have 
an impact on the severity or 
experience of 
endometriosis? 
0 0 0 0 0 0 0 0 1 1 9.50 2 3 4 
13 
How are endometriosis-
related digestive and 
bowel-related symptoms 
best managed (including 
surgical, medical and non-
medical treatments)? 
0 1 0 0 1 1 0 0 2 0 6.20 5 24 29.5 
14 
How can endometriosis be 
prevented? 
1 1 1 0 0 1 1 0 0 1 4.83 6 37 41.5 
15 
How can side-effects of 
medical treatments of 
endometriosis be avoided? 
0 0 0 0 0 0 1 0 0 0 7.00 1 4 4 
226 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









How can the diagnosis of 
endometriosis be 
improved? 
6 2 1 1 1 1 1 3 1 0 4.00 17 119 70 
17 
How can we prevent 
endometriosis in women 
and/or young girls with a 
family history of the 
disease? 
3 1 2 0 1 0 1 2 2 0 4.75 12 75 61 
18 
How can women most 
effectively and safely 
manage their endometriosis 
symptoms if they would 
like to become pregnant? 
1 1 0 0 1 1 0 0 1 0 4.60 5 32 35 
19 
How do we get 
endometriosis and its 
impact on employment and 
employability recognised 
by employers and those 
dealing with the 
unemployed? 
0 2 3 0 0 3 1 0 0 3 5.67 12 64 57 
227 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









How does endometriosis 
affect mental wellbeing 
(e.g. low mood, depression, 
lack of energy, stress, 
anxiety)? 
1 1 0 3 1 2 3 0 1 1 5.54 13 71 60 
21 
How does endometriosis 
and its treatment (medical 
or surgical) affect women 
with endometriosis in the 
long term? 
0 0 1 1 1 1 1 1 2 1 6.78 9 38 43 
22 
How does endometriosis 
impact on a woman’s 
quality of life (e.g. 
education, work, 
relationships)? 
1 0 0 2 1 0 1 2 1 0 5.75 8 42 47.5 
23 
How endometriosis in 
adolescents is best 
managed in a clinical 
setting? 
1 1 0 1 0 1 0 0 0 0 3.25 4 31 35 
228 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









If there is a link between 
endometriosis and other 
health conditions, can one 
diagnostic tool be 
developed? 
1 1 0 0 1 0 1 0 1 3 6.75 8 34 39 
25 
In what circumstances 
should endometriosis be 
classified and/or recognised 
as a disability? 
1 2 2 1 2 0 2 0 3 4 6.24 17 81 63.5 
26 
Is endometriosis a single 
disease or are there 
different disease subtypes 
which represent different, 
but related, pathological 
entities? 
0 1 0 1 0 0 2 0 2 0 6.33 6 28 35 
27 
Is endometriosis associated 
with miscarriages and/or 
ectopic pregnancy, and if 
so, what are the underlying 
causes? 
0 0 0 1 0 1 1 1 0 1 7.00 5 20 23.5 
28 
Is endometriosis hereditary 
and/or genetic? 
1 1 2 0 3 1 0 3 0 2 5.69 13 69 58.5 
229 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









Is it possible to develop a 
non-invasive screening tool 
to aid diagnosis of 
endometriosis? 
3 2 0 0 1 2 2 1 0 1 4.67 12 76 62 
30 
Is surgery necessary to treat 
severe endometriosis and if 
so, what is the outcome for 
women with deep 
infiltrating endometriosis 
and/or recto-vaginal 
endometriosis who do or do 
not undergo surgery? 
1 0 0 0 0 1 0 1 0 0 5.00 3 18 23.5 
31 
Is there a genetic test for 
endometriosis? 
0 0 1 0 0 0 1 1 1 1 7.40 5 18 23.5 
230 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









Is there a link between 
endometriosis and auto-
immune diseases, and 
endometriosis and/ or 
inflammatory disorders 
(e.g. MS, Lupus, RA, 
osteoarthritis, asthma, 
eczema and thyroid) and if 
so why? 
4 1 1 3 1 3 1 1 1 1 4.59 17 109 69 
33 
Is there a link between 
endometriosis and food 
intolerance? 
0 0 0 1 0 0 0 1 0 0 6.00 2 10 10.5 
34 
Is there a link between 
endometriosis and 
infections (e.g. candidiasis, 
bacterial vaginosis) and if 
so, could treatment identify 
infection? 
0 0 1 0 0 2 1 0 0 2 7.00 6 24 29.5 
35 
Is there a link between 
endometriosis and/or other 
chronic medical 
conditions? 
0 1 0 0 3 1 1 2 0 0 5.75 8 42 47.5 
231 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









What are the benefits of 
different hormonal 
treatments (e.g. Mirena 
IUS, contraceptive pill, 
GnRH agonists and 
progestogens) in managing 
the symptoms of 
endometriosis? 
1 1 2 1 0 0 0 0 1 0 3.67 6 44 47.5 
37 
What are the benefits of 
HRT after surgical and/or 
natural menopause in 
women with 
endometriosis? 
0 1 1 0 0 0 0 0 2 0 5.75 4 21 28 
38 
What are the most effective 
care and support pathways 
that can be offered to 
enable women with 
endometriosis and their 
support network to have a 
clear understanding of 
treatments and 
management provided by 
health care providers? 
0 0 2 1 1 1 1 0 3 0 6.11 9 44 47.5 
232 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









What are the most effective 
non-surgical ways of 
managing endometriosis-
related pain and/or 
symptoms (medical/non-
medical)? 
0 1 1 1 1 2 3 1 0 1 5.91 11 56 54.5 
40 
What are the most effective 
ways of educating 
healthcare professionals 
throughout the healthcare 
system resulting in reduced 
time to diagnosis and 
improved treatment and 
care of women with 
endometriosis? 
2 3 3 0 2 1 0 1 0 1 3.92 13 92 66 
41 
What are the most effective 
ways of maximising and/or 
maintaining fertility in 
women with confirmed or 
suspected endometriosis? 
0 0 1 0 2 0 1 1 2 0 6.57 7 31 35 
233 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









What are the outcomes 
and/or success rate of 
surgery (excision vs. 
ablation) for endometriosis, 
and does a particular type 
of surgery provide more 
benefits for certain patient 
groups? 
0 1 0 0 0 0 0 3 0 1 7.20 5 19 23.5 
43 
What are the outcomes 
and/or success rates for 
surgical or medical 
treatments which aim to 
cure treat endometriosis, 
rather than manage it? 
1 1 0 2 0 0 0 2 0 1 5.29 7 40 47.5 
44 
What are the outcomes 
and/or success rates of a 
hysterectomy and is it more 
effective for certain patient 
groups? 
0 0 0 1 0 0 1 0 0 1 7.00 3 12 14.5 
45 
What are the reasons for 
lack of access to treatment 
for endometriosis (e.g. 
surgical, medical, non-
medical, lack of 
specialists)? 
1 0 1 1 1 1 1 1 0 0 4.86 7 43 47.5 
234 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









What are the symptoms of 
bowel endometriosis? 
0 0 0 1 0 0 0 1 2 0 7.50 4 14 18 
47 
What can be done to reduce 
the risk and/or 
development of adhesions 
following treatment for 
endometriosis (e.g. 
surgery)? 
0 1 2 3 1 2 1 1 0 0 4.73 11 69 58.5 
48 
What can be done to stop 
endometriosis from 
recurring (e.g. after 
treatment)? 




6 3 0 0 0 0 0 1 1 2 3.77 13 94 67 
50 
What impact does 
pregnancy have on 
endometriosis (e.g. 
symptoms, recurrence)? 
0 0 0 1 1 0 0 0 2 1 7.40 5 18 23.5 
235 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









What information is the 
most effective in informing 
women and girls with 
endometriosis about the 
disease so they are enabled 
to make informed decisions 
about treatment(s) without 
causing anxiety in girls and 
women? 
0 1 0 0 0 0 0 1 0 0 5.00 2 12 14.5 
52 
What is the best way to 
monitor disease progress 
(e.g. regular check-up) 
once diagnosed with 
endometriosis? 
1 0 3 4 1 1 0 2 1 0 4.77 13 81 63.5 
53 
What is the earliest age at 
which endometriosis can be 
detected or and is it a 
different disorder in young 
people than in adults? 
0 0 2 1 2 0 0 0 0 0 4.00 5 35 40 
236 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









What is the effect of 
downregulation treatments 
(e.g. GnRH agonists) 
before or after surgery (e.g. 
disease detection; ease of 
resection; blood loss; 
improvement in symptoms 
and quality of life)? 
0 0 0 0 0 0 0 1 0 0 8.00 1 3 4 
55 
What is the efficacy of 
dietary regimes and/or 
nutritional supplements 
(e.g. dairy, non-dairy, 
gluten-free, vitamin B6, 
fish oils, and black cohosh) 
in managing the symptoms 
of endometriosis? 
0 0 0 3 0 5 0 1 1 2 6.58 12 53 53 
56 




(e.g. exercise, in managing 
the symptoms of 
endometriosis)? 
0 0 1 0 0 0 0 0 2 0 7.00 3 12 14.5 
237 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









What is the efficacy of 
non-medical therapies in 
managing symptoms of 




0 2 1 1 0 2 0 0 0 0 3.83 6 43 47.5 
58 
What is the link between 
menstruation and 
endometriosis (e.g. heavy 
bleeding)? 
0 0 0 0 1 0 0 0 0 1 7.50 2 7 8 
59 
What is the most effective 
way of managing the 
emotional and /or 
psychological and/or 





1 2 1 2 2 1 2 3 1 0 5.27 15 86 65 
60 
What is the most effective 
way of stopping 
endometriosis progressing 
and/or spreading to other 
organs (e.g. after surgery)? 
0 5 0 4 4 1 2 4 0 2 5.36 22 124 71 
238 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









What is the most efficient 
method of establishing the 
outcomes of treatments 
offered and how would 
women access this 
information to enable 
informed decision making? 
0 0 0 0 0 0 0 0 0 2 10.00 2 2 4 
62 
What is the natural history 
of endometriosis (e.g. how, 
and how quickly, does it 
progress and spread)? 
0 2 2 1 0 1 0 0 0 1 4.29 7 47 52 
63 
When does endometriosis 
start? 
0 0 0 0 0 0 0 0 1 0 9.00 1 2 4 
64 
Why do medical 
practitioners suggest that 
women with endometriosis 
have a baby as a cure? 
0 0 0 0 1 1 2 0 0 0 6.25 4 19 23.5 
65 
Why do the symptoms of 
endometriosis affect 
different women in 
different ways? 
0 0 0 1 0 0 0 0 0 1 7.00 2 8 9 
66 
Why do women with 
endometriosis have 
difficulty getting pregnant? 
0 0 1 1 0 0 2 1 1 0 6.33 6 28 35 
239 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









Why do women with 
endometriosis suffer from 
fatigue? 
0 0 1 2 3 0 2 1 2 1 6.33 12 56 54.5 
68 
Why does endometriosis 
affect the bowel? 
0 0 0 0 0 1 0 1 1 1 8.25 4 11 12 
69 
Why does endometriosis 
and/or symptoms recur 
after treatment, and how 
likely and/or quickly is it 
that endometriosis recurs 
after different treatments 
(medical treatment; 
surgical removal disease; 
hysterectomy)? 
0 0 1 0 3 1 2 0 0 1 6.00 8 40 47.5 
70 
Why does endometriosis 
cause pain? 
3 0 0 0 0 0 0 0 0 2 4.60 5 32 35 
71 
Why does endometriosis 
cause painful sex? 
0 0 1 0 0 1 0 0 2 2 7.83 6 19 23.5 
240 
 
Rank these 10 questions based on their importance. 1 (top) being the most important and 10 (bottom) being the least important 









Why is pain relief 
medication for 
endometriosis-related pain 
and/or related symptoms 
often not effective (e.g. 
over the counter or 
prescription)? 
0 1 1 0 0 0 0 1 0 0 4.33 3 20 23.5 
 
answered question 52 
  
 




A.4.5. Total scores 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
3 
Can a cure be developed for 
endometriosis? 
72 67 72 211 1 
16 
How can the diagnosis of 
endometriosis be improved? 
69 71 70 210 2 
49 What causes endometriosis? 70 72 67 209 3 
60 
What is the most effective way of 
stopping endometriosis progressing 
and/or spreading to other organs 
(e.g. after surgery)? 
68 69 71 208 4 
40 
What are the most effective ways of 
educating healthcare professionals 
throughout the healthcare system 
resulting in reduced time to 
diagnosis and improved treatment 
and care of women with 
endometriosis? 
71 64 66 201 5 
48 
What can be done to stop 
endometriosis from recurring (e.g. 
after treatment)? 
65 68 68 201 5 
32 
Is there a link between 
endometriosis and auto-immune 
diseases, and endometriosis and/ or 
inflammatory disorders (e.g. MS, 
Lupus, RA, osteoarthritis, asthma, 
67 62 69 198 7 
242 
 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
eczema and thyroid) and if so why? 
59 
What is the most effective way of 
managing the emotional and /or 
psychological and/or fatigue impact 
of living with endometriosis 
(including medical, non-medical 
and self-management methods)? 
64 65 65 194 8 
29 
Is it possible to develop a non-
invasive screening tool to aid 
diagnosis of endometriosis? 
59 70 62 191 9 
52 
What is the best way to monitor 
disease progress (e.g. regular 
check-up) once diagnosed with 
endometriosis? 
58 63 63.5 184.5 10 
25 
In what circumstances should 
endometriosis be classified and/or 
recognised as a disability? 
66 49 63.5 178.5 11 
17 
How can we prevent endometriosis 
in women and/or young girls with a 
family history of the disease? 
57 56 61 174 12 
2 
Are women with endometriosis at 
an increased risk of cancers, and if 
so which and how they can be 
prevented? 
62 53.5 56 171.5 13 
39 
What are the most effective non-
surgical ways of managing 
56 60 54.5 170.5 14 
243 
 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
endometriosis-related pain and/or 
symptoms (medical/non-medical)? 
28 
Is endometriosis hereditary and/or 
genetic? 
47 59 58.5 164.5 15 
20 
How does endometriosis affect 
mental wellbeing (e.g. low mood, 
depression, lack of energy, stress, 
anxiety)? 
61 38 60 159 16 
47 
What can be done to reduce the risk 
and/or development of adhesions 
following treatment for 
endometriosis (e.g. surgery)? 
51 48 58.5 157.5 17 
41 
What are the most effective ways of 
maximising and/or maintaining 
fertility in women with confirmed 
or suspected endometriosis? 
55 58 35 148 18 
35 
Is there a link between 
endometriosis and/or other chronic 
medical conditions? 
52 45 47.5 144.5 19 
62 
What is the natural history of 
endometriosis (e.g. how, and how 
quickly, does it progress and 
spread)? 
25.5 66 52 143.5 20 
244 
 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
14 
How can endometriosis be 
prevented? 
53 46.5 41.5 141 21 
19 
How do we get endometriosis and 
its impact on employment and 
employability recognised by 
employers and those dealing with 
the unemployed? 
63 21 57 141 21 
43 
What are the outcomes and/or 
success rates for surgical or 
medical treatments which aim to 
cure treat endometriosis, rather than 
manage it? 
34 57 47.5 138.5 23 
69 
Why does endometriosis and/or 
symptoms recur after treatment, 
and how likely and/or quickly is it 
that endometriosis recurs after 
different treatments (medical 
treatment; surgical removal disease; 
hysterectomy)? 
50 40 47.5 137.5 24 
55 
What is the efficacy of dietary 
regimes and/or nutritional 
supplements (e.g. dairy, non-dairy, 
gluten-free, vitamin B6, fish oils, 
and black cohosh) in managing the 
symptoms of endometriosis? 
48 35 53 136 25 
245 
 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
67 
Why do women with endometriosis 
suffer from fatigue? 
60 19 54.5 133.5 26 
45 
What are the reasons for lack of 
access to treatment for 
endometriosis (e.g. surgical, 
medical, non-medical, lack of 
specialists)? 
54 24 47.5 125.5 27 
36 
What are the benefits of different 
hormonal treatments (e.g. Mirena 
IUS, contraceptive pill, GnRH 
agonists and progestogens) in 
managing the symptoms of 
endometriosis? 
27 50 47.5 124.5 28 
66 
Why do women with endometriosis 
have difficulty getting pregnant? 
43 46.5 35 124.5 28 
11 
Does life style affect endometriosis 
(e.g. food, exercise, stress, 
alcohol)? 
44 38 41.5 123.5 30 
38 
What are the most effective care 
and support pathways that can be 
offered to enable women with 
endometriosis and their support 
network to have a clear 
understanding of treatments and 
39 36 47.5 122.5 31 
246 
 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
management provided by health 
care providers? 
26 
Is endometriosis a single disease or 
are there different disease subtypes 
which represent different, but 
related, pathological entities? 
23 61 35 119 32 
18 
How can women most effectively 
and safely manage their 
endometriosis symptoms if they 
would like to become pregnant? 
46 32.5 35 113.5 33 
1 
Are there any ways to predict 
which women are at risk of 
endometriosis to intervene early 
before the disease advanced? 
30 51 31 112 34 
57 
What is the efficacy of non-medical 
therapies in managing symptoms of 
endometriosis (e.g. CBT, 
acupuncture, physiotherapy, 
reflexology and ACT)? 
19 44 47.5 110.5 35 
72 
Why is pain relief medication for 
endometriosis-related pain and/or 
related symptoms often not 
effective (e.g. over the counter or 
prescription)? 
49 38 23.5 110.5 35 
247 
 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
70 
Why does endometriosis cause 
pain? 
33 41.5 35 109.5 37 
21 
How does endometriosis and its 
treatment (medical or surgical) 
affect women with endometriosis in 
the long term? 
40 25.5 43 108.5 38 
8 
Does a hysterectomy cure 
(symptoms of) endometriosis, and 
how do factors around 
hysterectomy affect outcomes? 
(e.g. age at hysterectomy; surgical 
approach and/or techniques; 
removal of ovaries)? 
41 29 35 105 39 
22 
How does endometriosis impact on 
a woman’s quality of life (e.g. 
education, work, relationships)? 
45 12.5 47.5 105 39 
42 
What are the outcomes and/or 
success rate of surgery (excision vs. 
ablation) for endometriosis, and 
does a particular type of surgery 
provide more benefits for certain 
patient groups? 
38 43 23.5 104.5 41 
248 
 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
24 
If there is a link between 
endometriosis and other health 
conditions, can one diagnostic tool 
be developed? 
29 31 39 99 42 
30 
Is surgery necessary to treat severe 
endometriosis and if so, what is the 
outcome for women with deep 
infiltrating endometriosis and/or 
recto-vaginal endometriosis who do 
or do not undergo surgery? 
21.5 53.5 23.5 98.5 43 
27 
Is endometriosis associated with 
miscarriages and/or ectopic 
pregnancy, and if so, what are the 
underlying causes? 
37 34 23.5 94.5 44 
13 
How are endometriosis-related 
digestive and bowel-related 
symptoms best managed (including 
surgical, medical and non-medical 
treatments)? 
42 22 29.5 93.5 45 
249 
 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
7 
Do early referrals to secondary 
and/or tertiary services and/or pain 
management services improve 
outcomes for women with 
endometriosis? 
16 55 19 90 46 
23 
How endometriosis in adolescents 
is best managed in a clinical 
setting? 
3 52 35 90 46 
53 
What is the earliest age at which 
endometriosis can be detected or 
and is it a different disorder in 
young people than in adults? 
12 25.5 40 77.5 48 
31 
Is there a genetic test for 
endometriosis? 
32 17.5 23.5 73 49 
10 
Does having endometriosis also 
alter fertility by having an impact 
on egg quality? 
35.5 16 17 68.5 50 
250 
 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
51 
What information is the most 
effective in informing women and 
girls with endometriosis about the 
disease so they are enabled to make 
informed decisions about 
treatment(s) without causing 
anxiety in girls and women? 
24 30 14.5 68.5 50 
37 
What are the benefits of HRT after 
surgical and/or natural menopause 
in women with endometriosis? 
11 28 28 67 50 
71 
Why does endometriosis cause 
painful sex? 
35.5 8 23.5 67 50 
65 
Why do the symptoms of 
endometriosis affect different 
women in different ways? 
14 41.5 9 64.5 54 
50 
What impact does pregnancy have 
on endometriosis (e.g. symptoms, 
recurrence)? 
21.5 14 23.5 59 55 
34 
Is there a link between 
endometriosis and infections (e.g. 
candidiasis, bacterial vaginosis) and 
if so, could treatment identify 
infection? 
18 11 29.5 58.5 56 
251 
 
ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
68 
Why does endometriosis affect the 
bowel? 
31 15 12 58 57 
44 
What are the outcomes and/or 
success rates of a hysterectomy and 
is it more effective for certain 
patient groups? 
20 23 14.5 57.5 58 
5 
Can we predict the cohort of 
women whose symptoms will not 
improve after excision of 
endometriosis? 
6 32.5 14.5 53 59 
6 
Do any treatments for 
endometriosis have higher risk of 
causing infertility? 
25.5 20 4 49.5 60 
9 
Does bowel resection have better 
results than “shave” operation for 
deep infiltrating endometriosis? 
7 27 10.5 44.5 61 
64 
Why do medical practitioners 
suggest that women with 
endometriosis have a baby as a 
cure? 
15 5 23.5 43.5 62 
46 
What are the symptoms of bowel 
endometriosis? 
17 6 18 41 63 
33 
Is there a link between 
endometriosis and food 
28 2 10.5 40.5 64 
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ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
intolerance? 
56 
What is the efficacy of non-dietary 
lifestyle changes and self-
management strategies, (e.g. 
exercise, in managing the 
symptoms of endometriosis)? 
8 17.5 14.5 40 65 
61 
What is the most efficient method 
of establishing the outcomes of 
treatments offered and how would 
women access this information to 
enable informed decision making? 
13 12.5 4 29.5 66 
63 When does endometriosis start? 10 10 4 24 67 
58 
What is the link between 
menstruation and endometriosis 
(e.g. heavy bleeding)? 
5 7 8 20 68 
12 
Does the menopause have an 
impact on the severity or 
experience of endometriosis? 
9 4 4 17 69 
54 
What is the effect of 
downregulation treatments (e.g. 
GnRH agonists) before or after 
surgery (e.g. disease detection; ease 
of resection; blood loss; 
improvement in symptoms and 
quality of life)? 
2 9 4 15 70 
15 How can side-effects of medical 4 1 4 9 71 
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ID Answer Options 
Women with endo* 
score 
HCP scores 
HCP with endo 
scores 
Total score Final rank 
treatments of endometriosis be 
avoided? 
4 
Can endometriosis be diagnosed 
during and after menopause? 





A.5. Endometriosis final workshop ranking calculations  










B Can a cure be developed for endometriosis? 7 1 1 9 
V What causes endometriosis? 6 2 2 10 
P 
What are the most effective ways of educating healthcare professionals throughout 
the healthcare system resulting in reduced time to diagnosis and improved treatment 
and care of women with endometriosis? 
5 3 7 15 
E How can the diagnosis of endometriosis be improved? 1 4 11 16 
K 
Is it possible to develop a non-invasive screening tool to aid diagnosis of 
endometriosis? 
2 15 3 20 
Q 
What are the most effective ways of maximising and/or maintaining fertility in 
women with confirmed or suspected endometriosis? 
10 5 5 20 
Y 
What is the most effective way of managing the emotional and /or psychological 
and/or fatigue impact of living with endometriosis (including medical, non-medical 
and self-management methods)? 













Is there a link between endometriosis and auto-immune diseases, and endometriosis 
and/ or inflammatory disorders (e.g. MS, Lupus, RA, osteoarthritis, asthma, eczema 
and thyroid) and if so why? 
12 11 9 32 
R 
What are the outcomes and/or success rates for surgical or medical treatments which 
aim to cure treat endometriosis, rather than manage it? 
9 10 17 36 
J Is endometriosis hereditary and/or genetic? 4 12 21 37 
Z 
What is the most effective way of stopping endometriosis progressing and/or 
spreading to other organs (e.g. after surgery)? 
16 13 12 41 
U What can be done to stop endometriosis from recurring (e.g. after treatment)? 18 20 4 42 
O 
What are the most effective non-surgical ways of managing endometriosis-related 
pain and/or symptoms (medical/non-medical)? 
20 17 6 43 
A 
Are women with endometriosis at an increased risk of cancers, and if so which and 
how they can be prevented? 
13 18 13 44 
N 
What are the benefits of different hormonal treatments (e.g. Mirena IUS, 
contraceptive pill, GnRH agonists and progestogens) in managing the symptoms of 
endometriosis? 
22 8 15 45 
AA 
What is the natural history of endometriosis (e.g. how, and how quickly, does it 
progress and spread)? 
3 19 23 45 













What is the best way to monitor disease progress (e.g. regular check-up) once 
diagnosed with endometriosis? 
17 21 10 48 
S 
What are the reasons for lack of access to treatment for endometriosis (e.g. surgical, 
medical, non-medical, lack of specialists)? 
19 7 26 52 
G 
How do we get endometriosis and its impact on employment and employability 
recognised by employers and those dealing with the unemployed? 
21 16 18 55 
C Does life style affect endometriosis (e.g. food, exercise, stress, alcohol) 29 9 19 57 
T 
What can be done to reduce the risk and/or development of adhesions following 
treatment for endometriosis (e.g. surgery)? 
14 28 16 58 
F 
How can we prevent endometriosis in women and/or young girls with a family 
history of the disease? 
23 22 20 65 
I 
In what circumstances should endometriosis be classified and/or recognised as a 
disability? 
30 27 14 71 
DD 
Why does endometriosis and/or symptoms recur after treatment, and how likely 
and/or quickly is it that endometriosis recurs after different treatments (medical 
treatment; surgical removal disease; hysterectomy)? 
15 30 28 73 
M Is there a link between endometriosis and/or other chronic medical conditions? 27 25 24 76 












CC Why do women with endometriosis suffer from fatigue? 24 23 30 77 
X 
What is the efficacy of dietary regimes and/or nutritional supplements (e.g. dairy, 
non-dairy, gluten-free, vitamin B6, fish oils, and black cohosh) in managing the 
symptoms of endometriosis? 
28 24 27 79 
H 
How does endometriosis affect mental wellbeing (e.g. low mood, depression, lack 
of energy, stress, anxiety)? 
25 29 29 83 
*Sorted lowest to highest 
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B Can a cure be developed for endometriosis? 1 1 1 3 
V What causes endometriosis? 2 2 2 6 
P 
What are the most effective ways of educating healthcare professionals throughout 
the healthcare system resulting in reduced time to diagnosis and improved treatment 
and care of women with endometriosis? 
3 3 3 9 
K 
Is it possible to develop a non-invasive screening tool to aid diagnosis of 
endometriosis? 
5 5 4 14 
Q 
What are the most effective ways of maximising and/or maintaining fertility in 
women with confirmed or suspected endometriosis? 
6 6 5 17 
E How can the diagnosis of endometriosis be improved? 4 4 12 20 
Y 
What is the most effective way of managing the emotional and /or psychological 
and/or fatigue impact of living with endometriosis (including medical, non-medical 
and self-management methods)? 
7 7 7 21 
R 
What are the outcomes and/or success rates for surgical or medical treatments which 
aim to cure treat endometriosis, rather than manage it? 
8 9 8 25 
L 
Is there a link between endometriosis and auto-immune diseases, and endometriosis 
and/ or inflammatory disorders (e.g. MS, Lupus, RA, osteoarthritis, asthma, eczema 
and thyroid) and if so why? 













What is the most effective way of stopping endometriosis progressing and/or 
spreading to other organs (e.g. after surgery)? 
12 12 6 30 
O 
What are the most effective non-surgical ways of managing endometriosis-related 
pain and/or symptoms (medical/non-medical)? 
13 10 11 34 
J Is endometriosis hereditary and/or genetic? 9 11 21 41 
N 
What are the benefits of different hormonal treatments (e.g. Mirena IUS, 
contraceptive pill, GnRH agonists and progestogens) in managing the symptoms of 
endometriosis? 
15 15 15 45 
U What can be done to stop endometriosis from recurring (e.g. after treatment)? 10 21 14 45 
W 
What is the best way to monitor disease progress (e.g. regular check-up) once 
diagnosed with endometriosis? 
18 18 9 45 
S 
What are the reasons for lack of access to treatment for endometriosis (e.g. surgical, 
medical, non-medical, lack of specialists)? 
19 19 13 51 
AA 
What is the natural history of endometriosis (e.g. how, and how quickly, does it 
progress and spread)? 
16 16 20 52 
D How can endometriosis be prevented? 17 17 19 53 
C Does life style affect endometriosis (e.g. food, exercise, stress, alcohol) 21 13 22 56 
G 
How do we get endometriosis and its impact on employment and employability 
recognised by employers and those dealing with the unemployed? 













Are women with endometriosis at an increased risk of cancers, and if so which and 
how they can be prevented? 
14 14 30 58 
T 
What can be done to reduce the risk and/or development of adhesions following 
treatment for endometriosis (e.g. surgery)? 
22 22 16 60 
F 
How can we prevent endometriosis in women and/or young girls with a family 
history of the disease? 
23 23 18 64 
I 
In what circumstances should endometriosis be classified and/or recognised as a 
disability? 
24 24 23 71 
DD 
Why does endometriosis and/or symptoms recur after treatment, and how likely 
and/or quickly is it that endometriosis recurs after different treatments (medical 
treatment; surgical removal disease; hysterectomy)? 
25 25 24 74 
M Is there a link between endometriosis and/or other chronic medical conditions? 26 26 25 77 
BB Why do women with endometriosis have difficulty getting pregnant? 27 27 27 81 
CC Why do women with endometriosis suffer from fatigue? 28 28 26 82 
X 
What is the efficacy of dietary regimes and/or nutritional supplements (e.g. dairy, 
non-dairy, gluten-free, vitamin B6, fish oils, and black cohosh) in managing the 
symptoms of endometriosis? 
29 29 28 86 
H 
How does endometriosis affect mental wellbeing (e.g. low mood, depression, lack 
of energy, stress, anxiety)? 
30 30 29 89 
*Sorted lowest to highest
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B Can a cure be developed for endometriosis? 1 1 1 3 
V What causes endometriosis? 2 2 2 6 
P 
What are the most effective ways of educating healthcare professionals throughout 
the healthcare system resulting in reduced time to diagnosis and improved treatment 
and care of women with endometriosis? 
3 3 3 9 
K 
Is it possible to develop a non-invasive screening tool to aid diagnosis of 
endometriosis? 
5 5 4 14 
Q 
What are the most effective ways of maximising and/or maintaining fertility in 
women with confirmed or suspected endometriosis? 
6 6 5 17 
E How can the diagnosis of endometriosis be improved? 4 4 12 20 
Y 
What is the most effective way of managing the emotional and /or psychological 
and/or fatigue impact of living with endometriosis (including medical, non-medical 
and self-management methods)? 
7 7 7 21 
R 
What are the outcomes and/or success rates for surgical or medical treatments which 
aim to cure treat endometriosis, rather than manage it? 
8 9 8 25 
Z 
What is the most effective way of stopping endometriosis progressing and/or 
spreading to other organs (e.g. after surgery)? 













What are the most effective non-surgical ways of managing endometriosis-related 
pain and/or symptoms (medical/non-medical)? 
13 10 11 34 
L 
Is there a link between endometriosis and auto-immune diseases, and endometriosis 
and/ or inflammatory disorders (e.g. MS, Lupus, RA, osteoarthritis, asthma, eczema 
and thyroid) and if so why? 
11 8 10 29 
J Is endometriosis hereditary and/or genetic? 9 11 21 41 
N 
What are the benefits of different hormonal treatments (e.g. Mirena IUS, 
contraceptive pill, GnRH agonists and progestogens) in managing the symptoms of 
endometriosis? 
15 15 15 45 
U What can be done to stop endometriosis from recurring (e.g. after treatment)? 10 21 14 45 
W 
What is the best way to monitor disease progress (e.g. regular check-up) once 
diagnosed with endometriosis? 
18 18 9 45 
S 
What are the reasons for lack of access to treatment for endometriosis (e.g. surgical, 
medical, non-medical, lack of specialists)? 
19 19 13 51 
AA 
What is the natural history of endometriosis (e.g. how, and how quickly, does it 
progress and spread)? 
16 16 20 52 
D How can endometriosis be prevented? 17 17 19 53 
C Does life style affect endometriosis (e.g. food, exercise, stress, alcohol) 21 13 22 56 
G 
How do we get endometriosis and its impact on employment and employability 
recognised by employers and those dealing with the unemployed? 













Are women with endometriosis at an increased risk of cancers, and if so which and 
how they can be prevented? 
14 14 30 58 
T 
What can be done to reduce the risk and/or development of adhesions following 
treatment for endometriosis (e.g. surgery)? 
22 22 16 60 
F 
How can we prevent endometriosis in women and/or young girls with a family 
history of the disease? 
23 23 18 64 
I 
In what circumstances should endometriosis be classified and/or recognised as a 
disability? 
24 24 23 71 
DD 
Why does endometriosis and/or symptoms recur after treatment, and how likely 
and/or quickly is it that endometriosis recurs after different treatments (medical 
treatment; surgical removal disease; hysterectomy)? 
25 25 24 74 
M Is there a link between endometriosis and/or other chronic medical conditions? 26 26 25 77 
BB Why do women with endometriosis have difficulty getting pregnant? 27 27 27 81 
CC Why do women with endometriosis suffer from fatigue? 28 28 26 82 
X 
What is the efficacy of dietary regimes and/or nutritional supplements (e.g. dairy, 
non-dairy, gluten-free, vitamin B6, fish oils, and black cohosh) in managing the 
symptoms of endometriosis? 
29 29 28 86 
H 
How does endometriosis affect mental wellbeing (e.g. low mood, depression, lack 
of energy, stress, anxiety)? 
30 30 29 89 
*Sorted lowest to highest 
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A.6. Examples of weights and sources of summary questions 
Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
Symptoms        
1.  Why does endometriosis cause pain?  109 76 (6HCP) 2 1 27 2 1 
2.  
Why do women with endometriosis have 
difficulty getting pregnant? 
90 73 (4HCP) 3 1 12 1 0 
3.  
Why is endometriosis and endometriosis 
associated pain and/ or symptoms not related to 
the severity of the disease? 
60 23 (1HCP) 3 0 33 0 1 
4.  
Why do the symptoms of endometriosis affect 
different women in different ways? 
47 32 3 0 11 0 1 
5.  
Why does endometriosis affect the bowel, and 
what are the symptoms of bowel endometriosis? 
40 32 4 1 3 0 0 
6.  
How does endometriosis impact on a woman’s 
QOL (e.g. education, work, relationship)? 
33 22 3 0 6 2 0 
7.  
Why do women with endometriosis suffer from 
fatigue? 
17 17 (2HCP) 0 0 0 0 0 
8.  Why does endometriosis cause painful sex? 16 15 0 0 1 0 0 
9.  
Does endometriosis cause damage to nerves 
and/or neuropathy and/or visceral hyperalgesia? 
8 6 0 0 2 0 0 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
10.  
Do symptoms of endometriosis correlate with 
location of adhesions? 
2 0 0 0 2 0 0 
11.  Does endometriosis cause food intolerance? 2 2 0 0 0 0 0 
12.  
What are the signs and symptoms of 
endometriosis? 
ESHRE *       
13.  
Is endometriosis linked to dysmenorrhea in 




      
14.  
What is the function of nerve fibres in eutopic 




      
Natural History        
15.  
What is the typical natural history of 
endometriosis and how does it progress (e.g. 
spread, age-dependence, stage, severity, 
location)? 
71 49 2 0 20 0 0 
16.  
Does advancing age and/or the menopause have 
an impact on the severity or experience of 
endometriosis? 
27 22 2 0 2 0 1 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
17.  
What is the earliest age at which endometriosis 
may be detected or become symptomatic and is 
it a different disorder in children and/or 
adolescents? 
11 9 0 0 2 0 0 
18.  
What impact does pregnancy and/or having a 
baby have on endometriosis (e.g. symptoms, 
recurrence)? 
9 8 0 0 1 0 0 
19.  
Why does endometriosis come back in some 
women but naturally resolve in others? 
8 4 1 0 3 0 0 
20.  
If left untreated can endometriosis result in life-
threatening conditions? 
8 5 3 0 0 0 0 
21.  
Does endometriosis behave like cancer and if 
so, why isn’t not treated as such? 
3 2 0 0 1 0 0 
22.  Does endometriosis affect the quality of eggs? 2 2 0 0 0 0 0 
Prevention        
23.  How can endometriosis be prevented? 139 89 16 1 32 0 1 
24.  
What can be done to prevent endometriosis 
from recurring (e.g. after treatment)? 
33 23 2 1 6 0 1 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
25.  
How can we prevent endometriosis in women 
and/or young girls with a family history of the 
disease? 
11 8 2 0 1 0 0 
Awareness        
26.  
How can doctors and nurses receive education 
to lead to more effective diagnosis, treatment 
and care of women with endometriosis? 
259 235 16 3 4 0 1 
27.  
How do we get endometriosis recognised by 
wider society (e.g. government, health 
authorities) as a serious condition?  
82 76 5 0 1 0 0 
28.  
What can be done to deliver specialist care to 
women with endometriosis (confirmed or 
suspected)? 
67 58 2 2 5 0 0 
29.  
How can research into endometriosis, its 
prevention and/or treatment improved (e.g. 
funding, engagement with pharma)? 
31 30 0 1 0 0 0 
30.  
How can endometriosis-related pain be 
measured and recognised by medical 
professionals (including in A&E)? 
25 22 3 0 0 0 0 
31.  
How can we raise awareness of endometriosis 
(without causing anxiety in girls and women)? 
21 18 1 1 1 0 0 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
32.  
Why is endometriosis not classified and/or 
recognised as a disability? 
20 18 0 0 2 0 0 
33.  
How do we develop factual information to 
enable women with endometriosis to be more 
informed about the disease so they are able to 
make informed decisions about treatment(s)? 
16 15 1 0 0 0 0 
34.  
How do we get endometriosis and its impact on 
employment and employability recognised by 
employers and those dealing with the 
unemployed? 
11 9 1 0 0 1 0 
35.  
What support services (e.g. support groups, 
psychological support, helpline, and social 
media groups) are available to help women and 
their partners manage their endometriosis to 
help them maintain a reasonable QOL? 
11 7 1 1 2 0 0 
36.  
How do we remove the stigma and taboos 
around endometriosis and discussion of its 
symptoms? 
6 5 (4HCP) 0 1 0 0 0 
37.  
What help and support is available to women 
who are disabled due the effects of 
endometriosis (e.g. employment, benefits, 
parking badges)? 
3 1 0 0 2 0 0 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
Treatment Options        
38.  
What are the most effective treatments for all 
types of endometriosis (e.g. surgical, medical or 
non-medical treatments)? 
261 173(9HCP) 19 6 61 1 1 
39.  
What are the most effective ways of managing 
endometriosis-related pain and/or symptoms? 
139 103(7HCP) 5 3 24 0 4 
40.  
What is the efficacy of dietary regimes and/or 
nutritional supplements (e.g. dairy, non-dairy, 
gluten-free, vitamin B6, fish oils, and black 
cohosh) in managing the symptoms of 
endometriosis? 
123 106(4HCP) 11 1 3 0 2 
41.  
What are the outcomes and/or success rate of 
surgery (excision vs. ablation) for 
endometriosis, and does a particular type of 
surgery provide more benefits for certain 
patient groups? 
94 64 5 1 21 0 3 
42.  
What is the efficacy of non-medical therapies in 
managing symptoms of endometriosis (e.g. 
CBT, acupuncture, physiotherapy, reflexology 
and ACT)? 
63 42 2 0 18 0 1 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
43.  
What is the efficacy of non-dietary lifestyle 
changes and self-management strategies, (e.g. 
exercise, in managing the symptoms of 
endometriosis)? 
57 43 (3HCP) 2 0 10 2 0 
44.  
What are the benefits of different hormonal 
treatments (e.g. Mirena IUS, contraceptive pill) 
in managing symptoms of endometriosis? 
55 45 1 0 7 0 2 
45.  
What are the most effective ways of 
maximising and/or maintaining fertility in 
women with confirmed or suspected 
endometriosis)? 
51 39 (7HCP) 2 0 9 0 1 
46.  
What is the most effective way of stopping 
endometriosis progressing and/or spreading to 
other organs (e.g. after surgery)? 
44 34 (2HCP) 2 0 8 0 0 
47.  
What new treatments are being researched, 
which aim to reduce the development of 
endometriosis and/or its symptoms? 
43 30 (6HCP) 0 0 10 1 2 
48.  
What are the reasons for lack of access to 
treatment for endometriosis (e.g. surgical, 
medical, non-medical, lack of specialists)? 
40 31 1 1 7 0 0 
49.  What should the role of primary, secondary and 
tertiary health professionals be in endometriosis 
36 22 (3HCP) 3 0 11 0 0 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
care?  
50.  
What are the outcomes and/or success rate for 
surgical or medical treatments which aim to 
cure endometriosis, rather than manage it? 
35 30 (1HCP) 0 0 5 0 0 
51.  
What are the outcomes and/or success rate of a 
hysterectomy and is it more effective for certain 
patient groups? 
27 23 1 1 2 0 0 
52.  
How can women most effectively and safely 
manage their endometriosis symptoms if they 
would like to become pregnant? 
24 20 0 1 3 0 0 
53.  
How are endometriosis-related digestive and 
bowel-related symptoms best managed 
(including surgical, medical and non-medical 
treatments)? 
10 10 0 0 0 0 0 
54.  
What are the most effective ways of managing 
symptoms of suspected endometriosis? 
9 4 1 0 4 0 0 
55.  
How is fatigue due to endometriosis best 
managed (including both medical and non-
medical treatments)? 
9 9 0 0 0 0 0 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
56.  
What are the benefits of HRT after surgical 
and/or natural menopause in women with 
endometriosis? 
8 3 1 0 2 0 2 
57.  
What is the most effective way of managing the 
emotional and /or psychological impact of 
living with endometriosis (including medical, 
non-medical and self-management methods)? 
8 7 0 0 1 0 0 
58.  
Is surgery necessary to treat severe 
endometriosis and if so, what is the outcome for 
women with deep infiltrating endometriosis 
and/or recto-vaginal endometriosis who do or 
don’t undergo surgery? 
3 0 0 0 3 0 0 
59.  
The human microbiome project has found we 
are a living biosphere. Could treatment identify 
infection? 
2 1 0 0 0 0 1 
60.  
What are the options for women with 
endometriosis who have not responded to 
medical and/or surgical treatments? 
2 2 0 0 0 0 0 
61.  
How are endometriosis-related urinary 
symptoms best managed (including surgical, 
medical and non-medical treatments)? 
1 1 0 0 0 0 0 
62.  What is the effectiveness of psychological 1 0 0 0 1 0 0 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
intervention to manage the mental imagery 
associated with endometriosis with the aim of 
reducing the distress potentially associated with 
these images? 
63.  
Do any treatments for endometriosis have 
higher risk of causing infertility?  
1 1 0 0 0 0 0 
64.  
If stem cells do play a role in endometriosis 
development, can they also be used to help 
derive effective treatment in the long term? 
1 1 0 0 0 0 0 
65.  
Does bowel resection have better results than 
“shave” operation for deep infiltrating 
endometriosis? 
1 0 0 0 1 0 0 
66.  
Why do women with endometriosis still 
experience pain despite treatment (e.g. surgical, 
medical)?  
1 1 0 0 0 0 0 
67.  
What is the best management, with respect to 
reproductive outcome after ART, of ovarian 
endometriotic cysts of 3 cm or more in women 
with an indication for treatment with ART? 
ESHRE * 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
68.  
What is the benefit of using anti-adhesion 
agents in surgery for endometriosis-associated 
pain? 
ESHRE *       
69.  
How endometriosis in adolescents is best 
managed in a clinical setting? 
ESHRE *       
70.  
What is effectiveness and safety of anti-




      
71.  
Can manipulation of the apoptotic pathway be 




      
72.  
What is the role of miRNAs in (eg biomarkers 
and therapeutic tools) in endometriosis? 
WES and 
WERF● 
      
Co-morbidities        
73.  
Is there a link between endometriosis and auto-
immune diseases and endometriosis and or 
inflammatory disorders (e.g. MS, Lupus, RA, 
osteoarthritis, asthma, eczema and thyroid) and 
if so why? 
73 58 (1HCP) 14 0 1 0 0 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
74.  
Is there a link between endometriosis and/or 
other chronic conditions (e.g. chronic fatigue 
syndrome, headaches, migraine, neurological 
conditions other painful conditions and 
hormonal related conditions and fibromyalgia)? 
48 41 (3HCP) 4 0 3 0 0 
75.  
How does endometriosis affect mental 
wellbeing (e.g. low mood, depression, lack of 
energy, stress, anxiety)? 
25 18 1 0 5 1 0 
76.  
Are women with endometriosis at an increased 
risk of cancers, and if so which and how they 
can be prevented? 
25 14 (1HCP) 5 0 6 0 0 
77.  
Is endometriosis linked to any other diseases 
and/or conditions (e.g. adenomyosis, fibroid, 
connective tissue disorders, Lyme disease, 
ovarian cysts and sarcoidosis)?  
24 21 (1HCP) 0 0 3 0 0 
78.  
Is endometriosis associated with miscarriages 
and/or pregnancy loss (any trimester) and/or 
ectopic pregnancy and/or infertility, and if so, 
what are the underlying causes? 
17 16 (1HCP) 0 0 1 0 0 
79.  
How is endometriosis linked to urinary 
symptoms and function (e.g. Fowler’s 
syndrome, kidney stones)? 
17 14 1 0 2 0 0 
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Number Summary Questions Weight Pt/pt rep 
Past 
history 
Undiagnosed HCPs Research Guidelines 
80.  
Is endometriosis linked to any infections (e.g. 
candidiasis, bacterial vaginosis and other 
bacterial infections)?  
9 8 (1HCP) 0 0 1 0 0 
81.  
What is the connection between bowel 
endometriosis and non-coeliac gluten sensitivity 
and/or coeliac disease and/or diary intolerance 
and/or inflammation? 
6 6 0 0 0 0 0 
82.  
Is endometriosis linked to dizziness and/or 
vertigo and/or sinus inflammation?  
4 4 0 0 0 0 0 
83.  
How does endometriosis affect cognition (e.g. 
memory, concentration, confusion)? 
3 2 0 0 0 1 0 
84.  
Can miscarriages and/or termination of 
pregnancy cause endometriosis? 
2 0 0 0 2 0 0 
85.  
What is the connection between bowel 
endometriosis and/or tap water and/or bottled 
water? 
2 2 0 0 0 0 0 
86.  
Is there a link between endometriosis and heart-
related conditions (e.g. arrhythmia)?  
2 2 0 0 0 0 0 
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87.  
Is there a connection between low level of 
vitamin D and endometriosis?  
2 2 0 0 0 0 0 
88.  
Is there a link between endometriosis and gum 
swelling and/or toothache? 
2 2 0 0 0 0 0 
Treatment Outcomes        
89.  How can endometriosis be cured? 245 
220 
(2HCP) 
7 6 12 0 0 
90.  
How does endometriosis and its treatment 
(medical or surgical) affect women with 
endometriosis in the long term (e.g. 
psychological wellbeing)?  
40 31 (3HCP) 4 0 5 0 0 
91.  
How likely and/or quickly is it that 
endometriosis recurs after different treatments 
(medical treatment; surgical removal disease; 
hysterectomy)? 
37 30 (2HCP) 7 0 0 0 0 
92.  
Why does endometriosis and/or symptoms recur 
after treatment? 
29 26 0 0 2 1 0 
93.  
How can side-effects of medical treatments of 
endometriosis be improved? 
27 24 0 0 3 0 0 
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94.  
What support and/or care should be given to 
women with endometriosis and their supporters 
during and after treatment (both successful and 
unsuccessful) by different practitioners (e.g. 
GP, nurses, and specialists)? 
23 21 (1HCP) 1 0 1 0 0 
95.  
Does a hysterectomy cure (symptoms of) 
endometriosis, and how do factors around 
hysterectomy affect outcomes? (e.g. age at 
hysterectomy ; surgical approach and/or 
techniques; removal of ovaries) 
19 17 0 0 2 0 0 
96.  
What is the effect of a pituitary and/or ovarian 
downregulation before or after surgery (e.g. 
disease detection; ease of resection; blood loss; 
improvement in symptoms and QOL)? 
12 2 0 0 10 0 0 
97.  
What can be done to reduce the risk and/or 
development of adhesions following treatment 
for endometriosis (e.g. surgery)?  
10 3 3 0 3 0 1 
98.  
Why do some patients respond better than 
others to treatments of endometriosis (e.g. 
hormone, surgery)? 
10 6 (1HCP) 1 0 3 0 0 
99.  How can outcomes (e.g. pain, fertility, 9 3 0 0 6 0 0 
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conception rate, QOL) of different 
endometriosis treatments be improved and 
women made aware of their relative efficacy? 
100.  
What measures can be taken to improve QOL 
and/or pain and help endometriosis in the long-
term? 
9 7 0 0 2 0 0 
101.  
Do the side-effects of GnRHs and/or 
downregulation hormones for the treatment of 
endometriosis outweigh the benefits? 
8 7 0 0 1 0 0 
102.  
Why is pain relief medication for 
endometriosis-related pain and/or related 
symptoms often not effective (e.g. over the 
counter or prescription)? 
6 5 0 0 1 0 0 
103.  
What is the best way to monitor disease 
progress (e.g. regular check-up) once diagnosed 
with endometriosis? 
4 3 (1HCP) 0 0 0 0 1 
104.  
What are long-term solutions for treatment of 
endometriosis in women who do not want a 
hysterectomy? 
3 2 0 0 1 0 0 
105.  
How can long-term endometriosis-related pain 
and/or its symptoms best be treated? 
3 1 0 0 2 0 0 
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106.  
What are long-term solutions for treatment of 
endometriosis in women who wish to have 
children? 
3 3 (1HCP) 0 0 0 0 0 
107.  
Why do medical practitioners suggest that 
women with endometriosis have a baby as a 
cure? 
3 3 0 0 0 0 0 
108.  
Why do medical practitioners suggest that 
women with endometriosis have a hysterectomy 
as a cure? 
3 3 0 0 0 0 0 
109.  
Can hormonal treatments for endometriosis 
impact negatively on fertility? 
2 2 0 0 0 0 0 
110.  
Do early referrals to secondary and/or tertiary 
services and/or pain management services 
improve outcomes for women with 
endometriosis? 
2 1 0 0 1 0 0 
111.  
Is there evidence that laparoscopic cystectomy 
for an endometrioma(s) is superior to open 
surgery in terms of competence of disease 
removal and/or post-operative scaring?  
2 0 0 0 1 0 1 
112.  
Can we predict the cohort of women whose 
symptoms will not improve after excision of 
endometriosis? 
1 0 0 0 1 0 0 
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Causes        
113.  What causes endometriosis?  601 
458 
(15HCP &  
1 empl) 
32 3 107 1 0 
114.  Is endometriosis hereditary and/or genetic? 145 
121 
 (3HCP & 
1 empl) 
8 0 16 0 0 
115.  
Does life style affect endometriosis (e.g. food, 




1 0 3 0 0 
116.  
What is the link between menstruation and 
endometriosis (e.g. heavy bleeding)? 
21 20 1 0 0 0 0 
117.  
What factors exacerbate the development of 
and/or the symptoms of endometriosis? 
8 6 0 1 1 0 0 
118.  Is endometriosis present in foetal tissue? 8 7 0 0 1 0 0 
119.  
What factors put women and/or girls at risk of 
developing endometriosis (e.g. environmental, 
IVF, hormones, kidney removal, acne, 
microchimerism, viral and other diseases)? 
6 4 1 0 0 0 1 
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120.  
Is endometriosis a single disease or are there 
different disease subtypes which represent 
different, but related, pathological entities? 
4 2 0 0 2 0 0 
121.  What is the prevalence of endometriosis? 2 0 0 0 2 0 0 
122.  
Why does the immune system not eradicate the 
endometriosis? 
1 0 1 0 0 0 0 
123.  
What is the role of endogenous and exogenous 
anti-inflammatory mediators in the 




      
124.  
What is the role of macrophages in 
endometriosis, and in particular does increased 
macrophage activation and reduced 




      
125.  
What is role of oxidative stress in the 
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126.  
What is contribution of endometrial and 
endometriotic lesion lymphangiogenesis to the 
development of endometriosis? 
WES and 
WERF● 
      
127.  
Is there a role for neuroangiogenesis in 
development of endometriosis? 
WES and 
WERF● 
      
128.  
What is the role of endometrial stem cell 
biology, in initiating endometriosis, and does 




      
129.  
What is the role of eutopic endometrium in the 




      
130.  
What is the biology and function of 




      
131.  
What are the mechanisms that underlie fibrosis 
and adhesion formation in the peritoneal cavity 
of women with endometriosis? 
WES and 
WERF● 
      
Diagnosis        
132.  Why does it take so long to diagnose 230 193 (5HCP 20 6 11 0 0 
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endometriosis? & 1 empl) 
133.  
Is it possible to develop a non-invasive 
screening tool to aid diagnosis of 
endometriosis? 
80 50 (5HCP) 4 1 22 1 2 
134.  
How can the diagnosis of endometriosis be 
improved? 
74 47 (1empl) 6 3 18 0 0 
135.  
How can we avoid requiring surgery to make a 
diagnosis of endometriosis? 
30 17 (2HCP) 3 2 7 1 0 
136.  
Can endometriosis be diagnosed during 
adolescence to prevent further damage in the 
future? 
15 8 4 0 3 0 0 
137.  How is endometriosis diagnosed? 14 8 (2HCP) 0 0 5 0 1 
138.  Is there a genetic test for endometriosis? 13 10 1 0 2 0 0 
139.  
Are there any ways to predict which women are 
at risk of endometriosis to intervene early 
before the disease advanced? 
4 2 0 0 2 0 0 
140.  
Can endometriosis be diagnosed during and 
after menopause? 
2 2 0 0 0 0 0 
141.  If there is a link between endometriosis and 
other health conditions, can one diagnostic tool 
1 1 0 0 0 0 0 
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be developed? 
Definitions of A7 abbreviations:- 
* ESHRE: - European Society of Human Reproduction and Embryology guideline 2014. 
● WES and WERF: - World Endometriosis Society (WES) and World Endometriosis Research Foundation (WERF) consensus workshop 15 
March 2008. 
Pt/Pt rep  patient with endometriosis / patient representative    HCPs  healthcare professionals    Emp employer 
Past ht  past history of endometriosis                                    Undiag Waiting diagnosis 




A.7. Interim prioritisation refined questions  
No Refined Questions 
1.  Can a cure be developed for endometriosis? 
2.  How can the diagnosis of endometriosis be improved? 
3.  What causes endometriosis? 
4.  
What is the most effective way of stopping endometriosis progressing 
and/or spreading to other organs (e.g. after surgery)? 
5.  
What are the most effective ways of educating HCP throughout the 
healthcare system resulting in reduced time to diagnosis and improved 
treatment and care of women with endometriosis? 
6.  
What can be done to stop endometriosis from recurring (e.g. after 
treatment)? 
7.  
Is there a link between endometriosis and auto-immune diseases, and 
endometriosis and/ or inflammatory disorders (e.g. MS, Lupus, RA, 
osteoarthritis, asthma, eczema and thyroid) and if so why? 
8.  
What is the most effective way of managing the emotional and /or 
psychological and/or fatigue impact of living with endometriosis 
(including medical, non-medical and self-management methods)? 
9.  
Is it possible to develop a non-invasive screening tool to aid diagnosis of 
endometriosis? 
10.  
What is the best way to monitor disease progress (e.g. regular check-up) 
once diagnosed with endometriosis? 
11.  
In what circumstances should endometriosis be classified and/or 
recognised as a disability? 
12.  
How can we prevent endometriosis in women and/or young girls with a 
family history of the disease? 
13.  
Are women with endometriosis at an increased risk of cancers, and if so 
which and how they can be prevented? 
14.  
What are the most effective non-surgical ways of managing 
endometriosis-related pain and/or symptoms (medical/non-medical)? 
15.  Is endometriosis hereditary and/or genetic? 
16.  
How does endometriosis affect mental wellbeing (e.g. low mood, 
depression, lack of energy, stress, anxiety)? 
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17.  
What can be done to reduce the risk and/or development of adhesions 
following treatment for endometriosis (e.g. surgery)? 
18.  
What are the most effective ways of maximising and/or maintaining 
fertility in women with confirmed or suspected endometriosis? 
19.  
Is there a link between endometriosis and/or other chronic medical 
conditions? 
20.  
What is the natural history of endometriosis (e.g. how, and how quickly, 
does it progress and spread)? 
21.  How can endometriosis be prevented? 
22.  
How do we get endometriosis and its impact on employment and 
employability recognised by employers and those dealing with the 
unemployed? 
23.  
What are the outcomes and/or success rates for surgical or medical 
treatments which aim to cure treat endometriosis, rather than manage it? 
24.  
Why does endometriosis and/or symptoms recur after treatment, and how 
likely and/or quickly is it that endometriosis recurs after different 
treatments (medical treatment; surgical removal disease; hysterectomy)? 
25.  
What is the efficacy of dietary regimes and/or nutritional supplements 
(e.g. dairy, non-dairy, gluten-free, vitamin B6, fish oils, and black cohosh) 
in managing the symptoms of endometriosis? 
26.  Why do women with endometriosis suffer from fatigue? 
27.  
What are the reasons for lack of access to treatment for endometriosis 
(e.g. surgical, medical, non-medical, lack of specialists)? 
28.  
What are the benefits of different hormonal treatments (e.g. Mirena IUS, 
contraceptive pill, GnRHa and progestogens) in managing the symptoms 
of endometriosis? 
29.  Why do women with endometriosis have difficulty getting pregnant? 
30.  Does life style affect endometriosis (e.g. food, exercise, stress, alcohol)? 
31.  
What are the most effective care and support pathways that can be offered 
to enable women with endometriosis and their support network to have a 
clear understanding of treatments and management provided by healthcare 
providers? 
32.  
Is endometriosis a single disease or are there different disease subtypes 
which represent different, but related, pathological entities? 
288 
 
No Refined Questions 
33.  
How can women most effectively and safely manage their endometriosis 
symptoms if they would like to become pregnant? 
34.  
Are there any ways to predict which women are at risk of endometriosis to 
intervene early before the disease advanced? 
35.  
What is the efficacy of non-medical therapies in managing symptoms of 
endometriosis e.g. CBT, acupuncture, physiotherapy, reflexology and 
Acceptance and Commitment Therapy? 
36.  
Why is pain relief medication for endometriosis-related pain and/or 
related symptoms often not effective (e.g. over the counter or 
prescription)? 
37.  Why does endometriosis cause pain? 
38.  
How does endometriosis and its treatment (medical or surgical) affect 
women with endometriosis in the long term? 
39.  
Does a hysterectomy cure (symptoms of) endometriosis, and how do 
factors around hysterectomy affect outcomes? (e.g. age at hysterectomy; 
surgical approach and/or techniques; removal of ovaries)? 
40.  
How does endometriosis impact on a woman’s QOL (e.g. education, 
work, relationships)? 
41.  
What are the outcomes and/or success rate of surgery (excision vs. 
ablation) for endometriosis, and does a particular type of surgery provide 
more benefits for certain patient groups? 
42.  
If there is a link between endometriosis and other health conditions, can 
one diagnostic tool be developed? 
43.  
Is surgery necessary to treat severe endometriosis and if so, what is the 
outcome for women with deep infiltrating endometriosis and/or recto-
vaginal endometriosis who do or do not undergo surgery? 
44.  
Is endometriosis associated with miscarriages and/or ectopic pregnancy, 
and if so, what are the underlying causes? 
45.  
How are endometriosis-related digestive and bowel-related symptoms best 
managed (including surgical, medical and non-medical treatments)? 
46.  
Do early referrals to secondary and/or tertiary services and/or pain 
management services improve outcomes for women with endometriosis? 
47.  How endometriosis in adolescents is best managed in a clinical setting? 
48.  
What is the earliest age at which endometriosis can be detected or and is it 
a different disorder in young people than in adults? 
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49.  Is there a genetic test for endometriosis? 
50.  
Does having endometriosis also alter fertility by having an impact on egg 
quality? 
51.  
What information is the most effective in informing women and girls with 
endometriosis about the disease so they are enabled to make informed 
decisions about treatment(s) without causing anxiety in girls and women? 
52.  
What are the benefits of HRT after surgical and/or natural menopause in 
women with endometriosis? 
53.  Why does endometriosis cause painful sex? 
54.  
Why do the symptoms of endometriosis affect different women in 
different ways? 
55.  
What impact does pregnancy have on endometriosis (e.g. symptoms, 
recurrence)? 
56.  
Is there a link between endometriosis and infections (e.g. candidiasis, 
bacterial vaginosis) and if so, could treatment identify infection? 
57.  Why does endometriosis affect the bowel? 
58.  
What are the outcomes and/or success rates of a hysterectomy and is it 
more effective for certain patient groups? 
59.  
Can we predict the cohort of women whose symptoms will not improve 
after excision of endometriosis? 
60.  
Do any treatments for endometriosis have higher risk of causing 
infertility? 
61.  
Does bowel resection have better results than “shave” operation for deep 
infiltrating endometriosis? 
62.  
Why do medical practitioners suggest that women with endometriosis 
have a baby as a cure? 
63.  What are the symptoms of bowel endometriosis? 
64.  Is there a link between endometriosis and food intolerance? 
65.  
What is the efficacy of non-dietary lifestyle changes and self-management 
strategies, (e.g. exercise, in managing the symptoms of endometriosis)? 
66.  
What is the most efficient method of establishing the outcomes of 
treatments offered and how would women access this information to 
enable informed decision making? 
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67.  When does endometriosis start? 
68.  
What is the link between menstruation and endometriosis (e.g. heavy 
bleeding)? 
69.  
Does the menopause have an impact on the severity or experience of 
endometriosis? 
70.  
What is the effect of downregulation treatments (e.g. GnRH agonists) 
before or after surgery (e.g. disease detection; ease of resection; blood 
loss; improvement in symptoms and QOL)? 
71.  How can side-effects of medical treatments of endometriosis be avoided? 




A.8. Final workshop participants roles 
HCPs 
Clinical psychologist with a special interest in endometriosis and pelvic pain 
Clinical psychologist  
Specialist nurse  
4 obstetrics and gynaecology consultants 
Anaesthesia and pain medicine consultant 
Practice nurse with interest in women’s health 
GP and woman with endometriosis 
GP with special interest  
Patient Representatives 
Woman with endometriosis, commissioner, NICE, EUK 
2 Patient representative (husbands) 
2 Woman with endometriosis, EUK support group leader 
5 Woman with endometriosis 
Woman with endometriosis, ex EUK support group leader, EUK volunteer advocate 
Woman with endometriosis, EUK volunteer advocate 
Woman with endometriosis, EUK helpline volunteer 
Woman with endometriosis, EUK support group leader and advocate 
Observers 
Clinical fellow, JLA data analyst, PSP coordinator and JLA SG. 
Researcher and JLA SG 
PSP lead 
EUK and JLA SG 
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Endometriosis (womb lining outside the womb) affects 6-10% of women and is 
associated with debilitating chronic pelvic pain.  It costs the UK > £2.8 billion per 
year in loss of productivity. Endometriosis is managed surgically or medically.  
However, ~75% symptoms recur after surgery and available medical treatments 
(‘anti-hormones’) have undesirable side effects and are contraceptive. Omega-3 
purified fatty acids (PUFA) have been shown in animal models to reduce factors that 
are thought to lead to endometriosis-associated pain, have minimal side effects and 
no effects on fertility. We plan to perform a feasibility study to inform planning of a 
future multicentre trial to evaluate the efficacy of PUFA in the management of 
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Endometriosis is a common, chronic inflammatory disease, affecting 6-10% of 
women of reproductive age
1
.  Endometriosis is defined by endometrial tissue 
implanted in ectopic sites, usually within the peritoneal cavity.  It is associated with 
chronic pelvic pain, pain during menstruation, pain during intercourse and an 
increased likelihood of infertility
2
. Endometriosis is managed surgically or 
medically.  However, ~75% symptoms recur after surgery and available medical 
treatments (‘anti-hormones’) can cause menopause-like symptoms and are 
contraceptive
3
.  There exists an unmet clinical need for better treatments for 
endometriosis with few or minimal side effects and that have no effect on fertility.  
B.4.1.2. RATIONALE FOR STUDY 
We are exploring a new treatment strategy involving highly purified Omega-3 fatty 
acids (PUFA). 
PUFA are a dietary supplement and have been shown in in-vitro laboratory and 
animal models to reduce factors that lead to endometriosis-associated pain.   In an in-
vitro laboratory study, it has been demonstrated that specific PUFA ratios have a 
suppressive effect on the survival of endometrial cells
4.  
 In a study using a rat model 
of endometriosis, specific PUFA ratios have been shown to reduce the inflammation 
associated with endometriotic lesions and suppress progression of the disease
5
.  
To determine whether PUFA will reduce endometriosis-associated pain requires a 
large multicentre RCT.  We propose a two centre feasibility study to inform the 
planning of this future RCT.  
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B.4.2. STUDY OBJECTIVES 
B.4.2.1. OBJECTIVES 
B.4.2.1.1. Primary Objective 
To determine whether it is possible to achieve acceptable recruitment and retention 
rates within defined inclusion/exclusion criteria.  
B.4.2.1.2. Secondary Objectives 
To determine the acceptability to patients of the proposed methods of recruitment, 
randomisation and treatments. 
B.4.2.2. ENDPOINTS 
B.4.2.2.1. Primary Endpoint 
a. The proportion of screened women who are eligible for the trial. 
b. The proportion of eligible patients randomised into the study.  
c. The proportion of randomised patients who take the supplement and complete 
questionnaires at final follow up.  
B.4.2.2.2. Secondary Endpoints 
The remaining data (effectiveness and acceptability of proposed methods of 
recruitment, randomisation, treatments and questionnaires to study the effect of 
PUFA in the management of endometriosis-associated pelvic pain) will be used to 
refine the research methodology of a future large RCT. STUDY DESIGN 
A two-arm parallel randomised controlled pilot feasibility study. 
We will aim to recruit as many participants as possible within 12 months with the 
goal of reaching at least 60 (max 80) between two centres in Edinburgh and Oxford.  
Eligibility will be determined after monitoring pain scores over a 4 week period. If 
eligible, participants will be randomised to PUFA or comparator, and receive 
treatment for 8 weeks.  Pain scores will be monitored over the last 4 weeks, score of 
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4 on at least 2 occasions is required.  Unblinding will take place at the end of the 
study when all participants have completed the treatment phase. 
B.4.4. STUDY POPULATION 
B.4.4.1. NUMBER OF PARTICIPANTS 
Women (aged 18-50) with a known diagnosis of endometriosis and associated pelvic 
pain of at least 3 months duration will be recruited from gynaecology outpatient 
departments in NHS Lothian and NHS Oxford Trust.  We will recruit as many 
women as possible within a 12 month period. 
B.4.4.2. INCLUSION CRITERIA 
Aged 18-50 years 
Known endometriosis diagnosed from previous laparoscopy  
Pain of at least 3 months duration located in the true pelvis 
Worst pain score ≥ 4 over 4 weeks as measured by Numerical Rating Score (NRS) 
Ability to provide informed consent 
B.4.4.3. EXCLUSION CRITERIA 
Unable to take/allergic to fish / PUFA / peanuts / soyabean 
Insulin dependent diabetes 
Pregnant 
Taking contraindicated medications (anticoagulants) 
Breastfeeding 
B.4.4.4. CO-ENROLMENT 
Other studies eg Pre-empt look at treatment of endometriosis using routine clinical 
methods.  Participant can take part in both studies as there is no cross-over of 




B.4.5. PARTICIPANT SELECTION AND ENROLMENT 
B.4.5.1. IDENTIFYING PARTICIPANTS 
Women will be identified by their clinician and asked if they will talk to the clinical 
research fellow.  Recruitment may be in a clinic environment and patients will only 
be approached once permission has been given by the participant to their direct 
clinical care team. 
B.4.5.2. CONSENTING PARTICIPANTS 
If they agree, they will then be given a patient information leaflet and will be asked if 
they are happy to be contacted to get their decision on whether they wish to 
participate.  The patient will be given the option of the research team contacting them 
or will be given the team’s number to contact if interested in participating. This will 
give them the minimum of an hour to read the patient information sheet, ask any 
questions and make an informed choice about whether to participate or not. This 
might be after a clinic appointment so patients may be asked to go away and consider 
the information and come back on another day.   Participants will be consented by a 
member of the clinical research team.  Consent will only be taken by GCP trained 
members of staff who are on the delegation log. 
B.4.5.3. SCREENING FOR ELIGIBILITY 
If participants express an interest in the study they will be assessed to determine 
whether they fulfil all the potential eligibility criteria.  Eligibility for treatment will 
be based on the worst of the 4 weekly NRS.  A worst pain score (NRS) of greater 
than or equal to (≥) 4 is required for randomisation to treatment. 
B.4.5.4. INELIGIBLE AND NON-RECRUITED PARTICIPANTS 
The following information will be monitored and collected: 
 Demographic information (age, initials, date of clinic appointment) 





B.4.5.5.1. Randomisation Procedures 
Eligible women will be randomised to either PUFA or comparator. The 
randomisation scheme will be drawn up by an independent person who is not 
involved in the study and the allocated treatment codes will be put into sealed, 
consecutively numbered opaque envelopes.  When a patient is randomised into the 
study, she will receive the treatment indicated in the next available envelope.  These 
will be kept with the clinical research fellow in a secure office. 
B.4.5.5.2. Treatment Allocation 
After randomisation, participants will be allocated an oral treatment pack.  The 
participants will be allowed to use other medication (including analgesics) 
throughout the study period.  These concomitant medications will be recorded. 
The treatment allocated is a licensed supplement (Omacor).   
B.4.5.5.3. Emergency Unblinding Procedures 
The blinding code will only be broken in emergency situations for reasons of patient 
safety, where knowledge of the treatment administered is necessary for the treatment 
of a serious adverse event or when required by local regulatory authorities.  
Participants whose randomisation codes are broken will cease treatment, but will 
continue to be followed up.  The Investigator must document the reason for breaking 
the blind in the participant’s source documents and in the investigator site master 
File.  If participant requires to be unblinded in an emergency then the clinical 
research fellow or pharmacy should be contacted. 
B.4.5.5.4. Withdrawal of Study Participants 
Participants may discontinue from the trial at any time at their own request, or they 
may be withdrawn at the discretion of the investigator or sponsor for safety, 
behavioural or administrative reasons. Withdrawal may be from treatment or from 
the whole trial.  
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Withdrawal from treatment 
If a participant wishes to withdraw from treatment but is willing to complete follow-
up  she will be asked to  return for a final visit to complete questionnaires and any 
adverse events will be followed up to resolution. 
Withdrawal of consent 
If a participant wishes to withdraw consent the investigator will inquire about the 
reason for withdrawal and request that the subject return all unused supplements.  
With permission all data obtained up to point of withdrawal will be used.   
Loss to follow up 
If a participant does not return for a scheduled visit, every effort will be made to 




B.4.6. SUPPLEMENT AND COMPARATOR 
B.4.6.1. SUPPLEMENT 
B.4.6.1.1. SUPPLEMENT IDENTIFICATION 
Omacor 1000 mgs caps 
B.4.6.1.2. SUPPLEMENT MANUFACTURER 
ISG 
B.4.6.1.3. MARKETING AUTHORISATION HOLDER 
Pronova BioPharma Norge AS 




B.4.6.1.4. LABELLING AND PACKING 
Investigational Supplies Group (ISG) 
1 George Square, Edinburgh, EH8 9JZ 
B.4.6.1.5. STORAGE 
Below 25C 




Olive oil softgelatin capsules from EuroCaps 
B.4.6.3. DOSING REGIME 
Two capsules per day for 8 weeks. 
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B.4.6.4. DOSE CHANGES 
There will be no dose changes throughout the course of the study. 
B.4.6.5. PARTICIPANT COMPLIANCE 
Compliance will be measured via a treatment diary, text message at week 5-8.  
B.4.6.6. OVERDOSE 
There are no special recommendations. 
B.4.6.7. OTHER MEDICATIONS 
B.4.6.7.1. NON-INVESTIGATIONAL MEDICINAL PRODUCTS  
N/A 
B.4.6.7.2. PERMITTED MEDICATIONS 
No restrictions. 
B.4.6.7.3. PROHIBITED MEDICATIONS 
None.  Precautions should be taken when taken in conjunction with anti-
coagulants. 
B.4.7. STUDY ASSESSMENTS 
B.4.7.1. SAFETY ASSESSMENTS 
 Medical history 
 Pregnancy test 




B.4.7.2. STUDY ASSESSMENTS 
(-4 weeks):  Visit 1  
    Informed consent 
    Screening for eligibility, past medical history, BMI, 
Medication    use 
    Eligibility  
    Pain score (NRS) = average and worst score over 
previous                              week     
    Pain assessment 
Week -3   Pain score (NRS) 
Week -2   Pain score (NRS)  
Week-1   Pain score (NRS) 
 
Week 0 (Baseline) Visit 2 
    Eligibility confirmed 
    Randomisation and treatment allocation 
    Treatment diary 
    Questionnaires  
                                  Pregnancy test  
Week 0-8   Treatment phase 
    Pain assessment 
Week 5   Pain score (NRS) 
Week 6   Pain score (NRS)  
Week 7   Pain score (NRS)  
Week 8   Visit 3 
    Pain score (NRS) 
    Adverse events 
    Questionnaires    
    Collection of treatment diary 
    Collection of any unused study medications 
    




B.4.8. DATA COLLECTION 
Screening:  A clinical research fellow team will carry out a screening visit to assess 
eligibility.  All data will be recorded on a CRF and transferred to a secure database.   
Participant Log:  The clinical research fellow will keep an electronic log of women 
who fulfil the eligibility criteria, women who are invited to participate in the study, 
women recruited and women who leave the trial early.  Reasons for non-recruitment 
(eg non-eligibility, refusal to participate, administrative error) will also be recorded. 
We will attempt to collect reasons for non-participation from women who decline to 
take part after previously providing contact details.  We will ask, with permission the 
reason for not wanting to participate as this will give us useful information on the 
design of future studies. During the course of the study, we will document reasons 
for withdrawal from the study and loss to follow-up. 
Treatment diaries: details are documented in Section 6.5.  
Questionnaires:  A questionnaire will be given to all participants at randomisation 
and on trial completion (baseline and 8 weeks).  This will include questions to 
capture the baseline demographic and clinical characteristics of the participants and 
include the following validated tools:   
Numerical rating score (NRS)  
SF-12 quality of life (SF-12) 
Brief Pain Inventory (BPI) 
Pain catastrophising (PCQ) 
PainDETECT™ Questionnaire (PDQ) 
Sexual Activity Questionnaires (SAQ) 
Brief Fatigue Inventory (BFI) 
General Health Questionnaire -12 (GHQ-12)  
Work and Productivity Activity Impairment Questionnaire- Specific Health Problem 
version 2.0 (WPAI-SHP) 




We are collecting multiple questionnaires to assess which ones give us the best 
outcomes for a future randomised controlled study and which ones are completed 
fully.  The pain questionnaires all ask about different aspects of pain eg neuropathic 
so we would like to know how acceptable the completion is as there can be some 
repetition. 
B.4.9. STATISTICS AND DATA ANALYSIS 
B.4.9.1. SAMPLE SIZE CALCULATION 
The emphasis in this study is to establish feasibility, not statistical significance.  This 
study is designed primarily to explore the effectiveness of the proposed field 
methodology: recruitment, retention and compliance. We will aim to recruit as many 
women as possible over a 12 month period.  We estimate that we will recruit ~ 4-5 
patients per month and will aim to recruit 60 patients. Data from this pilot study will 
be used to refine sample size calculations for any future RCT. 
B.4.9.2. PROPOSED ANALYSES 
Primary objective 
Determine recruitment and retention rates.  Using the information collected from the 
participant log, we will determine the number of patients recruited from the pool of 
eligible women and more than 50% recruitment will be deemed acceptable. While a 
retention rate of 100% would be ideal, we will consider a rate of 80% satisfactory. 
We will provide an estimate of the proportion and its 95% confidence interval. In 
addition, we will determine the nature and number of unanswered questions in each 
questionnaire.  We aim to determine whether the trial design will perform well 
enough in the field to warrant rolling out the study to full trial. All analysis will be 
carried out in the University of Edinburgh. 
Secondary objectives 
Acceptability of proposed methods of recruitment, randomisation, treatments, and 
questionnaires to study the effect of PUFA in the management of endometriosis-
associated pelvic pain will be assessed quantitatively using acceptability 
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questionnaires at end of study. Due to the conflicting literature about the benefits of 
methods such as prescription monitoring, pill counting and devices for monitoring 
the self-administration of medicines, data on blinding and compliance to treatment 
will also be derived from these questionnaires. We also aim to determine if treatment 
is acceptable in terms of self-reported compliance (from treatment diaries). Although 
this is a pilot study and the sample size is small, we will assess the effect of any non-
compliance on the LICKERT score by performing protocol and intention-to-treat 
analyses. This information will be used to inform the design of the future RCT.   
B.4.10. ADVERSE EVENTS 
The Investigator is responsible for the detection and documentation of events 
meeting the criteria and definitions detailed below.   
Participants will be instructed to contact their investigator at any time after 
consenting to join the trial if any symptoms develop.  All adverse events (AE) that 
occur after joining the trial must be reported in detail in the CRF or AE form.  In the 
case of an AE, the investigator should initiate the appropriate treatment according to 
their medical judgment.  Participants with AEs present at the last visit must be 




An adverse event (AE) is any untoward medical occurrence in a clinical trial 
participant which does not necessarily have a causal relationship with a supplement. 
An adverse reaction (AR) is any untoward and unintended response to a supplement 
which is related to any dose administered to that participant.  
A serious adverse event (SAE), serious adverse reaction (SAR). Any AE or AR 
that at any dose: 
 Results in death of the clinical trial participant; 
 Is life threatening*; 
 Requires in-patient hospitalisation^ or prolongation of existing 
hospitalisation; 
 Results in persistent or significant disability or incapacity; 
 Consists of a congenital anomaly or birth defect; 
 Results in any other significant medical event not meeting the criteria above. 
*Life-threatening in the definition of an SAE or SAR refers to an event where the 
participant was at risk of death at the time of the event. It does not refer to an event 
which hypothetically might have caused death if it were more severe. 
^Any hospitalisation that was planned prior to randomisation will not meet SAE 
criteria. Any hospitalisation that is planned post randomisation will meet the SAE 
criteria. 
Hospitalisation for a pre-existing condition eg exacerbation of pain due to 
endometriosis will not be considered a SAE but will be documented. 
A suspected unexpected serious adverse reaction (SUSAR) is any AR that is 
classified as serious and is suspected to be caused by the IMP, that it is not consistent 
with the information about the IMP in the Summary of Product Characteristics 
(Omacor) or Investigators Brochure.  As this is a supplement and not an IMP this 
is not anticipated.  
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B.4.10.2. IDENTIFYING AEs AND SAEs 
All AEs and SAEs will be recorded from the time a participant signs the consent 
form to take part in the study until end of treatment. 
Participants will be asked about the occurrence of AEs/SAEs at every visit during the 
study.  Open-ended and non-leading verbal questioning of the participant will be 
used to enquire about AE/SAE occurrence.  Participants will also be asked if they 
have been admitted to hospital, had any accidents, used any new medicines or 
changed concomitant medication regimens.  If there is any doubt as to whether a 
clinical observation is an AE, the event will be recorded. 
Common ailments, e.g. coughs and colds, will not be recorded as AEs.   
AEs and SAEs may also be identified via information from support departments e.g. 
laboratories.  
B.4.10.3. RECORDING AEs AND SAEs 
When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (e.g. hospital notes, laboratory and diagnostic reports) related to the 
event.  The Investigator will then record all relevant information in the CRF and on 
the SAE form (if the AE meets the criteria of serious). 
Information to be collected includes dose, type of event, onset date, Investigator 
assessment of severity and causality, date of resolution as well as treatment required, 
investigations needed and outcome.   
B.4.10.4. ASSESSMENT OF AEs AND SAEs 
Seriousness, causality, severity and expectedness will be assessed by the Principal 
Investigator. For randomised studies, AEs will be assessed as though the participant 
is taking supplements.  Cases that are considered serious, possibly, probably or 
definitely related to the supplement and unexpected (i.e. SUSARs) will be unblinded.  
The investigator is responsible for assessing each AE.   
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The chief investigator (CI) may not downgrade an event that has been assessed by an 
investigator as an SAE or SUSAR, but can upgrade an AE to an SAE, SAR or 
SUSAR if appropriate. 
B.4.10.4.1. ASSESSMENT OF SERIOUSNESS 
The Investigator will make an assessment of seriousness as defined in Section 10.1. 
B.4.10.4.2. ASSESSMENT OF CAUSALITY 
The investigator will make an assessment of whether the AE/SAE is likely to be 
related to the IMP according to the definitions below.   
 Unrelated: where an event is not considered to be related to the supplement. 
 Possibly Related: The nature of the event, the underlying medical condition, 
concomitant medication or temporal relationship make it possible that the AE 
has a causal relationship to the study drug. The assessment of causality will 
be made against the reference safety information found in the  
Where non Investigational Medicinal Products (NIMPs) e.g. rescue/escape drugs are 
given:  if the AE is considered to be related to an interaction between the  
supplement and the NIMP, or where the AE might be linked to either the IMP or the 
NIMP but cannot be clearly attributed to either one of these, the event will be 
considered as an AR. Alternative causes such as natural history of the underlying 
disease, other risk factors and the temporal relationship of the event to the treatment 
should be considered and investigated. The blind should not be broken for the 
purpose of making this assessment.  
B.4.10.4.3. ASSESSMENT OF EXPECTEDNESS 
If an event is judged to be an AR, the evaluation of expectedness will be made based 
on knowledge of the reaction and the relevant product information documented  
B.4.10.4.4. ASSESSMENT OF SEVERITY 
The investigator will make an assessment of severity for each AE/SAE and record 
this on the CRF or SAE form according to one of the following categories: 
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Mild: an event that is easily tolerated by the participant, causing minimal discomfort 
and not interfering with every day activities. 
Moderate: an event that is sufficiently discomforting to interfere with normal 
everyday activities. 
Severe: an event that prevents normal everyday activities. 
Note: the term ‘severe’, used to describe the intensity, should not be confused with 
‘serious’ which is a regulatory definition based on participant/event outcome or 
action criteria.  For example, a headache may be severe but not serious, while a 
minor stroke is serious but may not be severe. 
B.4.10.5. REPORTING OF SAEs/SARs/SUSARs 
Once the investigator becomes aware that an SAE has occurred in a study 
participant, the information will be reported to the ACCORD Research Governance 
& QA Office immediately or within 24 hours. If the Investigator does not have all 
information regarding an SAE, they should not wait for this additional information 
before notifying ACCORD.  The SAE report form can be updated when the 
additional information is received. 
The SAE report will provide an assessment of causality and expectedness at the time 
of the initial report to ACCORD according to Sections 10.4.2, Assessment of 
Causality and 10.4.3, Assessment of Expectedness. 
The SAE form will be transmitted by fax to ACCORD on +44 (James Lind Alliance 
Endometriosis Top 10 Priorities)131 242 9447 or may be transmitted by hand to 
the office or submitted via email to Safety.Accord@ed.ac.uk. Only forms in a pdf 
format will be accepted by ACCORD via email. 
Where missing information has not been sent to ACCORD after an initial report, 
ACCORD will contact the investigator and request the missing information.  
All reports faxed to ACCORD and any follow up information will be retained by the 
investigator in the investigator site file (ISF). 
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B.4.10.6. REGULATORY REPORTING REQUIREMENTS 
The ACCORD Research Governance & QA Office is responsible for 
pharmacovigilance reporting on behalf of the co-sponsors (University of Edinburgh 
and NHS Lothian). 
The ACCORD Research Governance & QA Office has a legal responsibility to 
notify the relevant ethics committee (Research Ethics Committee “REC”) that 
approved the trial).  Fatal or life threatening SUSARs will be reported no later than 7 
calendar days and all other SUSARs will be reported no later than 15 calendar days 
after ACCORD is first aware of the reaction.   
ACCORD will inform investigators at participating sites of all SUSARs and any 
other arising safety information. 
B.4.10.7. FOLLOW UP PROCEDURES 
After initially recording an AE or recording and reporting an SAE, the investigator 
will follow each participant until resolution or death of the participant.  Follow up 
information on an SAE will be reported to the ACCORD office. 
AEs still present in participants at the last study visit will be monitored until 
resolution of the event or until no longer medically indicated. 
B.4.11. PREGNANCY 
Pregnancy is not considered an AE or SAE; however, the investigator will collect 
pregnancy information for any female participants who become pregnant while 
participating in the study.  The investigator will record the information on a 
pregnancy notification form and submit this to the ACCORD office within 14 days 
of being made aware of the pregnancy. 




B.4.12. TRIAL MANAGEMENT AND OVERSIGHT ARRANGEMENTS 
B.4.12.1. TRIAL MANAGEMENT GROUP 
The trial will be coordinated by a project management group, consisting of chief 
investigator, the trial manager and clinical research fellow. 
The trial manager will oversee the study and will be accountable to the chief 
investigator.  The trial manager will be responsible for checking the CRFs for 
completeness, plausibility and consistency.  Any queries will be resolved by the 
investigator or delegated member of the trial team.  
A delegation log will be prepared for each site, detailing the responsibilities of each 
member of staff working on the trial.   
B.4.12.2. TRIAL STEERING COMMITTEE 
N/A  
B.4.12.3. DATA MONITORING COMMITTEE  
N/A 
B.4.12.4. INSPECTION OF RECORDS 
Investigators and institutions involved in the study will permit trial related 
monitoring and audits on behalf of the sponsor, REC review, and regulatory 
inspection(s).  In the event of an audit or monitoring, the investigator agrees to allow 
the representatives of the sponsor direct access to all study records and source 
documentation. In the event of regulatory inspection, the investigator agrees to allow 
inspectors direct access to all study records and source documentation. 
B.4.12.5. RISK ASSESSMENT 
An independent risk assessment will be performed by an ACCORD Clinical Trials 
Monitor to determine if monitoring is required and if so, at what level. An 
independent risk assessment will also be carried out by the ACCORD quality 
assurance group to determine if an audit should be performed before/during/after the 
study and if so, at what locations and at what frequency. 
B.4.12.6. STUDY MONITORING AND AUDIT 
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An ACCORD Clinical Trials Monitor or an appointed monitor will visit the 
investigator site prior to the start of the study and during the course of the study if 
required, in accordance with the monitoring plan if required. Risk assessment will 
determine if audit, by the ACCORD QA group, is required. Details will be captured 
in an audit plan. Audit of investigator sites, study management activities and study 
collaborative units, facilities and 3
rd
 parties may be performed. 
B.4.13. GOOD CLINICAL PRACTICE 
B.4.13.1. ETHICAL CONDUCT 
The study will be conducted in accordance with the principles of the International 
Conference on Harmonisation Tripartite Guideline for Good Clinical Practice (ICH 
GCP). 
A favorable ethical opinion will be obtained from the appropriate REC and local 
R&D approval will be obtained prior to commencement of the study. 
B.4.13.2. COMPLIANCE 
B.4.13.3. INVESTIGATOR RESPONSIBILITIES 
The investigator is responsible for the overall conduct of the study at the site and 
compliance with the protocol and any protocol amendments.  In accordance with the 
principles of ICH GCP, the following areas listed in this section are also the 
responsibility of the Investigator.  Responsibilities may be delegated to an 
appropriate member of study site staff.   
B.4.13.3.1. Informed Consent 
The investigator is responsible for ensuring informed consent is obtained before any 
protocol specific procedures are carried out.  The decision of a participant to 
participate in clinical research is voluntary and should be based on a clear 
understanding of what is involved. 
Participants must receive adequate oral and written information – appropriate 
participant information and informed consent forms will be provided.  The oral 
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explanation to the participant will be performed by the investigator or qualified 
delegated person, and must cover all the elements specified in the participant 
information sheet and consent form. 
The participant must be given every opportunity to clarify any points they do not 
understand and, if necessary, ask for more information.  The participant must be 
given sufficient time to consider the information provided.  It should be emphasised 
that the participant may withdraw their consent to participate at any time without loss 
of benefits to which they otherwise would be entitled. 
The participant will be informed and agree to their medical records being inspected 
by regulatory authorities and representatives of the sponsor(s) but understand that 
their name will not be disclosed outside the hospital. 
Investigator or delegated member of the trial team and the participant will sign and 
date the informed consent form to confirm that consent has been obtained.  The 
participant will receive a copy of this document and a copy filed in the ISF and 
participant’s medical notes. 
B.4.13.3.2. STUDY SITE STAFF 
The investigator must be familiar with the supplement, protocol and the study 
requirements.  It is the investigator’s responsibility to ensure that all staff assisting 
with the study are adequately informed about the supplement, protocol and their trial 
related duties. 
B.4.13.3.3. DATA RECORDING 
The principle investigator is responsible for the quality of the data recorded in the 
CRF at each investigator site. The source data plan identifies which source data 
correspond to CRF data and states which data are recorded directly into the CRF. 
B.4.13.3.4. INVESTIGATOR DOCUMENTATION 
Prior to beginning the study, each investigator will be asked to provide particular 
essential documents to the ACCORD Research Governance & QA Office, including 
but not limited to: 
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 Curriculum vitae (CV) signed and dated by the investigator indicating that it 
is accurate and current. 
The ACCORD Research Governance & QA Office will ensure all other documents 
required by ICH GCP are retained in a Trial Master File (TMF), where required, and 
that appropriate documentation is available in local ISFs. 
B.4.13.3.5. GCP TRAINING 
All study staff must hold evidence of appropriate GCP training.  
B.4.13.3.6. CONFIDENTIALITY 
All evaluation forms, reports, and other records must be identified in a manner 
designed to maintain participant confidentiality.  All records must be kept in a secure 
storage area with limited access.  Clinical information will not be released without 
the written permission of the participant.  The investigator and study site staff 
involved with this study may not disclose or use for any purpose other than 
performance of the study, any data, record, or other unpublished, confidential 
information disclosed to those individuals for the purpose of the study.  Prior written 
agreement from the sponsor or its designee must be obtained for the disclosure of 
any said confidential information to other parties. 
B.4.13.3.7. DATA PROTECTION 
All investigators and study site staff involved with this study must comply with the 
requirements of the Data Protection Act 1998 with regard to the collection, storage, 
processing and disclosure of personal information and will uphold the Act’s core 
principles. Access to collated participant data will be restricted to those clinicians 
treating the participants, representatives of the sponsor(s) and representatives of 
regulatory authorities. 
Computers used to collate the data will have limited access measures via user names 
and passwords. 




B.4.14. STUDY CONDUCT RESPONSIBILITIES 
B.4.14.1. PROTOCOL AMENDMENTS 
Any changes in research activity, except those necessary to remove an apparent, 
immediate hazard to the participant in the case of an urgent safety measure, must be 
reviewed and approved by the chief investigator.   
Amendments to the protocol must be submitted in writing to the appropriate REC, 
and local R&D for approval prior to participants being enrolled into an amended 
protocol. 
B.4.14.2. PROTOCOL VIOLATIONS AND DEVIATIONS 
Prospective protocol deviations, i.e. protocol waivers, will not be approved by the 
sponsors and therefore will not be implemented, except where necessary to eliminate 
an immediate hazard to study participants. If this necessitates a subsequent protocol 
amendment, this should be submitted to the REC, and local R&D for review and 
approval if appropriate. 
Protocol deviations will be recorded in a protocol deviation log and logs will be 
submitted to the sponsors every 3 months. Each protocol violation will be reported to 
the sponsor within 24 hours of becoming aware of the violation. 
B.4.14.3. SERIOUS BREACH REQUIREMENTS 
A serious breach is a breach which is likely to effect to a significant degree: 
(a) The safety or physical or mental integrity of the participants of the trial; or 
(b) The scientific value of the trial. 
If a potential serious breach is identified by the chief investigator, principal 
investigator or delegates, the co-sponsors (accord.seriousbreach@ed.ac.uk) must be 
notified within 24 hours.  It is the responsibility of the co-sponsors to assess the 
impact of the breach on the scientific value of the trial, to determine whether the 
incident constitutes a serious breach and report to regulatory authorities and research 
ethics committees as necessary.  
327 
 
B.4.14.4. STUDY RECORD RETENTION 
All study documentation will be kept for a minimum of 5 years from the protocol 
defined end of study point. When the minimum retention period has elapsed, study 
documentation will not be destroyed without permission from the sponsor. 
B.4.14.5. END OF STUDY 
The end of study is defined as the last participant’s last visit.   
The investigators and/or the co-sponsor(s) have the right at any time to terminate the 
study for clinical or administrative reasons.  
The end of the study will be reported to the REC and within 90 days, or 15 days if 
the study is terminated prematurely.  The investigators will inform participants of the 
premature study closure and ensure that the appropriate follow up is arranged for all 
participants involved. 
A summary report of the study will be provided to the REC and within 1 year of the 
end of the study. 
B.4.14.6. CONTINUATION OF DRUG FOLLOWING THE END OF STUDY 
Participants will be unblinded at the end of the study and if they wish to continue 
treatment these are available across the counter at any pharmacy/health food shops. 
B.4.14.7. INSURANCE AND INDEMNITY 
The co-sponsors are responsible for ensuring proper provision has been made for 
insurance or indemnity to cover their liability and the liability of the chief 
investigator and staff. 
The following arrangements are in place to fulfil the co-sponsors' responsibilities: 
 The protocol has been designed by the chief investigator and researchers 
employed by the University and collaborators.  The University has insurance 
in place (which includes no-fault compensation) for negligent harm caused by 
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poor protocol design by the chief investigator and researchers employed by 
the University. 
 Sites participating in the study will be liable for clinical negligence and other 
negligent harm to individuals taking part in the study and covered by the duty 
of care owed to them by the sites concerned.  The co-sponsors require 
individual sites participating in the study to arrange for their own insurance or 
indemnity in respect of these liabilities. 
 Sites which are part of the United Kingdom's Nation Health Service will have 
the benefit of NHS Indemnity. 
 Sites out with the United Kingdom will be responsible for arranging their 
own indemnity or insurance for their participation in the study, as well as for 
compliance with local law applicable to their participation in the study. 
 The manufacturer supplying supplement has accepted limited liability related 
to the manufacturing and original packaging of the study drug and to the 
losses, damages, claims or liabilities incurred by study participants based on 
known or unknown adverse events which arise out of the manufacturing and 
original packaging of the study drug, but not where there is any modification 
to the study drug (including without limitation re-packaging and blinding). 
B.4.15. REPORTING, PUBLICATIONS AND NOTIFICATION OF RESULTS 
B.4.15.1. AUTHORSHIP POLICY 
Ownership of the data arising from this study resides with the study team.  On 
completion of the study, the study data will be analysed and tabulated, and a clinical 




The clinical study report will be used for publication and presentation at scientific 
meetings. Investigators have the right to publish orally or in writing the results of the 
study. 
Summaries of results will also be made available to investigators for dissemination 
within their clinics (where appropriate and according to their discretion). 
B.4.15.3. PEER REVIEW 
The study has been internally peer reviewed. 
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Patient Information Sheet 
“PurFECT”: Purified Fatty acids for Endometriosis Clinical Trial 
You have been asked to take part in our research study because you have 
endometriosis and pelvic pain.  Before you decide whether you wish to take part, it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following leaflet carefully. Ask us if there is 
anything that is not clear or if you would like more information.  Please take time to 
decide whether or not you wish to take part. 
What is the purpose of the study? 
Endometriosis (when womb lining implants outside the womb) is an inflammatory 
condition that affects 6-10% of women and is associated with chronic pelvic pain. 
Treatment includes surgery to remove the endometriosis lesions and hormone-type 
treatments which can cause unpleasant menopause-like symptoms and are also 
contraceptives.  Purified fatty acids (PUFA, or highly purified fish oils) are known to 
have anti-inflammatory pain-killing properties. PUFA have some side effects 
(detailed below) but do not affect fertility.  We would like to see if PUFA can reduce 
the pain related to endometriosis. In this pilot study we will give an equal number of 
women PUFA or a comparator (dummy oil capsule).  We would like to see what you 
think about being in the study to allow us to design a bigger trial that will help us 





Do I have to take part? 
No. It is up to you to decide whether or not you wish to take part.  This will not 
affect your care or legal rights in any way.   
What will happen to me if I take part? 
Firstly you will be asked to sign a consent form which will be fully explained to you 
and you will have time to read this before you sign, to ensure you are happy with all 
the points.  You will then be asked some questions to confirm that you meet the 
initial study requirements.  Following this you will be asked some questions about 
your previous medical history and any medicines which you are taking. 
We will then ask you to text us your average and worst pain scores every week over 
the next 4 weeks. You will be reminded via a text message.  This will only take about 
5 minutes each week.    
Once we have received all of your pain scores we will contact you and let you know 
what happens next.  It may be the case that your pain scores will mean that this will 
be the end of your participation in the study.   
If you have pain scores which match our requirements for the study then you will be 
asked to come into the hospital for another visit with the research team.  This visit 
should last no more than 45 minutes.  During this visit you will be asked to complete 
some questionnaires (some of which ask some personal questions but you can choose 
not to answer these) and a pregnancy test will be carried out.   
You will then be given at random PUFA or comparator.  Neither you, nor the 
research team, will know what you are given until the study ends.  You will take one 
capsule twice a day for eight weeks.  You will also be given a treatment diary and 
shown how to fill this out.  This will need to be completed every week for the eight 
weeks you are in the study.  This should only take you about 5 minutes to complete 
each week.  This will give us a record of how many capsules you take.  We will 
contact you briefly a few weeks into the study just to check how you are and if you 
are happy to continue (this will take about 5 minutes).  During the last four weeks, 
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you will again be asked to text us your worst and average pain score each week. You 
will be reminded via a text message.  At the end of the 8 weeks you will be asked to 
attend the hospital to complete some questionnaires.  This visit will take about 45 
minutes again.  Reasonable travel expenses can be given for this visit. 
During the course of the study you can continue to take any pain medication you are 
currently prescribed we will just ask you to tell us about them. 
What are the possible disadvantages and risks of taking 
part? 
All treatment can sometimes cause side effects. If you experience any side effects, or 
are worried about them, contact us on 0131 242 2692 or your GP. 
The most common side effects of PUFA are stomach problems, including bloating, 
pain, constipation, diarrhoea, indigestion, wind, nausea or vomiting.  Uncommon 
side effects are headaches, dizziness and a rash.  You can stop taking the medication 
at any time if you are bothered by anything mentioned. 
Some of the questionnaires ask personal questions but you are free not to answer 
these if you are not comfortable doing so.  You complete all the questionnaires in 
private.  
What are the possible benefits of taking part? 
We cannot guarantee any benefit as the effects of this supplement on pain are 
unknown and you may be given a placebo.  The possible benefit in participating in 




What will happen if I don’t want to carry on with the 
study? 
You are free to withdraw from the study at any time without giving a reason.  A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care that you receive.  If you withdraw we may still wish, with your 
permission, to use any anonymised data obtained as a result of your participation.   
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with 
the clinical researchers who will do their best to answer your questions. If you 
remain unhappy and wish to complain formally, you can do so through the NHS 
Complaints Procedure.  Contact: Freepost NHS Lothian, 2-4 Waterloo Place, 
Edinburgh, EH1 3EG.  Phone 0131 536 3370.  Email 
feedback@nhslothian.scot.nhs.uk  
    
Will my taking part in this study be kept confidential? 
Yes. All information which is collected about you during the course of the research 
will be kept strictly confidential. You will be allocated a unique code and your 
responses to the questions will be held in a coded form in a secure central database 
which is only accessible to the research team. Your responses will not be identified 
when the results of the study are published.  However, we do ask permission to 
contact your GP to let them know that you are taking part in the study.  
What will happen to the results of the current research 
study?  
The results of this study will be published e.g. in medical journals, reports and 
textbooks. The anonymised data will be stored for ten years at the University of 
Edinburgh and may be considered for possible use in future ethically approved 




Who is organising and funding the research? 
The research is being organised by Professor Andrew Horne (Consultant 
Gynaecologist) and sponsored by the University of Edinburgh and NHS Lothian. It is 
being funded by the University of Edinburgh. 
Who has reviewed the study? 
This study has been given a favourable ethical opinion for conduct in the NHS by the 
South East Scotland REC 01. NHS management approval has also been obtained. 
Contact details: 
You may contact our clinical research team directly by telephoning Dr Ibtisam 
Abokhrais on 0131 242 2692.  If you require any further information from a doctor 
who is not involved in any way in this study you can contact Dr Colin Duncan on 
0131 242 6222. 
 





























B.6.4. Work and productivity impairment questionnaire-specific health problem 




































































B.8. Treatment diary 
 
Please fill in the number of capsules you have taken each day. 
Please complete every day 
Study medication 
Week 1  Please circle how many capsules you take each day 
Monday 0 1 2 
Tuesday 0 1 2 
Wednesday 0 1 2 
Thursday 0 1 2 
Friday 0 1 2 
Saturday 0 1 2 
Sunday 0 1 2 
 
Please complete every day 
 Other medication that you take for your pain 
Drug  Week 1 
State name 


















        
        
        
        
        




B.9. Statistical analysis plan 
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Reviewer (name and role) Linda Williams, Senior Statistician 
Reviewer Signature and Date  
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Abbreviations and definitions for statistical analysis plan 
 
Abbreviation / Acronym Meaning 
CPP Chronic Pelvic Pain 
NRS Numerical Rating Scale 
GHQ General Health Questionnaire 
SF-12 Short Form-12 Quality of Life 
BPI Brief Pain Inventory 
PCQ Pain Catastrophizing Questionnaire 
SAQ Sexual Activity Questionnaire 
WPAIQ 
Work And Productivity Activity 
Impairment Questionnaire 
BFI Brief Fatigue Inventory 
PUFA Purified Fatty Acids  
RCT Randomised Controlled Trial 
IQR Inter-Quartile Range  
NHS National Health Service 
Diag lap Diagnostic Laparoscopy  




Protocol Document that details the rationale, 
objectives, design, methodology and 
statistical considerations of the study 
Statistical analysis plan Pre-specified statistical methodology 
documented for the trial, either in the 
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This document gives a detailed statistical analysis plan for the PurFECT trial, and 
should be read in conjunction with the current trial protocol.  
B.9.2. Background and rationale 
The background and rationale for the trial are outlined in detail in the protocol. In 
brief, PurFECT is a double blind randomised controlled trial of the efficacy of 
purified fatty acids (PUFA) for women with endometriosis-associated pain. 
B.9.3. Study objectives  
The primary objectives are to assess recruitment and retention rates. Whereas the 
secondary objectives are to determine the effectiveness/acceptability to participants 
of the proposed methods of recruitment/randomisation/treatments/questionnaires, to 
inform the sample size calculation and to refine the research methodology for a 
future large randomised controlled trial.  
B.9.4. Description of study design 
PurFECT is a double blind randomised controlled trial; see  Appendix  B.9.13.1 for 
trial schema. Participants were recruited from NHS Lothian within the United 
Kingdom and randomised in a 1:1 ratio to PUFA or a comparator (olive oil). 
Participants, investigator, clinical fellow and other attending clinicians will remain 
blind to the trial drug allocation for the duration of the treatment phase and will not 
have access to the trial number-treatment allocation code. 
B.9.5. Study comparisons 
All references in this document to ‘group’ refer to treatment A and treatment B, as it 
still unknown which of them is PUFA or the comparator.   
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B.9.6. Outcome measures 
B.9.6.1. Primary outcome(s) 
The primary objectives are to assess recruitment and retention rates. Recruitment is 
defined as the proportion of eligible patients who agreed to participate from the 
number approached. Retention is defined as the proportion of the participating 
patients who completed both baseline and follow up visits. 
B.9.6.2. Secondary outcomes 
• The two summary measures of the Short Form-12 quality of life (SF-12 
Version 2) survey (Ware et al., 1995). 
- Mental Component Summary (0 = worst outcome, 100 = best outcome). 
- Physical Component Summary (0 = worst outcome, 100 = best outcome). 
• The two domains of the Brief Pain Inventory (BPI Short form): a 
comprehensive instrument for pain assessment (Keller et al., 2004). 
- Pain Severity (0 = best outcome, 10 = worst outcome). 
- Pain Interference (0 = best outcome, 10 = worst outcome). 
• The global fatigue score from the Brief Fatigue Inventory (BFI): a tool to 
measure the severity of fatigue in adults (0 = best outcome, 10 = worst 
outcome) (Mendoza et al., 1999). 
• General Health Questionnaire (GHQ): a tool to identify psychological distress 
(0 = best outcome, 12 = worst outcome) (Jackson, 2007).  
• The four domains of the Work and Productivity Activity Impairment 
Questionnaire (WPAIQ): a tool for assessing impairments in paid work and 
activities (Margaret et al., 2008). 
- Absenteeism (0 = best outcome, 10 = worst outcome). 
- Presenteesism (0 = best outcome, 10 = worst outcome). 
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- Work Productivity Loss (0 = best outcome, 100 = worst outcome). 
- Activity Impairment (0 = best outcome, 100 = worst outcome). 
• The three domains and total score of the pain catastrophizing scale (PCQ): 
one of the most widely used instruments for measuring catastrophic thinking 
related to pain (Sullivan et al., 1995). 
- Rumination (0 = best outcome, 16 = worst outcome). 
- Magnification (0 = best outcome, 12 = worst outcome). 
- Helplessness (0 = best outcome, 24 = worst outcome). 
- Total (0 = best outcome, 52 = worst outcome). 
• The three domains of the Sexual Activity Questionnaire (SAQ): a valid, 
reliable and acceptable measure for describing the sexual functioning of 
women in terms of pleasure and discomfort (Thirlaway et al., 1996). 
- Pleasure (0 = worst outcome, 18 = best outcome). 
- Discomfort (0 = best outcome, 6 = worst outcome). 
- Habit (0 = worst outcome, 3 = best outcome).  
- Tired (0 = best outcome, 3 = worst outcome). 
• PainDetect™: is a new screening questionnaire to identify neuropathic 
components in patients (0 = best outcome, 35 = worst outcome) (Mathieson 
and Lin, 2013). 
• Acceptability: is a questionnaire to make the running of the study better in the 
future (1 = best outcome, 60 = worst outcome) (Hunsley, 1992) . 
Other summary outcomes comprise: 
• Average and worst pain scores recorded on a numerical rating scale (NRS). 
Weekly pain scores (ranging from 0 = No pain, 10=Worst pain imaginable) 
were recorded during the first four weeks before randomisation as well as the 
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final four weeks of treatment (weeks 5-8 post randomisation) in the form of: 
i) ‘average pain this week’ and ii) ‘worst pain this week’. Average pain score 
will be taken as the average of i) and worst pain score as the worst response 
from ii). 
• Number of attendances to healthcare professionals for chronic pelvic pain 
(CPP) will be recorded in questions at baseline and end of treatment 
questionnaires. 
• Use of concomitant medications will be recorded to identify any reductions in 
analgesic use. 
B.9.6.3. Timing of outcomes 
Pain scores (NRS) will be recorded in the pre-randomisation phase when a 
participant’s eligibility is being assessed (4 weekly measurements prior to 
randomisation) and in the final four weeks of treatment (weeks 5-8 post 
randomisation).  
B.9.7. Randomisation 
Randomisation will be performed locally at the University of Edinburgh (UOE) 
using opaque closed envelops. 
B.9.8. Sample size 
The emphasis in this study is to establish feasibility, not statistical significance.  This 
study is designed primarily to explore the recruitment and retention rates. The aim is 
to recruit as many women as possible over a 12 month period.  We estimated that we 
will recruit about 4-5 patients per month and aimed to recruit a maximum of 40 
patients. Data from this pilot study will be used to refine sample size calculations for 
any future RCT. A sample size of 40 will allow us to detect a difference of 0.65SD at 
a significance level of 5%.  
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B.9.9. General statistical considerations 
B.9.9.1. Analysis populations 
All analyses (primary and secondary outcomes) will be by intention to treat (Gupta, 
2011). Patients will be analysed in the treatment group to which they were 
randomised (Wang et al., 2007). 
B.9.9.2. Definition of compliance  
Compliance will be monitored by self-reported treatment diaries which are returned 
to me, ‘the clinical fellow’ at visit 3 (week 8). Compliance defined by the following 
categories: ≥ 75% good compliance; 50-75% reasonable compliance; < 50% poor 
compliance.  
B.9.9.3. Levels of confidence and P-values 
For the co-primary outcome measures, estimates of treatment effects will be 
presented with 95%, two-sided confidence intervals. P-values will be reported from 
two-sided tests at the 5% significance level. For all other secondary outcomes 
estimates will be presented with 99%, two-sided confidence intervals. A two-sided P-
value of ≤ 0.01 will be considered statistically significant. 
B.9.9.4. Timing of primary analysis  
The primary analysis for the study will occur after all randomised women have 
completed primary and secondary outcomes (following the 8 week assessment time-
point) and the corresponding outcome data have been entered onto the study database 
and validated as being ready for analysis.  
B.9.9.5. Timing of other analyses  
Not applicable; no longer-term follow up following the primary analysis is proposed. 
B.9.9.6. Handling missing data 
In the first instance, analysis will be completed on received data only after every 
effort is made to follow up all participants to minimise any potential bias. 
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Participants will be excluded from the primary analyses if they have less than 2 pain 
scores available or they withdraw or are lost to follow-up prior to final assessment.  
B.9.10. Proposed statistical methods 
B.9.10.1. Description of population flow  
A flow diagram (recommended by CONSORT) (Schulz et al., 2010) will be 
produced to describe the patient flow through each stage of the study. A template for 
reporting is given in ( Appendix  B.9.13.2). 
B.9.10.2. Baseline characteristics 
The study population will be tabulated as per ( Appendix  B.9.13.3). Categorical data 
will be summarised by frequencies and percentages. Continuous data will be 
summarised by the number of responses, mean and standard deviation. Median and 
interquartile range (IQR) will used if data appears skewed (Altman and Doré, 1990).  
B.9.10.3. Compliance to allocation 
A cross-tabulation of allocated treatment by the compliance categories stated in 
section 9.2 will be produced (proportions and percentages). A template for reporting 
compliance is given in ( Appendix  B.9.13.4). 
B.9.10.4. Analysis methods – primary outcome 
A point estimate and 95% Confidence Interval will be reported for recruitment and 
retention, in order to inform the sample size calculation for a larger trial. 
B.9.10.5. Analysis methods – secondary outcomes 
A template for reporting the secondary outcomes is given in ( Appendix  B.9.13.5). 
Analysis will be performed in a similar fashion to the primary outcome for all 
domains in the following questionnaires: SF-12, BPI, BFI, GHQ, WPAIQ, PCQ, 
SAQ and PainDETECT™ (and acceptability for the end of the study). The change 
from baseline to follow up will be calculated for each patient, and then these changes 
will be compared between group A and group B by the t-test. Should the distribution 
not be symmetric, transformations and log will be applied to the data.  
364 
 
B.9.10.6. Analysis methods – other summaries 
Number of attendances to healthcare professionals for CPP, use of concomitant 
medications, summary of painkiller use, blinding assessment and summary of overall 
health will be summarised as per ( Appendix  B.9.13.6 to  B.9.13.9). Categorical data 
will be summarised by frequencies and percentages. Continuous data will be 
summarised by the number of responses, mean and standard deviation. Median and 
IQR will used if data was skewed. 
B.9.10.7. Safety data 
The proportion and percentage of patients experiencing any serious adverse event 
(SAES) will be presented by different groups. The total number of SAEs in each 
group will also be given along with a descriptive table of the events including the 
causality assessment and whether hospitalisation was required.  
B.9.11. Statistical software 
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B.9.13. Appendices of statistical analysis plan 










B.9.13.3. Baseline characteristics by treatment arm and all subjects  
 
Randomised Treatment All 
Participants Treatment A Treatment B 
N % N % N % 
Total number of participants randomised 
 





 Std. Deviation   







 Std. Deviation   
Range   
Highest education received 
Primary school       
Secondary school       
College/university       
Ethnicity 
Caucasian       
Other (Asian)       




Randomised Treatment All 
Participants Treatment A Treatment B 
N % N % N % 
Ex-smoker       
Never smoked       
Parity 
None       
1 or more       
Periods 
Yes       
No       
Pain during periods 
Yes       
No       
Pain during intercourse 
Yes       
No       
Previous gynaecological operations 
1       
2       
3 or more       
Type of endometriosis 
Peritoneal       




Randomised Treatment All 
Participants Treatment A Treatment B 
N % N % N % 
Deep       
Contraception 
Patch       
Nexplanon       
COC       
Depo-Provera       
POP       
Contraceptive ring       
Mirena       
Other       




B.9.13.4. Compliance to treatment allocation by group  
Time-Point Compliance 
Treatment A Treatment B 
N =  N =  
Week 1 
Both capsules (%)   
Only one capsule (%)   
None of capsules (%)   
Week 2 
Both capsules (%)   
Only one capsule (%)   
None of capsules (%)   
Week 3 
Both capsules (%)   
Only one capsule (%)   
None of capsules (%)   
Week 4 
Both capsules (%)   
Only one capsule (%)   
None of capsules (%)   
Week 5 
Both capsules (%)   
Only one capsule (%)   
None of capsules (%)   
Week 6 
Both capsules (%)   
Only one capsule (%)   
None of capsules (%)   
Week 7 
Both capsules (%)   
Only one capsule (%)   
None of capsules (%)   
Week 8 
Both capsules (%)   
Only one capsule (%)   




Treatment A Treatment B 
N =  N =  
8 Weeks 
Both capsules (%)   
Only one capsule (%)   
None of capsules (%)   
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B.9.13.5. Secondary outcome results  
  Randomised  Treatment 
 Treatment A 
 
Treatment B 
N Mean SD 
 










   (higher score = better) 
Physical_component_summary_baseline_ 
score 
          
Physical_component_summary_8_weeks_
score 
          
Change from baseline (8 weeks-baseline)            
Mental_component_summary_baseline_ 
score 
          
Mental_component_summary_8_weeks_ 
score 
          







Randomised  treatment 
 Treatment A 
 
Treatment B 
N Mean SD 
 








 (higher score = worse) 
Pain severity baseline score           
Pain severity week 8 score           
Change from baseline (8 weeks-baseline)             
Pain interference baseline score           
Pain interference week 8 score           





  Randomised  treatment 
 Treatment A 
 
Treatment B 
N Mean SD 
 








 (higher score = worse) 
Global fatigue baseline Score           
Global fatigue week 8 score           






Randomised  treatment 
 Treatment A 
 
Treatment B 
N Mean SD 
 








 (higher score = worse) 
Global baseline score           
Global week 8 score           





Randomised  treatment 
 Treatment A 
 
Treatment B 
N Mean SD 
 








 (higher score = worse) 
Absenteeism_baseline_score           
Absenteeism_week_8_score           
Change from baseline (8 weeks -baseline)             
Presenteesism_baseline_score           
Presenteesism_week_8_score           
Change from baseline (8 weeks -baseline)             
Work_productivity_loss_baseline_score           
Work_productivity_loss_week_8_score           
Change from baseline (8 weeks -baseline)             
Activity_impairment_baseline_score           
Activity_impairment_week_8_score           





Randomised  treatment 
 Treatment A 
 
Treatment B 
N Mean SD 
 






PCQ (higher score = worse) 
Rumination
7
_baseline_score           
Rumination_week_8_score           
Change from baseline (8 weeks-baseline)             
Magnification
8
_baseline_score           
Magnification_week_8_score           
Change from baseline (8 weeks -baseline)             
Helplessness
9
_baseline_score           
Helplessness_week_8_score           
Change from baseline (8 weeks-baseline)             
Total
10
_baseline_score           
Total_week_8_score           




  Randomised  treatment 
 Treatment A 
 
Treatment B 
N Mean SD 
 






SAQ (higher score = better) 
Pleasure
11
_baseline_score           
Pleasure_week_8_score           
Change from baseline (8 weeks-baseline)             
Discomfort
12
_baseline_score           
Discomfort_week_8_score           
Change from baseline (8 weeks -baseline)             
Habit
13
_baseline_score           
Habit_week_8_score           
Change from baseline (8 weeks -baseline)             
Tired
14
_baseline_score           
Tired_week_8_score           





Randomised  treatment 
 Treatment A 
 
Treatment B 
N Mean SD 
 








 (higher score = worse) 
Global baseline score           
Global week 8 score           
Change from baseline (8 weeks -baseline)             
1 Difference more than 0 indicates better score with PUFA.  
2 SF-12 version 2 scores range from 0-100, where low scores are bad and high scores are good. 
3 BPI scores range from 0-10, where low scores are good and high scores are bad. 
4 BFI scores range from 0-10, where low scores are good and high scores are bad. 
5 GHQ scores range from 0-12, where higher scores represent higher levels of mental distress. 
6 WPAIQ scores range from 0-100, where low scores are good and high scores are bad indicating greater impairment and less productivity. 
7 PCQ rumination scores range from 0-16, where low scores are good and high scores are bad. 
8 PCQ magnification scores range from 0-12, where low scores are good and high scores are bad. 
9 PCQ helplessness scores range from 0-24, where low scores are good and high scores are bad. 
10 PCQ total scores range from 0-52, where low scores are good and high scores are bad. 
11 SAQ pleasure scores range from 0-18, where low scores are bad and high scores are good. 
12 SAQ discomfort scores range from 0-6, where low scores are bad and high scores are good. 
13 SAQ habit scores range from 0-3, where low scores are bad and high scores are good. 
14 SAQ tired scores range from 0-3, where low scores are bad and high scores are good. 











GP (baseline)    
GP (follow-up)    
Hospital outpatients (baseline)   
Hospital outpatients (follow-up)   
Practice nurse (baseline)   
Practice nurse (follow-up)   
Physiotherapist (baseline)   
Physiotherapist (follow-up)   
Alternative therapist (baseline)   
Alternative therapist (follow-up)   
 






Use of analgesia since starting the study 
Less   
More   






B.9.13.8. Randomised treatment and treatment participant thought they had received 
 Randomised Treatment 
Treatment A 
 (N=14) 
Treatment B  
 (N= 13) 






   
B.9.13.9. Overall health change with treatment 




Overall health change with treatment
 

























B.9.14. Statistical analysis plan approval 
This statistical analysis plan has been read and approved by: 
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Appendix  D. Poster presentations 
 
394 
 
 
